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ABSTRACT
Objectives
To identify genetic markers to predict biochemical outcome after radical prostatectomy 
and in a separate study to assess methylation, an epigenetic change, in metastatic 
prostate cancer cell lines.
Materials and Methods
One group o f patients with PSA relapse and another non-relapse group were matched. 
DNA was extracted from the radical prostatectomy specimens, amplified using thirty 
microsatellite markers and genotyping performed.
PC3, LNCaP and DU145 metastatic prostate cancer cell lines and control cell lines were 
cultured in the demethylating agent 5-Aza-2 deoxycytidine (5AzaCdR), in parallel with 
untreated cells. p21WAFI/CIP1 mRNA expression was analysed by RT-PCR. DNA from 
untreated cell lines was modified with sodium bisulphite and p2JHAf'ICIPI promoter 
sequencing performed.
Results
Allelic imbalance was significantly more common in the relapse than the non-relapse 
group at 10pl2.1(D10S211) (35% vrs 5%, p=0.03). Several markers showed a marked 
but not statistically significant difference between the two groups including: D1S158, 
D1S422, D2S222, D5S500, D6S314, D8S136, NEFL, D11S2000, D12S89, D12S1697, 
D13S269, D15S1232, D16S413 and D18S541.
RT-PCR demonstrated p 2 jnAf’1/CIPI was expressed at low or undetectable levels in 
metastatic prostate cancer cell lines but was reactivated by treatment with 5AzaCdR. 
Sequence analysis of the promoter revealed several sites of methylation at the 5’ end of
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a CpG island in the PC3, LNCaP and DU 145 cancer cell line DNA, including at a 
STAT1 binding site.
Conclusions
A significant association between loss of a locus at chromosome 1 Opl2.1 and 
biochemical progression after radical prostatectomy was found.
'y i W 4 F I  C I P I  • i  • I f  i *  1p21 expression was low in metastatic prostate cancer cell lines, but was
enhanced by demethylation. Several cytosine residues in the promoter region were 
methylated, in particular where STAT1 binds. The inhibition of the STAT1 signalling 
pathway by methylation of the p21nAFI CIPI promoter may inactivate the p21HAFI CIPI 
tumour suppressor gene in prostate cancer.
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CHAPTER 1
1.1 Introduction
Prostate cancer is an enigma. This makes it a fascinating disease to study but a 
controversial and often difficult disease to treat. While still localised (confined to 
prostate), prostate cancer is curable by radical surgery, radical external beam 
radiotherapy, brachytherapy or cryotherapy. Once the tumour has extended beyond the 
confines of the gland the chances of cure fall dramatically. For a patient with metastases 
curative therapy is not currently available and he has a median life expectancy of 18 
months. Yet, the majority of prostate cancers endemic in the male population will not 
cause any symptoms and will have no effect on the quality or quantity of that 
individual’s life. These tumours are termed ‘insignificant’ prostate cancers. To treat 
these patients would expose them to the inherent side effects and complications 
associated with radical therapies with no benefit in terms of their life expectancy.
To avoid treating patients inappropriately the decision to offer a patient radical surgery 
is based on the serum prostate specific antigen (PSA) level, a digital rectal examination 
(DRE) of the prostate, and the results of prostatic biopsy sometimes augmented by 
radiological or radio-isotopic imaging. Even when the results of these investigations are 
summated, between a quarter and a half of patients undergoing radical prostatectomy 
have disease outside the prostate (Han et al. 2001; Partin et al. 1993). Yet, by no means 
all of these men will develop disease progression.
Currently the pathologist provides the best prognostic indicators by examining the 
radical prostatectomy surgical specimen and reporting the grade, stage and the status of 
the resection margins. However, in recent years attention has focused on newer
13
molecular markers, potentially applicable to prostate biopsies, to identify patients who 
are best suited for radical treatment.
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1.2 Incidence of prostate cancer
The overall incidence of prostate cancer is rising in the UK. Europe and the United
States, such that prostate cancer is now the most commonly diagnosed life-threatening
malignancy in men. In the UK, the overall incidence is currently 21,400 new cases per
annum, with a rate of 74 cases per 100,000 men (National Statistics-
http://www.statistics.gov.uk/ststbase/datasets2.asp). The age-matched incidence gives a
better indication of the true incidence within an ageing population as it gives the
number of sufferers at different age intervals per 100,000 head of population. It is not
affected by the population size -  so for prostate cancer although the overall incidence of
the disease is rising rapidly, as more men are living longer, the age-matched incidence is
t V lrising more slowly (Figure 1.1). >  •
Figure 1.1. Prostate cancer age-specific incidence in G reat Britain (1979-2001).
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The age-matched incidence in the United States is over two fold higher than in the UK. 
despite similar mortality rates -  this probably reflects the greater use of PSA as a 
screening tool in America. Stamey published his seminal paper on the potential use of 
PSA in the diagnosis and management of prostate cancer in 1987 (Stamey et al. 1987). 
The incidence rates in the US subsequently showed a sharp increase in 1990 and then a 
decline in 1993 until settling in 1995. to a level substantially higher than the 1986 level 
(Shibata & Whittemore 2001). The UK witnessed a slower increase in age-matched 
incidence up to 1995. The incidence in men under 75 has continued to rise since 1995. 
Whereas, in older men the incidence has levelled off or fallen, presumably as more men 
are diagnosed at a younger age.
The mortality rates have shown a downward trend in both countries since the mid 
1990‘s, although the decrease is more dramatic in the US. Proponents of PSA screening 
have claimed these improved mortality rates reflect the rise in serum screening. Indeed 
the US and to a lesser extent the UK and Europe have seen a stage migration at 
diagnosis, where now a greater proportion of men are presenting with organ-confined 
disease (Bott et al. 2005c; Freedland et al. 2003; Han et al. 2001; Quinn et al. 2001). 
However, for an affect on mortality there would be an expected lead-time of 10-20 
years -  i.e. we would expect to see a reduction in mortality over the next few years, 
rather than a decade ago. Furthermore the reduction in mortality witnessed across the 
USA has been the same in regions of high and low levels of PSA screening (Brawley 
1997). While PSA testing may play some role, improvements in treatment or some othei^
factor must also be considered (Shibata & Whittemore 2001). —  (. ^
Autopsy and cystoprostatectomy studies looking at the incidence of clinically 
insignificant or latent prostate cancer in the population have revealed 30-50% of males
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bom in the western world have a life-time risk of developing prostate cancer (Franks 
1956; Villers et al. 1992). This figure varies depending on whether random or 
systematic whole-mount sections are examined (Lundberg & Berge 1970). When the 
entire gland is examined using whole-mount step sections at 4-5 mm intervals, foci of 
cancer are more commonly found and its prevalence increases with age, reaching 80% 
in men over 90 years old (Hirst & Bergman 1954). Hirst and Bergman showed this 
trend with advancing age was reflected in the incidence of clinical disease and 
mortality. They suggested there is a ‘latent* period of around 20 years during which 
such clinically unsuspected tumours progress and metastasise. It is estimated over an 
individuals lifetime 10% of men will develop symptoms and 3% will succumb to 
prostate cancer (Scardino, Weaver, & Hudson 1992).
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1.3 Prostate anatomy and physiology
An understanding of the anatomy of the prostate is essential to the understanding of its 
disease processes. McNeal defined the anatomical regions of the prostate: the peripheral 
zone, the transition zone, the central zone and the anterior fibromuscular zone (McNeal
In a 20 year old male the peripheral zone makes up 75% of the glandular prostate and 
forms the posterior, lateral and apical regions. It is composed of small acini, within a 
fine fibro-muscular stroma, whose ducts open into the urethra at and distal to the veru
occur posteriorly, this makes digital rectal examination important in the assessment of a 
man with suspected prostate cancer. However, small posterior tumours may not be 
palpable and 20% of prostate cancers occur anterior to the urethra (Bott et al. 2002), 
posing difficulty not only in clinical staging but also achieving an adequate biopsy of 
the anterior gland (Bott et al. 2002; Stamey et al. 1987).
The transition zone comprises 5% of the prostatic glandular tissue and in young men is 
an inverted cone shape encircling the urethra with its apex at the veru montanum. In 
older men with hyperplasia it may appear as lobes impinging on the prostatic urethra. 
The acini of the transition zone are similar to those of the peripheral zone, and are 
embedded in a dense stroma - more like the central zone. The ducts run parallel to the 
urethra, into which they open at the distal margin of the smooth muscle sphincter. 
Contained within the transition zone are the periurethral glands and their ducts open 
directly into the urethra. The transition zone is the site o f  20% jbf prostate cancers and 
the site of benign prostatic hyperplasia development. Tumours arising in the transition 
zone have distinct pathological features, which may reflect differences in their
1972).-^
montanum. The peripheral zone is the site % o f  prostatic cancers and the majority
genotype. Transition zone tumours are reported to have a lower incidence of 
extracapsular and metastatic spread and to be of lower Gleason grade than peripheral 
zone tumours (Grignon & Sakr 1994; Noguchi et al. 2000). In contrast, they tend have 
greater tumour volume and have high PSA production when still confined to the 
prostate (Stamey. Dietrick. & Issa 1993). Several workers have reported significant 
differences in biochemical free survival in favour of transition zone tumours 
(Erbersdobler et al. 2002b; Noguchi et al. 2000). though the question to what extent 
genetic variation between cancers arising from the different zones or the anatomical 
location dictates tumour behaviour remains to be answered .
The central zone, representing 25% of the glandular prostate, is an inverted pyramid, 
which sourrounds the ejaculatory ducts. Its base forms the prostatic base and its apex 
lies at the verumontanum. The acini are large and square in outline with marked 
infoldings and a sourrounding compact muscle component. The ducts of the vasa 
deferentia and seminal vesicles enter the central zone and coalesce to form the 
ejaculatory ducts, which open into the urethra at the verumontanum. Less than 10% of 
prostatic neoplasms originate in the central zone (McNeal et al. 1988).
The anterior fibromuscular stroma accounts for 30% of the prostate mass and forms the 
entire anterior surface of the prostate, extending as a continuum from the detrusor 
muscle of the bladder to the striated sphincter distal to the prostatic apex. It merges 
laterally with the ‘capsule’ and the glandular prostate is fused with its posterior surface. 
This stroma was thought to be void of glands, however recently Tiguert et al. identified 
prostate acini within it (Tiguert et al. 1999). These acini have at least a theoretical risk 
of undergoing malignant transformation.
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The prostate is described as having a ‘prostatic capsule’. This is important as tumour 
penetration through the capsule is one of the most fundamental prognostic features. 
However, in reality this is a 2-3mm condensation of fibrous tissue with occasional 
muscle fibres, which separates the prostatic glandular tissue from the periprostatic 
connective tissue. It not a true capsule (like the renal capsule) as it is incomplete and is 
an intrinsic and inseparable part of the gland (Ayala et al. 1989). Although, where 
present, this condensation of fibrous tissue may offer an anatomical barrier against 
extraprostatic extension of tumour, it is absent at the prostatic apex. Here there is little 
or no barrier against local spread to adjacent structures.
The majority o f tumours arise in the peripheral zone at the prostatic apex (Bott et al. 
2002; Byar & Mostofi 1972). Byar and Mostofi showed that tumour was present in one 
or two of the apical sections in 75% of 208 men undergoing radical prostatectomy (Byar 
& Mostofi 1972). The short inferior neurovascular pedicles enter the prostate at the apex 
and, as prostate cancer has a propensity to invade along the tissue planes surrounding 
nerves, this is a common site for extraprostatic disease. Furthermore, the surgical 
dissection at the apex is limited by the proximity of the external urethral sphincter and 
the neurovascular bundles, rendering the apex the most common site for positive 
surgical margins (Blute et al. 1997; Bott & Kirby 2002; Obek et al. 1999).
These observations suggest that the location of malignancy within the prostate may 
influence its presentation, its pathological behaviour and its treatment.
The function of the prostate is not fully understood. Secretions from the sexual 
accessory glands constitute 99% of the ejaculate, with 1% being spermatozoa. The 
ejaculatory fluid is produced by the seminal vesicles, the prostate and Cowper’s glands.
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The prostatic contribution consists of citrate, zinc, polyamines (spermine, spermidine 
and putrescine) as well as antioxidants (superoxide dismutase) and prostate specific 
antigen (PSA) (Narayan et al. 2000). Citrate is thought to act as a buffer and as an 
energy source. Zinc is found in high levels in seminal fluid and may act as an inhibitor 
o f citrate metabolism. In benign prostatic hyperplasia zinc levels are increased, while in 
cancer zinc levels are substantially lower. Low levels of zinc permit increased 
metabolism of citrate presumably as an energy source for the malignant cells, and citrate 
levels are consequently lower in prostate cancer tissue(Costello, Franklin, & Narayan 
1999).
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1.4 Natural history of prostate cancer and active surveillance
The natural history of prostate cancer is the clinical and pathological manifestations of 
the tumour from its inception until death of the untreated host. This depends on the 
malignant nature of the cancer and also the life expectancy of the individual.
The development and subsequent progression of prostate cancer is reliant on the 
acquisition of genetic changes that convert a benign epithelial cell through a malignant 
cell with invasive potential, to a cell capable of metastasising and in some cases 
becoming hormone independent. The adaptation by the tumour requires specific genetic 
changes at each step to allow progression -  the multi-hit hypothesis (Figure 1.2).
Figure 1.2. Genetic changes underlying the initiation and progression of 
prostate cancer
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This hypothesis underlies how, by being able to identify specific changes at each step, 
we will be able to predict disease outcomes and target new therapeutic interventions. In 
the meantime treatments are tailored according to our understanding of prostate cancer 
gained from large, but unrandomised case series.
Gaining information regarding the natural history of a life-threatening condition is 
almost impossible. Attempting to randomise patients with anything other than low stage 
and low-intermediate grade prostate cancer to receive ‘no treatment’ is unethical. 
Therapeutic intervention, which may alter the natural history of the disease, is 
frequently required as the untreated cancer progresses. As a result good quality data for 
‘conservative’ management is lacking. We rely on unrandomised or pooled data 
gathered from patients who have not received radical therapy for a variety of reasons. 
Comparing these cohorts with the large series of patients selected for radical treatment 
is questionable. What is more, staging information in these ‘watch and wait’ series is 
based on clinical findings, which are inherently crude.
Chodak et al. published a pooled analysis o f 6 unrandomised studies containing 828 
patients managed by either observation alone or observation and delayed hormonal 
therapy, in men with clinically localised disease diagnosed with cytology or biopsy 
(Chodak et al. 1994). Disease-specific survival at 10 years (survival among only those 
patients who did not die of causes other than prostate cancer) was 87% for those with 
well or moderately differentiated tumours (Gleason grade 2-4 and 5-7 respectively) 
compared with 34% for those with poorly differentiated disease (Gleason 8-10). An 
argument for radical therapy is that overall survival after treatment approximates to 
overall survival in the general population. However, the authors of this study concluded
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that the same outcome could be achieved by observation alone in patients with a 
Gleason score o f 7 or less.
Table 1.1. Outcome of patients undergoing active surveillance (Chodak et al. 1994)
Percent of patients (95% Cl)
5 years 10 years
Disease-specific survival
Grade 1 98(96-99) 87(81-91)
Grade 2 97(93-98) 87(80-92)
Grade 3 67(51-79) 34(19-50)
Metastasis-free survival
Grade 1 93(90-95) 81(75-86)
Grade 2 84(79-89) 58(49-66)
Grade 3 51(36-64) 26(13-41)
The metastases free rate at 10 years in the Chodak study was 81% for well 
differentiated, 58% for moderately differentiated and 26% for poorly differentiated 
prostate cancers. Although 81% of patients with moderately differentiated tumours were 
not dying of prostate cancer during the study period, nearly 40% progressed to 
potentially painful and symptomatic distant metastases. In this study, the mean patient 
age was 70 years. The mean age for men considered for radical treatment is 60, so in 
these men, who have a 20-25 year life-expectancy longer follow-up for conservative 
treatment is required.
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A longitudinal study in a single catchment area in Sweden examined the role of 
conservative treatment o f prostate cancer (Johansson et al. 1997). However, for the 
reasons outlined, it was not randomised and was therefore biased as men with high- 
grade tumours received radiotherapy and were excluded. The study cohort included men 
with clinically localised disease, locally advanced disease and metastatic disease; the 
15-year disease-specific survival was 89%, 57% and 6%, respectively. Of interest, there 
was no survival benefit between those who received initial androgen deprivation 
therapy and those in whom it was delayed; and importantly they found grade, more than 
stage, was the most powerful predictor of survival. Indeed, 6% of men with well- 
differentiated tumours died within 15 years from prostate cancer, compared with 17% 
with moderately differentiated and 57% with poorly differentiated disease, regardless of 
stage.
In a study from Connecticut, survival was modelled on a proportional hazards 
regression, Gleason score and co-morbid status were the only two variables of 
significance (Albertsen et al. 1995). They concluded the age-adjusted survival for men 
with Gleason 2-4 tumours was similar to that o f the general population and so 
questioned the use of aggressive therapy in this group. The maximum life lost for men 
with Gleason 5-7 tumours was 4 to 5 years and 6 to 8 years for men with Gleason 8-10 
tumours. The Connecticut group drew up computer formulae, that include Gleason 
grade and co-morbid features, to estimate age-adjusted life year gains (Albertsen et al. 
1996), and more recently updated this to include men aged between 55-74 (Albertsen et 
al. 1998).
Whilst all these studies can be criticised for their lack of randomisation, their relatively 
short follow-up and the inherent inaccuracy o f clinical staging they do all show a
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consistent pattern; the Gleason score is currently the most useful indicator of the natural 
history of prostate cancer. Furthermore, the Connecticut nomograms incorporating the 
Gleason score and patient co-morbidity can be used in the clinic to counsel patients on 
treatment choices armed with an accurate prediction of their survival.
The prostate specific antigen (PSA) has played a role in altering the natural history of 
this disease. PSA can affect the lead-time to diagnosis, as demonstrated by the 
longitudinal Physician’s Health Study. This showed that a single PSA measurement can 
detect 80% of prostate cancers diagnosed at least 5 years before they become clinically 
apparent (Gann, Hennekens, & Stampfer 1995). What is more, PSA detected cancers are 
more aggressive, but generally of lower stage, than cancers detected ‘incidentally’ at 
transurethral resection o f the prostate (TURP). Soh et al. reported a single surgeon 
series from 1983-1995 (Soh et al. 1997). Prior to 1989 most radical prostatectomies 
were performed in response to cancer diagnosed on TURP (T la and Tib). Since 1989, 
most tumours were diagnosed as a result o f a raised PSA, tumours diagnosed more 
recently are higher grade, but lower stage.
The role o f serum PSA as a predictor o f disease progression in men under active 
surveillance was assessed in another Swedish study, which selected 658 well men bom 
in 1913 who were 67 years old at randomisation (Hugosson et al. 2000) A blood sample 
was extracted and stored frozen and the group followed for 15 years. Patients’ 
management was according to local protocols and no patient had PSA screening or 
curative treatment for prostatic cancer. Fifty-two (7.9%) men developed clinical prostate 
cancer and in these men the risk of dying o f the disease was related to the serum PSA at 
age 67. If at the age of 67 the PSA was <3ng/ml, 5% developed clinical cancer, if the 
PSA was 3-10ng/ml, 30% developed the disease and if the PSA was >10ng/ml 50% 
men developed clinical prostate cancer.
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In recent years there has been an increasing vogue for active surveillance. While the 
proponents accept there is no long-term outcome data for active surveillance they claim 
the number of men over treated by radical therapies warrants further investigation 
(Parker 2004). Men are observed by measuring their PSA monthly and by repeating the 
biopsy Gleason score every 18 months. Patients with a PSA doubling time less than 1 
year or men who are up graded to Gleason 8-10 on re-biopsy are referred for radical 
therapy. Up to 80% of men may be prevented from undergoing radical treatment, it 
remains to be seen how many patients ‘spared’ radical treatment eventually die of 
prostate cancer compared with a treated group. Furthermore, optimal surveillance 
programmes have not been established so the correct PSADT to trigger treatment is 
currently unknown, and there is a reliance on the Gleason score from prostate biopsies 
that prone to sampling and interpretative errors.
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1.5 Staging prostate cancer
Staging is the systematic classification of cancer extent and as with the vast majority of 
carcinomas, the extent o f prostatic cancer both in terms of the primary site and the 
secondary or metastatic sites has a profound effect on "curability’ and on prognosis. The 
clinical staging of prostate cancer may include a digital rectal examination (DRE), 
prostatic biopsy. Computer Tomography (CT) or Magnetic Resonance Imaging (MRI) 
to ascertain the local stage and radio-isotope bone-scan, Positron Emission Tomography 
(PET), CT or MRI to assess metastatic spread.
The adoption of an agreed classification of tumour extent enables comparisons to be 
made between different stages of disease and allows data from different centres to be 
compared in a meaningful way. Two staging classifications are used to describe the 
extent of prostate cancer the TNM (Tumour, Node and Metastases) and the Whitmore- 
Jewet staging system. These systems incorporate clinical and pathological tumour 
extent running in parallel
In 1956 Whitmore subdivided prostate cancer into four clinical stages: Stage I 
represents clinically latent disease, Stage II early but palpable disease, Stage III locally 
advanced disease without metastases and Stage IV distant metastases irrespective of the 
local stage. These categories were subsequently revised by Prout and Jewett. This 
revised system was adopted in the US initially but has now been largely superseded by 
the TNM classification.
The TNM classification (Table 1.2) has been used to categorise all solid cancers and has 
been promoted by the Union Internationale Contre le Cancer (UICC), the American 
Joint Committee for Cancer (AJC) and other international bodies since the 1970’s. The
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TNM classification recognises the limitations of clinical staging by differentiating post- 
surgical or pathological staging by the pre-fix ‘p \  It is now the most frequently used 
staging system in prostate cancer and will be the system of choice in this thesis.
Table 1.2. TNM classification of prostate cancer (UICC 6th edition, 2002)
T1 Impalpable and not visible on imaging
T la Tumour incidental finding in <5% tissue resected at TURP
T ib Tumour incidental finding in >5% tissue resected at TURP
T ic Tumour identified by needle biopsy
T2 Tumour confined within the prostate
T2a Tumour involves one half o f one lobe, or less
T2b Tumour involves more than one half o f one lobe, but not both lobes
T2c Tumour involves both lobes
T3 Tumour extends through the prostatic capsule
T3a Unilateral or bilateral extracapsular extension
T3b Tumour invades seminal vesicle(s)
T4 Tumour is fixed  or invades adjacent structures other than the seminal 
vesicles’, bladder neck, external sphincter, rectum, levator muscles or 
pelvic wall
N - X, 0 ,1 Lymph nodes - Not assessed, no regional metastases, regional node 
metastases
M l - a, b, c Distant metastases -  non-regional lymph node metastases, bone 
metastases, other site
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1.6(a) Grading prostate cancer
The diagnosis o f prostate cancer requires the histological examination of cancer tissue. 
Once established the glandular architecture and the cellular differentiation are assessed 
to grade the disease. Several grading systems have been proposed, though the Gleason 
system, described in 1974 (Gleason & Mellinger 1974), remains the standard (Figure 
1.3).
Gleason, in conjunction with the Veterans Administration Co-operative Urological 
Research Group (VACURG), described the overall pattern of growth of the tumour as 
examined at low magnification (40-100x). The cytological characteristics seen at higher 
magnification were not part o f Gleason’s description. The patterns were correlated with 
clinical outcome by an independent observer and 5 patterns were found to be associated 
with prognosis. Where more than one pattern was present in a cancer, patient mortality 
fell between that seen in the two patterns in pure form. Hence the two predominant 
patterns were recorded in order of area and summated as the Gleason sum score e.g 
Gleason 3+4. In tumours o f pure pattern the number was doubled e.g 3+3. Since 
Gleason’s original description, variation has existed as to whether the second pattern 
reported in biopsy specimens should be the second most frequent area or the highest 
pattern grade. Generally, the two dominant areas are still reported and summated to give 
the overall Gleason score (Bostwick et al. 2000). The highest grade may also be 
reported if different from the predominant patterns as this area, although small, maybe 
of prognostic importance, particularly at biopsy where sampling error may result in the 
dominant tumour being under-represented.
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Figure 1.3 The Gleason grading system of prostate cancer
The problem with the Gleason scoring system is that it is a rigid scoring system based 
on an architectural pattern that is a continuum. The score categorises patterns 1-5, these 
groupings do not demonstrate malignant potential in the same stepwise fashion. Gleason 
sum 2-5 tumours behave in a similar manner and some authors have categorised these 
as ‘insignificant’ tumours, unlikely to affect the quality or quantity of the patient’s life 
(Epstein, Walsh, & Brendler 1994; Jack et al. 2002). However, within the Gleason sum 
category 7 two distinct groups exist, 3+4 and 4+3, which are associated with differing 
outcomes. In a radical prostatectomy series reported from the University of Texas, 2.7% 
of 73 patients with 3+4 disease developed biochemical relapse compared with 12.8% of 
86 men with 4+3 disease (p=0.02) after a minimum 48 months follow-up (Babaian et al. 
2001). Johns Hopkins have also reported their experience of Gleason 7 disease in 564 
men (Han et al. 2000). A significant recurrence-free survival advantage was found in 
men who underwent radical prostatectomy for Gleason 3+4 compared with those with 
Gleason 4+3 disease (p<0.0001). An artificial neural network, logistic regression, and 
proportion hazard models all demonstrated the importance of the Gleason 7 constituent 
parts in predicting patient outcome (Han et al. 2000; Partin et al. 2001).
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There is significant inter and intra-observer variability in the Gleason scoring system. 
Inter-observer variability may be as high as 23%, usually as a result of under-grading 
Gleason pattern 3 and 4 (Gleason 1992; Steinberg et al. 1997). Gleason himself 
reported a 50% intraobserver variation (Gleason 1992). These differences may be 
reduced by the reporting pathologist re-examining the slides and by review of all cancer 
diagnoses by specialist uropathologists (Steinberg et al. 1997). In practice, in the UK, 
this is not usually feasible. Never the less, the Gleason score currently offers one of the 
best prognostic indicators in prostate cancer.
1.6(b) Tumour multifocality
Prostatic cancer is both a heterogeneous and multifocal disease. It is usually made up of 
a dominant or index tumour consisting o f several different sub-clones at different stages 
of tumour development - hence the Gleason scoring system includes two grading 
patterns. Frequently, there are also other smaller foci of adenocarcinoma within the 
prostate that are genetically distinct or non-clonal (Bostwick et al. 1998). The Stanford 
group, using 3mm step sections, reported 83% of 486 men treated by radical 
prostatectomy had multiple tumour foci (Wise et al. 2002). The median number of 
additional foci was 2.0 (range 0-12), however the total volume of these additional 
tumours was <0.5cm in 234 (58%) cases. Interestingly, an increasing number of 
smaller cancers had a beneficial effect on PSA failure rates. The index tumour volume 
was a powerful determinant of PSA failure, however there was a decline in the size of 
the index tumour with each increase in the number of smaller cancers. Rashid et al. also 
found that the index cancer and not the multifocality predicted PSA free survival 
(Rashid, Wojno, & Marcovich 1999) and Haggman et al. concluded the most significant 
malignant features were always represented in the index tumour and less commonly in
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the remaining foci (Haggman et al. 1997a). A more recent study has disputed these 
findings, and has identified genetic changes in metastases, which were only detectable 
in the smaller foci (Isaacs, De Marzo, & Nelson 2002). However, it is usually the largest 
focus that contains the highest-grade tumour and it is usually this tumour that dictates 
clinical outcome.
The fact that several genetically different tumours co-exist within one prostate has 
hampered the search for molecular markers in prostatic cancer as homogeneous samples 
are hard to obtain. With the advent of laser capture of individual cells and cell-sorting 
techniques, which enable the isolation of relatively pure populations of malignant cells, 
these difficulties have been partially circumvented. Now the difficulty is in selecting the 
correct cell or population for investigation.
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1.7 Localised prostate cancer
Localised prostatic cancer is cancer that is organ confined, that is it has not spread 
beyond the fibromuscular ‘capsule’ and at this stage the cancer is curable.
1.7(a) Presentation
In England and Wales 52% of new cases o f prostate cancer are thought to be localised 
to the prostate (T1/2N0M0) (National Institute for Clinical Excellence 2002). Organ 
confined disease is unlikely to cause lower urinary tract symptoms, as tumours that are 
large enough to encroach on the urethra are usually locally advanced. Patients with 
localised disease are usually diagnosed following transrectal ultrasound guided biopsies 
performed as a result o f an abnormal feeling prostate on digital rectal examination 
(DRE) and/or an elevated serum prostate specific antigen (PSA). A minority are 
detected incidentally after transurethral resection of the prostate for benign prostatic 
hyperplasia. The proportion o f men diagnosed with cancer after TURP has fallen since ^ o
the introduction o f PSA testing. From the Utah hospital discharge database, cancer was ^  --'i'1' «■
— yi c
detected in 39% of men undergoing TURP between 1980-1984 compared with 7.4% ^—  . .  ^ , ,  ,
between 1995-1999 (Merrill & Wiggins 2002). In a recent UK series of 1001 men / .  / 
undergoing radical prostatectomy between 1988 and 2001 cancer diagnosed exclusively ^
/> /
on TURP tissue accounted for 5% of cases (Bott et al. 2005c), which compares with 6- >
K /
9% in other series (Quinn et al. 2001; Renshaw et al. 1999; van den Ouden et al. 1997).
A /
The mode of tissue diagnosis is relevant to findings in the radical specimen. Tumours 
diagnosed on TURP are more likely to represent transition zone cancer which is 
commonly of lower Gleason score than tumours arising in the peripheral zone (Bott et 
al. 2005c; Erbersdobler et al. 2002a; McNeal et al. 1988).
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1.7(b) Patient selection for radical prostatectomy
Patient selection involves correctly identifying those patients most likely to benefit from 
radical treatment. This is of paramount importance in men considered for radical 
prostatectomy where the desire to offer a potentially curative treatment has to be 
weighed up against the risk of finding disease outside the prostate where cure is less 
likely, or an insignificant tumour where cure is unnecessary.
Although there is no absolute means of identifying those individuals with pre-existing 
microscopic invasion o f extraprostatic tissue, methods are now available to establish 
those at highest risk. Preoperative risk factors have been combined to produce a 
statistical model which will predict pathological or biochemical outcome (Bott et al. 
2003c; Kattan et al. 1998; Partin et al. 2001).
1.7(c) Preoperative predictors of outcome 
1.7(c)!. Clinical Stage
V i f
The clinical stage is derived from the digital rectal examination (DRE) and imaging 
investigations. Assessment of clinical stage preoperatively is important as understaging 
prostate cancer may mean a patient receiving radical treatment with its inherent risk of 
complications without the benefit o f cancer cure, whereas to overstage denies a patient 
the chance for a potentially curative treatment.
Clinical stage is reported by some to predict pathological stage and biochemical 
outcome after radical prostatectomy (Hull et al. 2002; Partin et al. 2001), but not others 
(Babaian et al. 2001; Kattan et al. 2003; Stamey et al. 2000). In an update of Partin’s 
tables published in 2001 involving over 5000 men undergoing radical prostatectomy
63% had impalpable (T ic) prostate cancer and 46% had palpable but clinically localised 
disease (T2a-c) (Partin et al. 2001). At examination of the prostatectomy specimen 64% 
had organ confined disease, 30% extracapsular extension (pT3a), 4% seminal vesicle 
involvement (pT3b) and 2% lymph node positive disease. While the DRE incorrectly 
predicted organ-confined disease in 36% of men, it was a significant predictor of 
pathological stage in multinomial log-linear progression analysis (p<0.001) and was 
included in the tables. In van den Ouden’s series of 273 men 51% were clinically 
understaged and 8% overstaged (van den Ouden et al. 1997). Of note, 18% of men with 
cT3 disease were over-staged. This highlights the problem of current preoperative 
predictors of outcome. Men with clinical T3 disease may be denied radical therapy as 
cure is considered unlikely, but nearly one in five of these men will potentially be 
excluded from curative treatment because of staging inaccuracies.
Clinical stage may predict biochemical outcome after radical prostatectomy. In 
Catalona’s series o f 1778 men, non-progression was reported in 79% (95% Cl 73-86) 
with cTl disease, 66% (62-69) for cT2 tumours and 44 (22-67) in men with cT3 disease 
(Catalona & Smith 1998). The log rank test comparing clinical stage and cancer 
recurrence was significant (p<0.001). However, using multivariate analysis in this 
series, and in other series (Babaian et al. 2001; Kattan et al. 2003; Stamey et al. 2000) 
clinical stage was not an independent predictor of disease-specific survival.
In summary clinical stage does have some prognostic importance, particularly when 
used in conjunction with other predictors, it is a simple and ‘non-invasive’ procedure to 
perform. But, it lacks sensitivity and even when performed by specialist prostate 
surgeons DRE fails to be an independent predictor of pathological stage or biochemical 
outcome in most series.
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1.7(c)2. PSA
The preoperative PSA has been shown to be a useful predictor of pathological stage and 
biochemical outcome after radical prostatectomy in most series (Catalona & Smith 
1998; Hull et al. 2002; Partin et al. 2001; Quinn et al. 2001), but not all (Babaian et al. 
2001). In the Washington series, PSA was significant in both univariate and 
multivariate analysis at predicting cancer outcome at 7 years, despite some ‘high-risk’ 
patients receiving adjuvant radiotherapy in this series (Catalona & Smith 1998). Similar 
findings were reported by others in both univariate and multivariate analysis (Kattan et 
al. 2003; Quinn et al. 2001). Hull et al. reported the preoperative variables PSA, biopsy 
Gleason score and clinical stage were all independent predictors of extracapsular 
extension, metastatic-free survival and disease progression (Hull et al. 2002). When the 
pathological features from the radical prostatectomy specimen were included in the 
multivariate analysis only the pathological stage and surgical margin status were 
significant independent predictors of progression, not the preoperative features. In other 
series PSA has failed to predict biochemical outcome (Babaian et al. 2001).
The most frequently sited inflection points for preoperative PSA are at 4, 10 and 
20ng/ml (D'Amico et al. 2000b; Hull et al. 2002; Pound et al. 1997; Quinn et al. 2001). 
In the most recent version o f Partin’s tables the PSA groups were subdivided in to five 
categories: 0-2.5, 2.6-4, 4.1-6.0, 6.1-10 and >10 (Partin et al. 2001). In such a large 
cohort these subcategories contributed significantly to the prediction of pathological 
stage, in smaller series it is unlikely such narrow intervals would be predictive. In other 
predictive nomograms PSA is considered a continuous variable and such artificial 
grouping is avoided (D'Amico et al. 2000b; Kattan et al. 1998).
Serum PSA values may be altered by other factors including: benign prostatic 
hyperplasia, prostatitis, ejaculation, tumour volume and tumour differentiation, as well
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as differences in assay technique. Whilst attempts have been made to increase the 
specificity o f PSA by measuring the free:total ratio, the PSA density etc these have been 
found to add little to the diagnostic power of PSA. Furthermore, in patients with a PSA 
within the range 2.5-6.0ng/ml, increasing age is more strongly associated with incurable 
prostate cancer than the PSA level (Carter, Epstein, & Partin 1999). On the other hand 
in men with PSA below the standard cut-off of 4.0ng/nl the cancer detection rate was 
between 15% - 25%, in the ERSPC and SWOG series (Raaijmakers et al. 2004; 
Thompson et al. 2004). In men with a ‘normal’ age-related PSA the chance of finding 
an insignificant tumour at radical prostatectomy was greater than in men with a higher 
PSA, yet a significant number of men with a ‘normal’ PSA have adverse pathological 
findings (Freedland et al. 2004). These studies demonstrate PSA alone cannot 
differentiate patients with early organ confined cancer from those with extraprostatic 
disease. Recently the PSA velocity has been used to predict outcome, before and after 
radical treatment. D’Amico reported a pretreatment PSA velocity of >2ng/ml/year was a 
significant risk factor for recurrence after radical prostatectomy and was associated with 
a significantly shorter time to death from prostate cancer (D'Amico et al. 2004a). In a 
separate study the same authors showed that a PSA doubling time after RP or EBRT of 
<3months was a significant predictor of prostate cancer mortality (D'Amico et al. 
2004b).
1.7(c)3. Biopsy Gleason score
The biopsy Gleason score independently predicts tumour stage (Partin et al. 1997; 
Partin et al. 2001) and biochemical outcome (Kattan et al. 2003). In a multicentre series 
o f 4,133 cases, 83% of men who had biopsy Gleason score 8-10 had extraprostatic 
extension, 24% seminal vesicle involvement and 20% lymph node metastases. Whereas,
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38% of men with biopsy Gleason score 6 or less had extracapsular extension, 4% had 
seminal vesicle invasion and 3% had lymph node involvement (Partin et al. 1997). 
Gleason biopsy score was a strong predictor of pathological stage (Partin et al. 1997).
A report from the same centre categorised men into biopsy Gleason 2-4, 5, 6, 7, 8-10. 
Using Kaplan-Meier actuarial recurrence-free analysis; a significant difference in 
biochemical outcome was seen between each group, except between Gleason 7 and 8-10 
(p=0.05) (Partin et al. 1993).
Studies comparing Gleason score at biopsy and the Gleason score of the whole tumour 
at radical prostatectomy show an approximate 50% correlation, even though therapeutic 
decisions are often based heavily on the biopsy Gleason score (Bott et al. 2005c; Bott et 
al. 2003a; Carlson et al. 1998). Correlation is improved when the primary pathologist 
re-examines the specimen and also reviews the slides in conjunction with 2-5 specialist 
uropathologists (Carlson et al. 1998). In the setting o f the National Health Service this is 
not practical and so patients and doctors must be aware of the inherent inaccuracy o f a 
biopsy Gleason. In our own series the biopsy and radical scores were identical in 
252/536 (47%), the biopsy score being lower and higher than the radical score in 
170/536 (32%) and 113/536 (21%), respectively (Bott et al. 2005c). For the purposes of 
the database, the biopsy Gleason score was the summation of the highest two grades in -
a biopsy series rather than the overall Gleason sco based on area. The radical ^
prostatectomy Gleason score was composed of the two Gleason grades occupying the 
largest areas. The biopsy Gleason score equalled the radical score +/-1 in 487/536 
(91%) of patients. Percentage agreement between biopsy and radical Gleason score 
increased with the number of cores submitted (37% agreement with < 5 cores, 48% with 
6 cores, 56% with > 7 cores, p=0.006). There was no association between level of
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agreement and number o f cores containing cancer, longest length invaded with cancer in 
a single core and the highest percentage of a single core invaded with cancer.
Lack of correlation occurs because of inadequate sampling and interpretative error. 
Sampling error may occur as prostate cancer is heterogeneous, the biopsied tumour may 
not be the same as the two largest areas o f tumour in the radical prostatectomy 
specimen, which constitute the radical Gleason score. Interpretative error occurs as a 
result of mechanical artefact, for example Gleason 3 acini maybe compressed during 
paraffin embedding mimicking sheets of malignant cells typical of the Gleason 5 
pattern. Alternatively interobserver variation occurs due to differences in interpretation 
of architectural patterns as well as level o f expertise.
1.7(c)4. Biopsy features
While TRUS alone is an insensitive tool for diagnosing and staging prostate cancer 
TRUS guided prostatic biopsies may be used to predict extracapsular disease and 
biochemical outcome. The number o f positive cores (Badalament et al. 1996; D'Amico 
et al. 2000b; Grossfeld et al. 2002), tumour location (base vrs mid vrs apex) 
(Badalament et al. 1996), percent tumour involvement (Badalament et al. 1996), highest 
Gleason score and presence o f Gleason 4 or 5 have all been used as preoperative staging 
tools (Orozco et al. 1998). The best predictor of outcome is the proportion of cores 
positive for cancer (Bostwick et al. 2000). In a validated series of 960 men, D’Amico 
reported of men with <34, 34-50 or >50% positive cores 79%, 59% and 43% had organ- 
confined disease, and the actuarial biochemical outcome at 4 years after surgery was 
86%, 48%, and 20%, respectively (D'Amico et al. 2000b). The percentage number of 
positive biopsy cores was an independent predictor of time to PSA progression. The use 
of the number of positive cores requires careful histological processing as the submitted 
specimens may not be whole or may fragment during fixation and embedding. Separate
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specimen pots and separate paraffin blocks for each core are usually required if the 
number of positive cores are to be used for prognostic information.
1.7(c)5. Preoperative imaging
The ability of imaging modalities to correctly stage prostate cancer remains limited. 
Extracapsular extension is often microscopic and current techniques are not of sufficient 
resolution to detect small breaches in the capsule. The apex of the prostate is the most 
frequent site for extracapsular disease but as the capsule is ill-defined in this region 
(31), it is difficult to distinguish extracapsular from organ-confined tumour. Where 
macroscopic tumour extension is present magnetic resonance imaging (MRI) is the most 
sensitive and specific technique available; nevertheless there is still a high rate of false 
positives as well as considerable interobserver variability (Table 1.3).
Table 1.3. Comparison of body coil and endorectal coil magnetic resonance 
imaging at detecting extracapsular extension of prostatic cancer.
Author Number Sensitivity Specificity Tesla Mode
Bott 2003 46 42% 78% 1 Bodycoii
Comudl002 30 66% 94% 1.5 Body coil
Deasy 1007 53 55% 91% 0.2 Bodycoii
Rifkin 1990 230 77% 57% 1.5 Bodycoii
Tuzel 109$ 61 38% 87% 1 Endorectal coil
Bates 1997 20 38% 100% 0.5 Endorectal coil
Tempany 1004 201 61% 62% 1.5 Body coil
Temparty 1994 183 60% 42% 1.5 Endorectal coil
(Bott et al. 2003b), (Comud et al. 1992), (Deasy et al. 1997), (Rifkin et al. 1990), (Tuzel 
et al. 1998), (Bates et al. 1997), (Tempany et al. 1994).
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D’Amico et al. suggested a role for endorectal MRI (eMRI) in predicting biochemical 
outcome after radical prostatectomy. While eMRI failed to add any useful clinical 
information in 81 % of over a thousand cases, it was clinically and statistically relevant 
in the 5-year PSA outcomes in the remaining ‘intermediate risk’ group (D'Amico et al. 
2000a). Others have highlighted the accuracy of MRI varies according to the expertise 
of the individual radiologist (Tempany et al. 1994), so the results achieved by D’Amico 
et al. need to be replicated in other centres. In a meta-analysis of MRI in prostate cancer 
staging it was noted there was significant heterogeneity of MRI results, in expert hands 
MRI improves staging performance (Engelbrecht et al. 2002)
Other modalities including transrectal ultrasound (TRUS) and pelvic CT are not 
sufficiently accurate to detect extracapsular extension. TRUS was no better than DRE in 
predicting extracapsular extension in a prospective multicentre study (Yu & Hricak 
2000). CT has a reported sensitivity o f between 55-75% at detecting extracapsular 
extension (Huncharek & Muscat 1996; Manyak & Javitt 1998). In a review of 25 
studies incorporating 4264 men with newly diagnosed prostate cancer who underwent 
staging CT, 0 and 1.1% of patients with PSA <20ng/ml and >20ng/ml, respectively had 
pelvic lymphadenopathy on CT crtiteria (Abuzallouf, Dayes, & Lukka 2004). CT is 
therefore not indicated for the vast majority of men being considered for radical 
prostatectomy, though may be of use in men with Gleason 8-10 or locally advanced 
cancer (American Urological Association (AUA) 2000).
Radio-isotope bone-scanning is a non-invasive tool for diagnosing bone metastases. In
newly diagnosed clinically localised prostate cancer, where the incidence of metastases
is rare and where present usually of low volume, bone-scans are unwarranted. In a
review of 8644 men in who 16.8% had positive scans, metastases were identified in 5%
of men with a PSA <20ng/ml and 2% in men with PSA <10ng/ml (Abuzallouf, Dayes,
& Lukka 2004). Men with clinically organ-confined disease had positive scans in 6% of
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cases and men with Gleason score <7, 5% had a positive scan. This and other studies 
therefore recommend staging bone scans in men with PSA exceeding 20ng/ml or with 
Gleason score 8 or above or in men with locally advanced disease (T3/4) (Abuzallouf, 
Dayes, & Lukka 2004; American Urological Association (AUA) 2000).
Positron emission tomography (PET), a non-invasive imaging modality, has been 
investigated for its use in staging prostate cancer. It relies on the increased uptake in 
tumours of a radiolabelled choline, flurine or glucose analogue and prostate cancer 
epithelial cells do not metabolise these compounds at a sufficent rate for detection. This 
technique is still under evaluation in prostate cancer, however it is likely only to be of 
benefit in the staging of prostate cancer that has metastasised as the false positive rate 
for extracapsular disease is unacceptably high (DeGrado et al. 2001; Hoh et al. 1998). In 
practice, radiological evidence o f extra-capsular disease is usually sought only in those 
men with a high risk -  those with a PSA >20ng/ml or with a Gleason score of 8 or
1.7(c)6. Circulating prostate cells
Several groups have tried to use preoperative PSA reverse transcriptase polymerase 
chain reaction (RT-PCR) positivity of blood to predict the likelihood of recurrence after 
radical prostatectomy. Some have found a positive correlation using this technique 
(Olsson et al. 1996) others have not (Ellis et al. 1998), further studies are awaited.
1.7(c)7. PSA density, PSA free:total ratio, PSMA
The PSA density (total PSA divided by the prostate volume), and the PSA free:total 
ratio (free PSA divided by the free PSA and the PSA bound to al-chymotrypsin) are
more
O*
43
assays used to try and enhance the sensitivity and specificity of PSA prostate cancer 
detection. To date however studies have not been conclusive in demonstrating 
prognostic potential over and above total PSA measurement (Epstein et al. 1994; 
Pannek et al. 1998; Raaijmakers et al. 2004; Ravery et al. 2000).
Newer techniques are evolving in an attempt to augment or improve on the ‘classical 
three’ preoperative predictors (biopsy Gleason grade, clinical stage and preoperative 
PSA score). Kattan et al. has included molecular markers, including Interleukin-6 
soluble receptor and Transforming Growth Factor betal, into nomograms used to 
predict biochemical failure after radical treatment and has demonstrated their 
independent prognostic importance (Kattan et al. 2003). Human kallikrein 2 (Hk2) has 
also been shown to predict organ confined disease after radical prostatectomy (Haese et 
al. 2003). DNA ploidy from prostatic biopsies has been reported as an independent 
predictor of outcome after radical prostatectomy (Ross et al. 1999), though this 
investigation is not available in most centres. To date the tables devised by Partin 
remain the most useful in the clinic as they incorporate easily obtainable variables 
combined to make simple-to-use tables. In the future, as in breast and other cancers, 
molecular markers are likely to replace the ‘classical’ triad by providing greater 
predictive capacity.
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1.8 Post-operative predictors of outcome
Currently available prognostic factors have been ranked by a multidisciplinary group of 
clinicians, pathologists and statisticians and subsequently endorsed by The World 
Health Organisation's Second International Consultation on Prostate Cancer (Bostwick 
et al. 2000). Category I are factors of proven prognostic importance and are currently 
used in patient management. These include the preoperative PSA, the TNM stage, the 
Gleason grade and the surgical margin status. Category II factors are those that have 
been extensively studied but whose importance remains to be validated in statistically 
robust studies e.g. tumour volume, histological type and DNA ploidy. Category III 
include all other factors not studied sufficiently to demonstrate their prognostic value - 
oncogenes, tumour suppressor genes, apoptosis genes as well as perineural invasion, 
neuroendocrine differentiation, microvessel density, nuclear roundness and chromatin 
texture (Bostwick et al. 2000).
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Table 1.4. Risk factors for recurrence after radical prostatectomy 
(Bostwick et al. 2000)
Pre-operative factors
Higher clinical stage 
Biopsy Gleason containing 4 or 5 
Pre-operative PSA >10ng/ml 
Greater number of positive biopsy cores
Post-operative features 
Category I
Higher stage 
Higher Gleason score 
Positive surgical margins 
Category II 
DNA ploidy 
Tumour volume
Histological type (signet ring, sarcomatoid, mucinous) 
Category III
Tumour suppresser genes 
Oncogenes 
Perineural invasion 
Neuroendocrine differentiation 
Microvessel density
Nuclear roundness and chromatin texture
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1.8(a) The Radical Prostatectomy Gleason Score
Gleason demonstrated a strong correlation between his grading system and patient 
mortality (Gleason & Mellinger 1974). Nowadays, the Gleason score is accepted as one 
of the most important predictors o f tumour stage, progression and survival (Babaian et 
al. 2001; Catalona & Smith 1998; Epstein, Pizov, & Walsh 1993; Gerber et al. 1996; 
Gleason 1992; Stamey et al. 2000; Steinberg et al. 1997). Epstein et al. categorised 
Gleason patterns after radical prostatectomy into four groups, Gleason sum 2-4, 4-6, 7 
and 8-9, in their series of 507 men (Epstein, Pizov, & Walsh 1993). There was no 
difference in terms of local progression or overall survival between men with Gleason 
scores 2-4 or 4-6. However, there was a highly significant difference between men with 
Gleason 2-6 compared with Gleason sum 7 or Gleason sum 8-9 (p<0.0001). There was 
also a highly significant difference between Gleason 7 and Gleason 8-10 (p=0.001) in 
local and overall progression. In this series, like several others (Gerber et al. 1996; 
Lemer et al. 1996; Zincke et al. 1994), the Gleason sum was the prognostic factor most 
strongly correlated with overall and local progression (p=0.0001).
Catalona reported on a series o f 1778 men who had undergone radical prostatectomy, 
using the log rank test the radical Gleason sum was a significant predictor of survival 
(Catalona & Smith 1998). The 7-year probability of nonprogression was 84% (79-89) 
for well differentiated (Gleason 2-4), 68% (64-73) for moderately differentiated 
(Gleason 5-7) and 48 (39-57) for poorly differentiated (Gleason 8-10) tumours. This 
study also highlighted the impact of high tumour grade on survival. O f the 103 men 
who had died of any cause, including those who died of prostate cancer, high tumour 
grade versus moderate or well differentiated was a significant predictor of death 
(p<0.0001). Other authors have also found only poorly differentiated tumours to be
independent predictors o f outcome in multivariate analysis (Stamey et al. 2000; van den 
O udenetal. 1997).
1.8(b) Pathological stage
The pathological stage of the radical prostatectomy specimen describes the extent of the 
tumour and when lymphadenectomy is performed the presence or absence of obturator 
lymph node metastases. The presence of capsular penetration - stage pT3a disease, is 
associated with poorer outcome than organ confined disease (Babaian et al. 2001; 
Paulson, Moul, & Walther 1990; Stamey et al. 1999; van den Ouden et al. 1997). 
Babaian et al. reported 5.4% of men with organ-confined disease, 17.8% with 
extraprostatic cancer extension and 61% with seminal vesicle invasion developed 
disease progression using Kaplan Meier outcome curves (Babaian et al. 2001). Quinn et 
al. reported their multivariate analysis of 732 Australian men who had undergone 
radical prostatectomy. Independent predictors of outcome in descending order were 
lymph node metastases, pT3 vrs pT2, seminal vesicle invasion, Gleason score and 
preoperative PSA (Quinn et al. 2001). Van den Ouden et al. reported capsular 
penetration (pT2 versus pT3) was a significant predictor of biochemical progression and 
clinical progression, but not cause specific survival (RR 2.5, 2.6, 2.4, respectively) (van 
den Ouden et al. 1997). Despite seminal vesicle involvement in 29% of cases in this 
study and lymph node metastases in 10% neither was an independent predictor in 
multivariate analysis, probably as there were only a few deaths from prostate cancer 
during the follow-up period.
Not all researchers however have found local pathological tumour stage to be an 
independent prognostic marker. Lemer et al. reported their series of nearly one thousand 
patients (Lemer et al. 1996). They found preoperative PSA, grade, DNA ploidy and
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clinical stage were highly significant indicators of progression in univariate analysis 
but, pathological stage and patient age did not significantly impact on progression free 
survival.
Stage pT3a can be further sub-classified into focal capsular penetration - where a few 
acini breach the ‘capsule’, or extensive capsular penetration where disease spread is 
more widespread, and these differences have prognostic implications. The results of the 
actuarial 5- and 10-year likelihood of freedom from PSA relapse in 894 men after 
radical prostatectomy for clinically localised prostate cancer according to pathological 
stage from the Johns Hopkins are shown in Table 1.5 (Partin et al. 1993).
Table 1.5. Actuarial biochemical free survival and prostate tumour stage 
(Partin et al. 1993)
Pathological stage Actuarial percentage (95%C1)
5 years 10 years
Organ confined 97 (94-99) 85 (67-94)
Focal capsular penetration 90 (84-95) 82 (82-90)
Established capsular penetration, low grade 88 (81-93) 54 (20-80)*
Established capsular penetration, high grade 68 (53-80) 42 (20-64)
Seminal vesicle involvement 47 (31-63) 43 (26-60)
Lymph node involvement 15 (6-29) -
* Eight year statistics
The Kaplan-Meier actuarial likelihood of PSA relapse was significantly different 
between stages. There was a significant difference between men with focal capsular 
penetration of any Gleason score and men with high-grade (Gleason >7) extensive
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capsular penetration, but not men with low-grade (Gleason <7) and extensive capsular 
penetration (p=0.06). Interestingly there was no significant difference in actuarial 
likelihood o f PSA relapse between men with extensive high-grade capsular penetration 
and those with seminal vesicle involvement (p=0.02). Not all studies have found the 
extent of extraprostatic pT3a disease to be significant (Babaian et al. 2001) and an 
agreed definition of focal and extensive capsular penetration is lacking (Bostwick et al.
The commonest site of capsular penetration is ir
bundles, posterolateral to the prostate. The neurovascular bundles contain the 
parasympathetic nerves to the corpora and lie outside the fibromuscular condensation 
or ‘capsule’ o f the prostate. Catalona and Bigg reported that all men who had 
extracapsular extension in the region of the neurovascular bundles also had positive 
surgical margins (Catalona & Bigg 1990). In men with induration in or around the 
lateral pedicle, wide excision o f the neurovascular bundle on that side did improve the 
chances of negative surgical margins and decrease the risk of disease recurrence; 
although using this criteria 30% of patients would have their neurovascular bundles 
excised unnecessarily as the cancer is organ confined (Graefen et al. 1998). Pound et al. 
compared the actuarial recurrence-free probabilities according to tumour stage and 
margin status in men potent and impotent postoperatively (Pound et al. 1997). The 
groups were similar for age, Gleason grade and stage. With all stages there was no 
difference in actuarial recurrence-free probability between the potent and impotent 
men. In appropriately selected patients nerve sparing can be performed without 
compromising cancer outcomes (Pound et al. 1997; Ward et al. 2004).
2000)
The pathological definition of seminal vesicle invasion is not standardised. Some report 
tumour in the peri-seminal vesicle fat as seminal vesicle invasion whilst others equate
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invasion only once tumour involves the muscle wall, most reports do not stipulate 
which definition was used. This has led to variation in the prognostic importance of 
seminal vesicle invasion. Most studies demonstrate only lymph node metastases 
exceeds the adverse prognosis associated with seminal vesicle invasion (D'Amico et al. 
1995; Pound et al. 1997; Quinn et al. 2001). Seminal vesicle invasion was found in 6- 
29% of men in reported radical prostatectomy series (D'Amico et al. 1995; Linzer et al. 
1996; Pound et al. 1997; Sofer et al. 2003; van den Ouden et al. 1997) and in 10% of 
men in the UCL database (Bott et al. 2005c). The biochemical progression free rate is 5- 
60% at 5 years (D'Amico et al. 1995; Pound et al. 1997; Sofer et al. 2003), the wide 
range reflecting the differences in definition of invasion.
Lymph node metastases found at radical prostatectomy are associated with an 
unfavourable prognosis (Catalona & Smith 1998; Epstein, Pizov, & Walsh 1993; 
Gervasi et al. 1989; Hull et al. 2002; Quinn et al. 2001; Stamey et al. 1999), 
independent of the volume o f metastatic malignant tissue (Gervasi et al. 1989). In many 
series using multivariate analysis lymph node metastases are the most significant 
predictors of progression (Hull et al. 2002; Quinn et al. 2001), and almost all men found 
to have nodal metastastese ultimately develop disease progression (Epstein, Pizov, & 
Walsh 1993).
The TNM system classifies invasion into a neighbouring structure as stage T4 disease. 
Invasion into the bladder is a rare event at radical prostatectomy and is associated with a 
poor outcome, bladder neck involvement will be discussed as a positive surgical 
margin.
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1.8(c) Positive surgical margins
A positive surgical margin is defined as the presence o f tumour at the inked surface of 
the resected specimen (Catalona & Smith 1998; Freedland et al. 2003; Ohori et al. 1995; 
Stamey et al. 1990) and implies incomplete excision of malignant tissue. An average of 
f  those undergoing radical prostatectomy are found to have positive surgical 
margins, although later series have a lower margin positive rate (Bott & Kirby 2002).
Stamey et a l subdivided positive surgical margins into two groups (Stamey et al. 1990). 
In the first group the cancer is cut through when it is outside the prostate boundaries 
into the fat, having penetrated the capsule -  a positive extraprostatic margin (Figure 
1.4c). In the second group the cancer is cut through inside the glandular area of the 
prostate due to inadvertent surgical incision of the periprostatic fascia and prostate 
capsule, which are missing from histological specimen -  a positive intraprostatic or 
iatrogenic margin (Figure 1.4b). The first group may be further subdivided into focal -  
where limited tumour reaches the inked limit in one or two sites, or extensive -  where 
multiple positive margins were present at different sites in the prostate (Blute et al. 
1998; Gleave et al. 1999). Epstein et al. demonstrated significantly different progression 
rates between those with negative (Figure 1.4a) compared with equivocal 
(intraprostatic positive margin), focal and extensive extraprostatic surgical margins 
(Epstein, Pizov, & Walsh 1993). However, the sub-classification of positive margins 
has not been standardised (Bostwick et al. 2000).
Several sites are designated with margin status, including the apex - the urethral limit, 
the base -  which includes the bladder neck margin, vasal and circumferential - anterior, 
lateral, rectal or posterior surface. The overall incidence o f positive surgical margins is 
very similar for each of the three approaches to radical prostatectomy - the retropubic,
perineal and laparoscopic (transperitoneal and retroperitoneal). However, the location of 
the positive margin varies. The apex is the most common site for positive margins in the 
retropubic and both laparoscopic approaches, whilst the anterior prostate is the most 
common site for the perineal approach (Abbou et al. 2000; Barocas et al. 2001; Blute et 
al. 1997; Bott et al. 2005c; Bott & Kirby 2002; Cathelineau et al. 2004; Epstein, Walsh, 
& Brendler 1994; Guillonneau & Vallancien 2000; Van Poppel et al. 1995; Watson, 
Civantos, & Soloway 1996; Weldon et al. 1995). Table 1.6 shows the incidence and site 
o f positive margins.
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Table 1.6. The site of non-iatrogenic (extraprostatic) solitary positive surgical 
margins after radical prostatectomy(Abbou et al. 2000; Bott & Kirby 2002; 
Epstein, Walsh, & Brendler 1994; Guillonneau & Vallancien 2000; Van Poppel et 
al. 1995; Watson, Civantos, & Soloway 1996; Weldon et al. 1995)
Author Stage
No. of 
margins
% site of solitary positive surgical margin
Apical Anterior Posterior Lateral Postero­
lateral
Bladder
neck
Other
Radical retropubic prostatectomy
Epstein
1994
Tic 29 31
shave
24 10 7 24 3
Watson
1996
T ic 17 59
shave
6 18 18
Van
Poppel
1995
T3 19 37
cone
53 10
Bott
2002
Tlc-T3 131 79
shave
16 2 2
Radical perineal prostatectomy
Weldon
1995
Tl-2 88 7
cone
25 - - 16 7 45
Laparoscopic radical prostatectomy
Abbou
2000
T2-3 4 50 50
(The cone and shave are two methods for deriving apical margin status. The cone 
technique involves amputating the distal 1.5cm of the prostate and the tissue is 
sectioned in a sagittal plane, with the urethra at the centre. Using the shave technique a 
section is taken for the most inferior part of the apicalparaffm block. The cone 
technique allows examination of the prostate at its most distal limit, although only 5pm 
for every 3-5mm section of the distal margin are examined histologically. The shave 
technique on the other hand is simpler and less time-consuming to perform and the 
entire surface area of the distal margin is examined).
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Figure 1.4 a) Low power of radical prostatectomy wholemount 
section dem onstrating organ confined prostate cancer (EPT = extra- 
prostatic tissue, E = edge of prostate, CAP = prostate cancer)
CAP
Figure 1.4 b) Low pow er of radical prostatectomy w holemount 
section dem onstrating an intraprostatic positive surgical margin
(CAP = nrostate cancer. IM = inked marpin'l
CAP
IM
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Figure 1.4 c) Low power of radical prostatectomy w holemount section 
dem onstrating extraprostatic carcinoma w ith a positive surgical margin (EPT = 
extra-prostatic tissue, E = edge of prostate, CAP = prostate cancer)
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Patients with positive surgical margins are at a significant risk of biochemical relapse -  
50-60% at 5 years, and subsequent clinical relapse, although by no means every patient 
will suffer eventual disease recurrence (Cheng et al. 1999; Epstein et al. 1996; Ohori et 
al. 1995; van den Ouden et al. 1993). Epstein et a l , reported 79% of men with negative 
margins were progression free over a 10-year period compared with 55% of those with 
positive margins (p<0.00001) (Epstein et al. 1996). The Johns Hopkins group 
subsequently demonstrated the effect o f Gleason grade on outcome in men with positive 
margins. They reported that positive surgical margins had no impact on 10-year 
probability o f biochemical recurrence in men with Gleason score less than 7. However, 
men who had a Gleason score of 7 and positive surgical margins did significantly worse 
than those with extracapsular extension and negative margins (Epstein et al. 1998).
Grossfeld et al. calculated that, after adjusting for PSA, pathological tumour stage and 
Gleason grade, patients with positive margins were 2.6 times more likely to have 
disease recurrence than those with negative margins (Grossfeld et al. 2000a). 
Furthermore patients with positive margins were significantly more likely to receive 
adjuvant or non-adjuvant secondary treatment (p=0.0001). Stamey et al. however 
contested these findings, stating that margin status is not an independent predictor o f 
failure after radical prostatectomy when adjusting for the percent of Gleason 4 and 5 
cancers, tumour volume and lymph node status (Stamey et al. 1999).
Cheng and co-workers examined the correlation between margin status and PSA relapse
in a series of 377 patients from the Mayo Clinic (Cheng et al. 1999). Their overall
margin positivity rate was 29%; 19% of patients had positive margins without
extracapsular disease (intraprostatic), 14% had extracapsular extension with negative
margins and 10% had both extracapsular extension and positive margins. Men with
organ confined disease and negative margins had a 90% 5-year progression-free
survival. In the cohort with positive margins the 5-year progression-free survival was
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78% for those without extracapsular extension and 55% for those with extracapsular 
extension.
Other authors have shown intraprostatic positive margins have little or no effect on 
outcome, at least in the medium term (Blute et al. 1998; Ohori et al. 1995). Ohori et al. 
reported 100% of men with intraprostatic positive margins were free from tumour 
recurrence after 5 years compared with 42% with positive margins and extracapsular 
extension (Blute et al. 1998). Barocas et al. compared 91 cases who had isolated 
intraprostatic margins with three groups matched for age, Gleason grade, preoperative 
PSA and clinical stage, at the Johns Hopkins (Barocas et al. 2001). Their follow-up was 
on average only 31 months, but they were able to show a 4.3% recurrence rate for men 
with organ-confined prostate cancer, 9.8% for specimen confined, margin negative 
cases, 10.9% for men with a positive intraprostatic surgical margin, but otherwise organ 
confined disease, and a 25% relapse rate for men with extracapsular disease and positive 
surgical margins. They concluded, from this small series, that inadvertent capsular 
incision, resulting in a positive intraprostatic limit, gave similar PSA outcomes to 
specimen-confined disease.
Features including the location, extent and number of positive margins may have an
impact on disease recurrence (Table 1.7) (Blute et al. 1997; Obek et al. 1999). From
The UCL database the positive margins o f 347 patients operated on by a single surgeon
were examined (Bott et al. 2003d). Apical margins were associated with a lower
incidence of PSA recurrence than other sites after a median 24 months (range 1 -89).
Solitary margins had lower recurrence rates (22%) than multiple positive margins
(53%). This is in agreement with the literature. Blute et al. reported that the site of
positive margins was a significant predictor of progression (Blute et al. 1997). Patients
with pT2N0 disease who had a single margin at either the apex/urethra or
anterior/posterior prostate or multiple positive margins in these sites had only slightly
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decreased clinical recurrence or PSA failure rates compared with patients with negative 
margins at 5 years (79%, 78%, 68% compared with 86% with negative margins). 
However, patients in whom the prostate base limit was positive had significantly lower 
clinical or PSA failure free rates - 56% at 5 years. The risk of PSA progression was 1.68 
times higher in men with positive margins after matching for Gleason score, pre­
operative PSA and DNA ploidy in this series.
Table 1.7. Biochemical recurrence and positive surgical margins
Margin status PSA recurrence
Bott 2003 Blute 1997 Obek 1999
AU margins- 14% 14% 7%
Single apical + 22% 21% *29%
Any single* 24% 23% 24%
Multiple+ 53% 32% (2) 43%
Number n=347 n=2334 n=495
Follow-up (snaths) 24 60 25
(Blute et al. 1997; Bott et al. 2003d; Obek et al. 1999)
* apical +/- other positive margins
Obek et al. reported similar findings from their series from Miami of 495 men with
clinical T1-T3 disease who underwent radical prostatectomy (Obek et al. 1999). After a
mean follow-up of 25.3 months their recurrence rate was significantly higher in men
with positive compared with negative surgical margins, 27.8% versus 6.9%
respectively, despite a quarter o f margin positive cases receiving adjuvant androgen
deprivation. These were not isolated margins and patients with other adverse
pathological features, such as seminal vesicle and lymph node involvement were
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included. However, they concluded that time to recurrence was shorter in patients older 
than 70, with a Gleason score of 7 or more, seminal vesicle invasion, multiple positive 
margins and a positive margin at the bladder neck or the posterolateral surface of the 
prostate. O f men with multiple positive margins 43% developed disease recurrence, 
compared with 24% of men with a single positive margin.
Solitary bladder neck margins occur in less than 5% of radical prostatectomy specimens 
(Soloway & Neulander 2000; Watson, Civantos, & Soloway 1996) and in the UCL 
radical prostatectomy database a bladder neck margin was the solitary positive margin 
in 10 (1%) of 968 cases (Bott et al. 2005c). Bladder neck involvement is almost 
invariably associated with adverse prognostic factors including large tumour volume, 
high preoperative PSA, high Gleason score, seminal vesicle involvement and lymph 
node metastases (Wieder & Soloway 1998).
Positive vas deferens margins are also associated with a poor prognosis. From the UCL 
Radical Prostatectomy series of 1001 men 16 (1.5%) had positive vasal margins, all 
these men also had positive seminal vesicles. In a series of 105 men undergoing radical 
prostatectomy 7 (6.7%) cases had vasal involvement; in these patients there was a 
significant correlation with seminal vesicle involvement, extracapsular extension, 
extensive carcinoma, Gleason score 7-10 and positive bladder neck margins. In this 
small series all five men with follow-up developed disease recurrence (Billis A, Freitas 
LLL, & Magna LA 2002).
Several groups have highlighted the prognostic difference between a focal compared 
with an extensive positive margin (Babaian et al. 2001; Epstein et al. 1996; Wieder & 
Soloway 1998). They reported focal margins were associated with recurrence in 40% 
and extensive margins had a 65% risk o f progression after 5-years follow-up (Epstein et
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al. 1996). In summary the site, number and extent of positive surgical margins all 
provide valuable prognostic information.
1.8(d) Tumour volume
O f the 998 cases with tumour volume measurements in the UCL database the median 
tumour volume was 2 ml, ranging from atypical acini (too small to measure) to 31 ml 
(Bott et al. 2005c). Some authors report tumour volume to be a significant independent 
predictor of disease relapse (Humphrey & Vollmer 1997; Renshaw et al. 1999; Stamey 
et al. 2000), though others contest these findings (Epstein et al. 1993; Salomon et al.
2003). This may reflect the different zone of origin of the tumour. Tumours arising in 
the transition zone tend to be larger (Stamey, Dietrick, & Issa 1993) but of lower grade 
and have lower risk of progression than peripheral zone tumours (Grignon & Sakr 1994; 
Noguchi et al. 2000). In studies where cancers of both peripheral and transition zone 
tumours are included, the tumour volumes may not be significant. In the one study 
where only the prognostic features o f peripheral zone tumours were examined the 
tumour volume was an independent predictor of disease relapse (Stamey et al. 2000). 
PSA concentrations correlate significantly with volume of prostate cancer in radical 
prostatectomy specimens (Stamey et al. 1989), it may be that in multivariate analysis 
involving PSA and tumour volume, tumour volume is not an independent variable. 
Tumour volume remains a category 2 prognostic factor.
1.8(e) Lymphovascular invasion
Overall lymphovascular invasion is reported in 5.2-13.2% of cases (Quinn et al. 2001;
Stamey et al. 2000; van den Ouden et al. 1997) and 9.1% in the UCL series. It is
strongly associated with Gleason score, pT stage, tumour volume and lymph node status
(p<0.001) (McNeal & Yemoto 1996). Vascular invasion has been found to be both the
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most significant risk factor (van den Ouden et al. 1997) and a significant but not an 
independent variable (Babaian et al. 2001; Stamey et al. 2000) for disease progression 
following radical prostatectomy. Many large series do not report invasion into the 
lymphatic of vascular spaces, further reports are required before this becomes a 
recognised independent prognostic feature.
1.8(f) DNA ploidy
Benign prostate cells and tumours of low stage and grade are diploid, as assessed by 
static or flow cytometry. As prostate cancer progresses several copies of the DNA 
within a single cell may be found -  aneuploid. Patients with aneuploid tumours have 
reduced survival and several authors report that DNA ploidy is an independent predictor 
of progression (Adolfsson 1994; Shankey et al. 1993). Furthermore, DNA ploidy status 
at biopsy can be used to predict ploidy status at radical prostatectomy (Ross et al. 1999). 
Despite these findings DNA ploidy remains a Category 2 prognostic factor, probably as 
the technology to assess ploidy status is not widespread and so multi-centre 
confirmation of its prognostic value is lacking.
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1.9 Neoadjuvant androgen deprivation
Neoadjuvant androgen deprivation has been shown to reduce the incidence of positive 
surgical margins and extracapsular disease in a number of studies (Goldenberg et al. 
1996; Lee, Warde, & Jewett 1999; Montironi et al. 1999; Soloway et al. 1995). This 
may be because the whole prostate shrinks allowing wider resection margins, down- 
staging of the tumour itself or because of difficulties with accurate pathological 
assessment after hormonal treatment (Wieder & Soloway 1998). However, there is no 
evidence from long-term prospective randomised trials that neoadjuvant androgen 
deprivation has any effect on biochemical relapse or survival (Goldenberg & et al 1997; 
Lee, Warde, & Jewett 1999; Soloway & et al 1997). Furthermore difficulties may arise 
giving the prostate specimen a reliable Gleason grade as androgen withdrawal affects 
the glandular architecture, so important prognostic information may be lost. Given the 
current data the routine use of neoadjuvant androgen deprivation before radical 
prostatectomy is unjustified (Lee, Warde, & Jewett 1999).
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1.10 Management of recurrent disease after radical prostatectomy
The incidence of prostatic cancer has remained fairly static over the last 8-10 years 
while the proportion of men with recurrent disease after radical treatment has fallen.
The advent of PSA testing in the late 1980s has meant more men are diagnosed and 
treated with lower stage disease, both in the US (Han et al. 2001) and in the UK (Bott et 
al. 2005c). The proportion of men from the radical prostatectomy databases held at 
University College London with organ confined disease rose significantly, from 30% 
between 1988 and 1991 to over 50% in 2001(p<0.001) (Bott et al. 2005c). Despite this 
‘stage migration’, 27-53% of men will develop prostate specific antigen (PSA) 
recurrence up to 10 years after radical prostatectomy (Hull et al. 2002; Pound et al. 
1997; Quinn et al. 2001; Trapasso et al. 1994; Zincke et al. 1994) and 16-35% of 
patients receive second-line treatment within 5 years of surgery (Fowler, Jr. et al. 1993; 
Lu-Yao et al. 1996). After radical prostatectomy half the men treated for recurrent 
disease receive external beam radiotherapy (EBRT) to the prostatic bed, with curative 
intent. In contrast, over 90% of men with relapse following radical radiotherapy receive 
palliative hormonal manipulation. This reflects the limited therapeutic options ^
patients who have had radical radiotherapy or brachytherapy, though this may 
with the increasing role o f salvage cryotherapy, salvage brachytherapy and in some
n
cases salvage prostatectomy. ^  .AW?*
64
1.10(a) Definition and timing of relapse
Following surgery the PSA should fall to undetectable levels within 4 weeks, given the 
half-life of PSA is 3.15 days (Oesterling et al. 1988). A PSA nadir that is not 
‘undetectable' represents either residual benign tissue or local/metastatic malignant 
prostatic tissue. A rising PSA following a detectable nadir is likely to represent 
metastatic disease.
There is no universally agreed PSA cut-off to define ‘recurrent disease’ following an 
undetectable PSA nadir (Bott 2004). This is because different assays have differing 
sensitivities and the contribution of residual benign glands to a postoperative PSA 
remains unresolved. The conventional assay, the Hybritech (Tandom-R), has a detection 
threshold o f O.lng/ml. Using this assay, Epstein et al. proposed a cut-off as >0.2ng/ml, 
given that 53% of men with this PSA value eventually develop clinical progression 
(Epstein, Pizov, & Walsh 1993). Lange et al. proposed a higher cut-off o f 0.4ng/ml as 
all men with a postoperative PSA at this level had detectable disease progression within 
49 months of surgery (Lange et al. 1989). The introduction of ultra-sensitive assays 
which are able to detect PSA to O.Olng/ml has meant men being diagnosed and treated 
for recurrence before their PSA reaches O.lng/ml (Doherty et al. 2000). While at this 
level potentially curative treatment is expedited there is at least a theoretical risk of 
treating residual benign glands only.
The seminal paper by Pound et al. demonstrated the extended period between 
biochemical failure after RP and the development of clinical progression (Pound et al.
1999). The median time for the 315 of 1,997 men to develop PSA relapse, defined as a 
serum value o f at least 0.2ng/ml, was 2.3 years. O f the 34% of these men who 
subsequently developed metastases, the median actuarial time to do so was 5 years from
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the time of PSA progression. Once men developed metastases the median time to death 
was just under 5 years (Pound et al. 1999). The probability and time to develop 
metastases was dependent on the Gleason score (5-7 or 8-10), the time to biochemical 
progression (>2 or <2 years) and the PSA doubling time (>10 or <10months). Using 
these variables ‘Pound tables’ have been constructed to predict the likelihood of clinical 
disease progression in men with biochemical recurrence after radical prostatectomy.
1.10(b) Site of relapse
The decision of what and when to treat depends on whether disease progression is 
confined locally to the prostatic fossa or whether distant spread has occurred. Local 
relapse alone occurs in 50% of cases and metastases with or without local recurrence in 
50% (Pound et al. 1997). Clinical and imaging modalities currently available are not o f ,
examination is not useful if men have an undetectable PSA (Pound et al. 1999) and is 
only sensitive once the PSA has been elevated for a median 2.3 years after surgery (Bott
2004). Less than 5% of bone-scans are positive until the PSA value is above 40-45ng/ml 
(Cher et al. 1998a). CT scans are not sufficiently sensitive at detecting local recurrence 
until the PSA is increasing by a rate o f more than 20ng/ml per year (Johnstone et al. 
1997). The sensitivity and specificity o f MRI is improving, though remains most 
sensitive at detecting nodal and bony metastases (Harisinghani et al. 2003; Hricak et al. 
2003). The role o f evolving technologies such as 111 Indium capromab and PET scanning 
in the diagnosis of recurrent disease has yet to be established. ^
The use of transrectal ultrasound (TRUS) guided anastomotic biopsies remains 
controversial. In a series from the University of California 54% of 114 men with 
persistently elevated PSA levels undergoing TRUS and biopsy had confirmed local 
recurrence, though a third o f men required more than one biopsy session (Connolly et
sufficient sensitivity to detect low volume locally recurrent disease, th e  digital rectal
al. 1996). In this study the median PSA level o f men with local recurrence was 5.7ng/ml 
(range 0.2-35). Saleem et a l  reported none o f 11 patients with normal DRE and a PSA 
<0.5ng/ml had a positive biopsy (Saleem et al. 1998). Shekarritz et a l found only 25% 
of patients with a PSA of <1 .Ong/ml had a positive biopsy compared with 71% of those 
with a PSA >1 .Ong/ml (Shekarriz et al. 1999). These studies highlight the lack of 
sensitivity o f TRUS and anastomotic biopsies at low PSA values, salvage radiotherapy 
is most effective while the PSA is still low. Scattoni et a l reported men undergoing 6-8 
anastomotic biopsies following a PSA recurrence or abnormality on DRE (Scattoni et 
al. 2003). No patient had evidence o f metastatic disease on bone-scan or abdominal CT. 
In 68 men with a PSA 1 .Ong/ml or below, 45% had biopsies containing tumour. From 
our own series of anastomotic biopsies 33% of 12 cases were positive for cancer 
recurrence, in a further 5 patients with negative biopsies the PSA stabilised after 
prostate bed radiotherapy, suggesting a high false negative rate (Foley et al. 2002). In 
addition, in 5 patients salvage radiotherapy for local recurrence was delayed by a benign 
anastomotic biopsy. Anastomotic biopsies are usually unwarranted, a positive result 
does not exclude metastatic disease and a negative result does not exclude local 
recurrence. Furthermore, a positive anastomotic biopsy is not associated with improved 
outcome after salvage radiotherapy (Koppie et al. 2001).
The best predictors of local versus metastatic recurrence are the pathological findings o f 
the radical prostatectomy specimen and the post-operative PSA parameters. Patients 
with Gleason grade >8 disease, positive seminal vesicles or lymph node metastases have 
a 95%, 86% and 100% likelihood of developing metastatic disease, respectively (Han et 
al. 2003). Conversely, biochemical relapse is more likely due to local failure alone if 
there are multiple positive surgical margins, extensive extracapsular disease, Gleason
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score <7 and an absence of nodal or seminal vesicle involvement (Anscher & Prosnitz 
1991; Connolly et al. 1996; Kupelian et al. 1996; Nudell et al. 1999).
The PSADT is a useful marker o f local versus distant recurrence after radical 
prostatectomy (Partin et al. 1994; Patel et al. 1997; Pound et al. 1999). Patel et al. 
reported a PSADT of <6months was indicative of metastatic disease in 77 men (Patel et 
al. 1997). Pound used a PSADT cut-off of <10months to indicate distant spread (Pound 
et al. 1999). Another study found the median PSA doubling time was 4.3 months for 
men who were ultimately found to have metastatic disease compared with 11.7 months 
for men with local failure alone (Trapasso et al. 1994). The problem lies in the men at 
an intermediate risk of metastatic disease. For these men nomograms, artificial neural 
networks or biostatistical equations incorporating the pathological and PSA features, 
and in some cases race, may be used to predict disease failure (Diblasio & Kattan 2003; 
Moul et al. 2001; Partin et al. 1995). While these are cumbersome to use in the clinic, 
some are now available on the internet and may facilitate the management of 
intermediate risk patients.
Lack of a PSA nadir below undetectable levels and PSA recurrence within a year of 
surgery all reduce the likelihood of remaining PSA free after salvage radiotherapy 
(Cadeddu et al. 1998). In general, men who develop PSA recurrence within 2 years of 
surgery, have tumour grade greater than 7, higher pathological stage, positive seminal 
vesicles or lymph node involvement are more likely to harbour metastatic disease and 
are better suited to systemic treatment (Han et al. 2003; Pound et al. 1999). Table 1.8 
shows the Johns Hopkins data comparing the pathological and PSA parameters in men 
who developed local versus metastatic disease relapse.
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Table 1.8. Comparison of Gleason score, pathological stage and timing of PSA 
recurrence by site of recurrence after anatomic radical prostatectomy 
 (Pound et al. 1997)_____________ _________________ _________________
Variable Local recurrence Distant metastases 
+/- local recurrence
Number of patients 41(34% 88(66%)
Gleason score
2-4 0% 0%
5-6 55% 45%
7 39% 61%
8-10 11% 89%
Pathological stage
Organ confined 40% 60%
Capsular penetration, negative 
surgical margins
54% 46%
Capsular penetration, positive 
surgical margins
48% 52%
Seminal vesicle involvement 16% 84%
Lymph node metastases 1% 93%
Timing of PSA recurrence
In 1 year 1% 93%
Within 1-2 years 10% 90%
After year 2 61% 39%
After year 3 74% 26%
Reproduced with kind permission from  A W Partin
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1.10(c) Treatment of relapse
The main management options available in patients who have biochemical failure after 
radical prostatectomy include active surveillance, prostate bed EBRT and hormonal 
manipulation. Attempts are being made to use salvage brachytherapy (Losa et al. 2003), 
chemotherapy and high intensity focused ultrasound (Kiel, Wieland, & Rossler 2000) in 
the management of local recurrence, though currently these techniques remain 
experimental. The decision on whether to treat or observe a patient with PSA only 
recurrence depends on the risks of clinical failure, perhaps aided by the Pound tables or 
biostatistical equations outlined above. In an American Urological Association 
questionnaire undertaken in 1998 only 13% of urologists said they would offer salvage 
radiotherapy following an asymptomatic PSA rise, 54% preferred observation and 31% 
opted for hormonal manipulation (Omstein et al. 1998). This is because the role of 
external beam radiotherapy in men with PSA recurrence after radical prostatectomy 
remains unresolved and the subject of ongoing research. To date no randomised study 
has been reported and small retrospective case series with limited follow-up have been 
conflicting. This is in part due to variation in patient selection, disparity in the definition 
of biochemical failure and differences in the use of adjuvant hormonal manipulation.
Studies reported highlight predictive factors that determine biochemical recurrence-free 
rates after salvage radiotherapy. Essentially where there is a high risk of metastases the 
likelihood of curative salvage treatment is reduced. The timing and dose of radiotherapy 
also impacts on PSA free survival.
The importance of the radical prostatectomy Gleason grade in men undergoing salvage 
radiotherapy was demonstrated in several studies (Cadeddu et al. 1998; Peyromaure et 
al. 2003; Tsien et al. 2003). In 57 patients, reported from the University of Michigan,
70
with a median follow-up o f 7 years the 5 and 8-year biochemical disease-free survival 
was 58% and 37%, respectively (Tsien et al. 2003). The only significant risk factor for 
progression was Gleason score. At 8 years biochemical-free survival for Gleason 2-6, 7. 
8-10 was 48%, 37% and 0%, respectively (Tsien et al. 2003). Cadeddu et al. reported no 
patients with Gleason score 9 or more, seminal vesicle invasion or lymph node 
metastases were PSA free 2 years after salvage radiation (Cadeddu et al. 1998).
The number o f adverse risk factors also impacts on PSA free survival. In 115 men 
receiving salvage radiotherapy for PSA recurrence or clinical local recurrence 70 
patients had radiotherapy and 45 men had neoadjuvant hormonal treatment before 
radiotherapy (Katz et al. 2003). The 4-year PSA relapse-free survival was 77% if men 
had positive surgical margins and no poor prognostic features, compared with 20% if 
they had one or more poor prognostic feature including seminal vesicle involvement, a 
pre-radiotherapy PSA >0.6ng/pl or extracapsular disease. In patients receiving 
radiotherapy alone, 39% were recurrence-free compared with 59% for those on 
combined radiotherapy and neoadjuvant treatment. Other studies have failed to show an 
improvement in PSA outcome with neoadjuvant treatment (Katz et al. 2003). The role 
of adjuvant hormonal manipulation in salvage radiotherapy after radical prostatectomy 
remains unresolved. This issue has been addressed in a randomised study: the Radiation 
Therapy Oncology Group (RTOG) 9601. This study is awaiting further follow-up 
before reporting.
Patients who receive radiotherapy after surgery fare better if the PSA falls to an 
undetectable level than those with a persistently detectable PSA (66% at 40 months 
compared with 20% at 12 months, respectively)(Coetzee, Hars, & Paulson 1996). What 
is more, men in whom the PSA rises more than one year after surgery have a better
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response to salvage EBRT (Cadeddu et al. 1998; Coetzee, Hars, & Paulson 1996; 
Grossfeld et al. 2000b).
The PSA level at which salvage treatment is given is critical in terms o f radiotherapy 
efficacy. The American Society of Therapeutic Radiology and Oncology (ASTRO) 
Consensus Panel recommended salvage EBRT be given when the PSA level is less than 
1.5ng/ml (Cox et al. 1999). Nudell et al. reported a cohort of 105 men treated with 
either adjuvant or salvage EBRT (Nudell et al. 1999). He defined disease free as the 
achievement and maintenance of a PSA of <0.2ng/ml; giving a 5-year overall disease- 
free survival of 43%. Outcomes were equivalent for the adjuvant and salvage EBRT 
groups where therapeutic irradiation was administered when the serum PSA was 
<1.Ong/ml (Figure 1.5). In 27 men receiving 60-67 Gy, Schild et a l reported 3-year 
progression-free survival of 76% with pre-radiotherapy PSA <l.lng/m l, compared with 
26% for pre-treatment PSA levels > l.lng /m l (Schild et al. 1994). Peschel et al. reported 
a series of 52 men who had either adjuvant or salvage EBRT. He found the pre­
operative PSA level, the pre-radiotherapy PSA and seminal vesicle involvement were 
significant risk factors for actuarial biochemical recurrence following post-operative 
radiotherapy. However, the risk of recurrence was most significant for a pre­
radiotherapy PSA of <0.3ng/ml (Peschel et al. 2000). The PSA cut-off to trigger salvage 
EBRT is variable; initiating salvage radiotherapy with a PSA <1.Ong/ml is likely to 
confer the best chance of biochemical survival. More data will be available on timing of 
salvage radiotherapy when two prospective randomised studies, European Organisation 
for Research and Treatment of Cancer (EORTC) 30943 and South West Oncology 
Group (SWOG) 8974 report.
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Figure 1.5 Time to develop PSA recurrence (PSA >2) after adjuvant radiotherapy 
(red) and salvage radiotherapy with a pre-treatm ent PSA <1.0ng/ml (green) and 
>1.Ong/ml (blue).
The dose of radiation is important in terms of biochemical disease-free survival after 
salvage therapy. Several studies have shown a dose of >64.8Gy is a significant 
prognostic factor for biochemical recurrence-free survival (Anscher, Clough, & Dodge 
2000; Valicenti et al. 1999). Valicenti et a l  reported a 3-year biochemical disease-free 
survival of 52% for salvage EBRT in high-risk patients, if men received a dose of 
>64.8Gy compared with 18% for those receiving <64.8Gy. In a study from Duke 
University 89 patients received salvage EBRT for persistently elevated or delayed PSA
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recurrence after RP, 72% had an undetectable PSA response, with a 4-year disease-free 
survival of 53%. The only significant prognostic factor for biochemical-free survival in 
multivariate analysis was radiation dose >65Gy. Following these and other studies the 
1999 ASTRO consensus statement recommended a salvage radiotherapy dose of at least 
64.8Gy (Cox et al. 1999).
Salvage radiotherapy is usually well tolerated and toxicity has been markedly reduced 
by 3-D conformal techniques. Although there are no prospective quality o f life studies 
reported, several studies demonstrate significant late genitourinary (GU) or rectal 
toxicity to be less than 10%. Using 3-D conformal EBRT the groups from Michigan and 
Memorial Sloane-Kettering found grade >2 late GU toxicity of 6.3-10% and grade >2 
rectal toxicity o f 8.9-12%, respectively (Katz et al. 2003; Tsien et al. 2003). The figures 
for the Michigan series were based on physician reporting and may underestimate the 
actual complication rate.
Hormonal manipulation is used frequently in men with presumed or confirmed 
metastatic disease after radical prostatectomy, though there is scant data to support this 
therapy in men with PSA only recurrence. No randomised study has been reported on 
the use of hormonal manipulation in lymph node negative men with biochemical failure 
after radical prostatectomy. The PSA level at which to institute therapy is unknown. 
Extrapolating from the major studies on hormonal therapy in patients with advanced 
disease, hormonal therapy either alone or as maximum androgen blockade, appears to 
have a small, but significant survival benefit, but more importantly reduces the risk of 
serious complications from disease progression (Bennett et al. 1999; Medical Research 
Council Prostate Cancer Working Party Investigators Group 1997; Messing et al. 1999). 
The Medical Research Council (MRC) study demonstrated modest improvements in
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cancer-specific survival in the immediate versus delayed hormonal therapy men with 
MO. MX or M l disease (Medical Research Council Prostate Cancer Working Party 
Investigators Group 1997). The greatest benefit was seen in men with MO disease -  
which may most closely reflect the post radical prostatectomy patients with biochemical 
recurrence alone.
The Casodex Early Prostate Cancer Program (EPC) is addressing the question of 
whether hormonal manipulation reduces the risk of recurrent disease. This has reported 
a relative reduction of 42% in clinical disease progression in all men with localised or 
locally advanced prostate cancer (Tl-4, NO/l/x, MO), treated with bicalutamide 150mg 
(Casodex, AstraZeneca) in conjunction with their standard treatment compared with 
standard treatment alone (9% versus 13.8%, respectively) (See et al. 2002). This was 
irrespective o f stage or primary treatment, although the North American arm (study 23), 
which consisted of a greater proportion of radical prostatectomy patients, failed to show 
such significant differences in progression rates. This data is still immature, with a 
median treatment time o f 2 years (range 1.8-2.5 years), unsurprisingly most men have 
responded to hormonal manipulation, whether this translates to an increase in survival 
as men inevitably become hormone refractory remains to be seen. A recent study 
comparing flutamide, another non-steroidal antiandrogen, versus no adjuvant treatment 
also found a reduction in rates o f disease progression after radical prostatectomy. 
However, following a median follow-up of 6.1 years there were no differences in terms 
of overall survival and considerable toxicity was reported in the flutamide arm. 
Bicalutamide is well tolerated in advanced prostate cancer (Anderson 2003; Kolvenbag, 
Iversen, & Newling 2001). Whether the favourable toxicity profile results in fewer 
withdrawals and enhanced efficacy remains to be seen.
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The role o f maximum androgen blockade or intermittent hormonal therapy remains 
contentious. The results o f further studies, including the SWOG, NCI Canada and the 
EORTC GU-Group (NCI-INT 9346/EORTC 30958), are required before these 
potentially beneficial developments become part of routine clinical practice.
The management of recurrent disease after radical prostatectomy will be greatly assisted 
by the publication of ongoing randomised studies. Still a significant proportion of men 
undergoing surgery develop PSA relapse and many of these men may be cured by 
second line therapies. Defining the population most likely to harbour local recurrence 
only is critical in deciding management strategies. Men with moderate grade disease 
(Gleason <7), who do not have nodal or seminal vesicle involvement, and develop a 
PSA relapse more than 2 years after surgery with a doubling time of > lyear and whose 
pre-treatment PSA is <1.5ng/ml are most likely to benefit from local treatment with 
salvage radiotherapy. Men with one or more poor prognostic feature may be offered 
hormonal manipulation, the PSA level to initiate this treatment remains unknown. In all 
men a balance must be made between exposing men to a treatment with little proven 
survival benefit, but with associated unwanted effects and the patient’s quality o f life.
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1.11 Molecular changes in prostate cancer
Prostate cancer, like all other cancers, develops and progresses as a consequence of an 
accumulation of genetic changes. While several putative genes have been isolated for 
the development of breast, ovarian (BRCA1. BRCA2) and colon cancer (hMLHl, 
hMSH2), the aetiology and pathogenesis of prostate cancer remains poorly understood. 
However with advances in molecular genetics it will be the analysis of the genetic code 
and its products that will, in the future, provide both prognostic information and targets 
for therapeutic intervention.
1.11(a) Background
Under normal conditions every cell in the body (except red blood corpuscles) has the 
same DNA, but perform a range o f functions. Abnormal changes in this DNA affect the 
expression and function of critical genes. Alterations in genes can result in altered 
mRNA expression and often, altered proteins. Although many changes may occur, 5-10 
specific alterations are required to convert a normal prostate epithelial cell into a 
malignant cell capable of invasion (Elo & Visakorpi 2001). In a small minority o f cases 
these alterations are inherited, in the majority however they are acquired or somatic 
mutations (Fearon & Vogelstein 1990; Kallioniemi & Visakorpi 1996). The problem for 
researchers is to identify: which genetic changes are important in cancer progression, 
which can be used to predict prognosis and which can act as targets for therapeutic 
intervention.
l . l l ( a ) l .  Oncogenes
A proto-oncogene is a normal regulatory gene. If its activity is increased as a
consequence o f genetic alteration it becomes an oncogene. Oncogenes are described as
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dominant as only one allele needs to be changed for a biological effect to occur. 
Modification o f the proto-oncogene to form an oncogene leads to a gain in function; this 
may be due to a qualitative or quantitative change in protein product. Alteration in the 
regulatory sequence, for example by amplification, brings about quantitative change in a 
normal product. Qualitative change generates abnormal protein product as a result o f 
mutation in the coding region or by rearrangement (translocation) of two genes resulting 
in production o f a fusion protein made up of parts of each participating gene.
Oncogenes implicated in prostate cancer include the RAS oncogenes, MYC, ERBB2, 
PSCA, EIF3S3 and the AR  gene. The RAS oncogene is activated by point mutation, the 
MYC gene is activated by amplification and ERBB2 is either amplified or modified 
through transcriptional or post-transcriptional deregulation. Amplification occurs 
relatively late in the development of prostate cancer; it is found in metastatic {MYC, 
PSCA, EIF3S3) and hormone refractory disease (AR). Altered regulation may be seen in 
the early as well as the later stages of cancer development.
l.ll(a )2 . Tumour suppressor genes
A tumour suppressor gene (TSG) encodes for an inhibitory protein whose function is 
lost in cancer. TSGs are inactivated by deletion of one or both genes or by a point 
mutation in one gene and deletion in the other. Three types of TSG have been described. 
Firstly, recessive TSGs, these are inactivated only if  both gene copies of a diploid cell 
are lost e.g. RB. Secondly, the dominant negative TSG where a mutation in one allele 
generates an abnormal protein that inactivates the normal product from the unaffected 
allele. p53 may be inactivated in this manner. Finally, haplo-insufficiency is where 
inactivation of one allele copy is sufficient to change the phenotype, for example PTEN.
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The majority o f TSGs code for proteins that complex with other effector proteins and 
inhibit their actions. Where an individual has a hereditary mutation of one TSG they 
have an increased susceptibility to develop cancer and for developing cancer at a 
younger age.
TSGs may be inactivated by mutation, deletion or by abnormal methylation. 
Methylation changes including hypermethylation, demethylation and redistribution of 
methyl groups have all been reported in prostate cancer (Ruijter et al. 1999). The 
significance of demethylation in prostate cancer is unknown (Bedford & van Helden 
1987), however hypermethylation is of importance. The promotor and exons at the 5’ 
end of some recognised TSG contain a high density of C-G (cytosine-guanine) repeats, 
called CpG islands. Hypermethylation of these CpG islands is believed to result in 
transcriptional inactivation o f the associated gene and is found in malignant tissues.
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1.11(b) Hereditary prostate cancer
In 1895, Dr Alfred Warthin’s seamstress told him she was convinced she would die 
from cancer as so many o f her family had. Indeed she died at a young age from 
endometrial cancer; this prompted Warthin to publish a description of her family, which 
included relatives dying prematurely from gastric, endometrial and colorectal cancers 
(Wartin 1913). Progress was made in understanding familial cancers in the 1960’s by 
Lynch (Lynch et al. 1966), Li (Li & Fraumeni, Jr. 1969) and Knudson (Knudson, Jr. 
1971) who systematically examined at risk families. Knudson went on to predict the 
‘two-hit’ hypothesis based on his study o f a rare eye tumour in children - 
retinoblastoma. He postulated the presence of regulatory TSGs that are normally 
involved in cell-cycle, apoptosis and proliferation. Humans normally have two copies of 
these TSG, one from each parent. Where inherited mutations occur one copy is affected. 
The remaining TSG maintains sufficient control of its regulatory function, however 
should a mutation occur in the other copy o f the TSG in one cell a malignant potential is 
acquired. This hypothesis was confirmed 20 years later when germ-line mutations in the 
RB gene were detected in hereditary retinoblastoma (Hogg et al. 1993).
The problem with studying familial prostate cancer is that as the incidence o f the 
disease in the general population is so high there is a high rate of sporadic cases 
amongst the familial cluster. Furthermore, these families undergo PSA screening which 
will further enhance the detection rate. Despite these factors, a family history of prostate 
cancer still confers an increased risk of being diagnosed with prostate cancer and of 
developing the disease at an earlier age. A man with a first-degree relative with prostate 
cancer has a relative risk of 2.0 (1.2-3.3, 95%CI), with a second-degree relative risk of 
1.7 (1.0-2.9) and with both a first and second degree relative an 8.8 (2.8-28.1) relative 
risk of developing prostate cancer (Steinberg et al. 1990).
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Further evidence for a hereditary component and a link with another histologically 
similar malignancy is that prostate cancer is higher in men who have relatives with 
breast cancer (Thiessen 1974; Tulinius et al. 1992). Likewise, the risk o f breast cancer is 
doubled in families with a history of prostate cancer (Anderson & Badzioch 1992; 
Sellers et al. 1994).
Hereditary prostate cancer is usually defined by the pedigree as no associated genes 
have yet been firmly identified. This definition therefore includes nuclear families with 
three cases o f prostate cancer, the presence of prostate cancer in each of three 
generations in the maternal or paternal lineage and a cluster of two relatives diagnosed 
with prostate cancer before the age of 55 years (Carter et al. 1993). Using this definition 
3-5% of patients with prostate cancer has hereditary disease. This definition however 
excludes families with a hereditary susceptibility to prostate cancer (with mutations in 
autosomal dominant susceptibility genes), so the true proportion is likely to be 5-10%.
1.1 l(b )l. Candidate genes
Prostate cancer susceptibility loci have been reported at lq24-25, lp36, lq42, 20ql3,
Xq27-28 (Ostrander & Stanford 2000), 16q23 (Suarez et al. 2000) and 17p(Tavtigian et
al. 2001) (Table 1.9). Several authors have reported a linkage (the inheritance o f a
recognised genetic marker with the disease) on the long arm of chromosome 1 (Cooney
et al. 1997; Hsieh et al. 1997; Smith et al. 1996). The exact site of the susceptible genes
on this chromosome region remains unclear; lq24-25, named HPC1 (Smith et al. 1996)
and lq42, termed PCAP (Berthon et al. 1998) have been implicated. Two further studies
confirmed linkage at the HPC1 locus on lq24-25 (Cooney et al. 1997; Hsieh et al.
1997), other studies did not (Berthon et al. 1998; Eeles et al. 1998; Mclndoe et al.
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1997). In a study from the CRC/BPG UK Familial Prostate Cancer Study Collaborators 
the incidence of allelic imbalance at HPC1 was low in both sporadic tumours and small 
prostate cancer families (Dunsmuir et al. 1998). The authors concluded HPC1 is 
unlikely to be acting as a TSG in the development of familial or sporadic prostate 
cancer.
Other candidate genes include the breast cancer susceptibility genes BRCA1 (17q21) 
and BRCA2 (13ql 2.3) and these confer a relative risk of prostate cancer of 3.0 and 2.6-
7.0 respectively (Eeles & the UK Familial Prostate Study Group & the CRC/BPG UK 
Familial Prostate Cancer Study Collaborators 1999). The UK/Canadian/Texan 
Consortium found up to 30% of familial clusters may be linked to BRAC1/2, although 
the confidence intervals were wide and included zero (Eeles et al. 1998). Indeed the UK 
Familial Prostate Cancer Study was unable to find any mutations in the BRAC1 gene but 
did find two germline mutations in BRCA2. They postulated the BRCA2 mutations may 
be a coincidental finding or may play a role in modifying the expression of another 
cancer gene (Eeles & the UK Familial Prostate Study Group & the CRC/BPG UK 
Familial Prostate Cancer Study Collaborators 1999). While an association between 
breast and prostate cancer clearly exists, the molecular basis for this association is not 
yet fully understood.
Using segregation analysis, prostate cancer was found 1.5 times more often in brothers 
than in fathers of men with prostate cancer (Schaid & Rowland 1998). This may 
indicate that prostate cancer is inherited in some families in a recessive or an X-linked 
way. A study of 360 families in North America, Sweden and Finland strongly 
implicated a region on the long arm of the X- chromosome at Xq27-28, which the
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authors named HPCX  (Xu et al. 1998). This gene accounted for 15-16% of cases in 
North America and 41% of Finnish cases of hereditary prostate cancer.
From the Utah Population database workers mapped an inherited predisposition to 
prostate cancer to the ELAC2 gene on chromosome 17p in 33 families (Tavtigian et al. 
2001). When the number of families studied increased to 127, the linkage was no longer 
significant as the prevalence of the mutation fell. The authors conclude this was due to 
the heterogeneity of the families involved. ELAC2 codes for a protein involved in 
interstrand-cross link repair mechanisms, which is consistent with a possible role in 
prostate cancer.
Table 1.9 Chromosomal loci reported to contain hereditary prostate cancer genes
Locus Putative gene Number of 
families
Two-point lod 
score
Multipoint lod 
score
lq24-25 HPC1 91 3.7 5.4
lq42 PCAP 47 2.7 3.1
lp36 CAPB 12 3.7 2.2
17p ELAC2 33 4.5
20ql3 HPC20 162 2.7 3.0
Xq27-28 HPCX 360 4.6 3.9
(The lod score is a statistical estimate of whether two (two-point) or several (multipoint) 
loci are likely to lie near each other on a chromosome, and are therefore likely to be 
inherited together, a score over 3 is statistically significant.)
Confirmatory studies showing weak or no linkage to these regions and a putative 
susceptibility gene has yet to be identified. This has led investigators to conclude that
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hereditary prostate cancer is a heterogeneous disease and no single gene is responsible 
for the high incidence in certain families. Alternatively, there may be no major 
susceptibility genes for prostate cancer as there is for say breast or colon cancer (Elo & 
Visakorpi 2001; Ostrander & Stanford 2000).
1.1 l(b)2. Low penetrance polymorphisms
Mutations in high penetrance susceptibility genes resulting in a significantly increased 
risk of prostate cancer are relatively uncommon in prostate cancer. On the other hand 
polymorphisms (the occurrence of allelic variations) in low penetrance genes increase 
the risk of developing the disease only modestly, but occur with greater frequency in a 
population. Low penetrance polymorphisms may therefore have a greater impact on the 
frequency of prostate cancer in the population as a whole.
The polymorphic CAG (cytosine-adenosine-guanine) repeat in the androgen receptor 
gene has been studied extensively. This codes for a polyglutamine tract o f varying 
lengths (dependent on the number of CAG repeats in the gene). Workers have shown an 
inverse relationship between the CAG repeat length and prostate cancer risk 
(Chamberlain, Driver, & Miesfeld 1994; Kazemi-Esfaijani, Trifiro, & Pinsky 1995; 
Stanford et al. 1997). In normal healthy males there are 13-30 CAG repeats, however 
African-American men have a higher prevalence of <22 CAG repeats in the AR gene 
(Irvine et al. 1995), and Chinese men have a higher prevalence of longer CAG repeats 
(Hsing et al. 2000). The prevalence of prostate cancer is higher in African-Americans 
and lower in Chinese man (Elo & Visakorpi 2001). Giovannucci et a l showed that if an 
individual had <18 CAG repeats they had an increased relative risk of 1.52 for 
developing prostate cancer compared with men with >26 CAG repeats (Giovannucci et 
al. 1997).
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Polymorphisms in the SRD5A2, the gene that codes for the enzyme 5 a-reductase type 
II, have been reported (Elo & Visakorpi 2001). 5 a-reductase is responsible for the 
conversion of testosterone to its more active metabolite dihydrotestosterone in the 
prostate. Polymorphisms in the SRD5A2 gene result in increased catalytic activity of 
this enzyme and are associated with an increased risk of developing prostate cancer 
(Jaffe et al. 2000).
The vitamin D receptor ( VDR) gene is also a polymorphic steroid hormone receptor 
gene implicated in prostate cancer. Vitamin D is antiproliferative to prostate cancer cell 
lines (Peehl et al. 1994; Skowronski, Peehl, & Feldman 1993) and low serum vitamin D 
may be associated with an increased risk of prostate cancer (Ahonen et al. 2000; Corder 
et al. 1993). Whether the VDR polymorphisms confer an increased susceptibility to 
prostate cancer remains contested (Blazer, III et al. 2000; Habuchi et al. 2000b; Ingles et 
al. 1998; Nelson & Wilding 2001; Taylor et al. 1996). However, a number o f vitamin D 
analogues are currently undergoing clinical trials for prostate cancer treatment and 
prevention (Nelson & Wilding 2001).
Other polymorphisms reported to influence the risk of developing prostate cancer 
include the cytochrome P450 family genes (CYP3A4 and CYP17). The ELAC2 gene 
may be a low as well as possibly a high penetrance gene (Habuchi et al. 2000a; Rebbeck 
et al. 1998; Rebbeck et al. 2000). Larger studies are required to corroborate these 
findings.
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1.11(c) Somatic changes
While some individuals develop tumours as a result o f inherited genetic changes all
tumours contain acquired or somatic alterations. Advances in the techniques used to 
examine these changes resulted in the identification o f chromosomal regions deleted or 
amplified that may play a role in tumourigenesis. Chromosomal changes have been 
identified in specific stages of disease progression with the average number of 
alterations significantly higher in distant metastases than primary tumours (Alers et al. 
2000).
One of the most widely reported techniques for examining chromosomal alterations is 
comparative genomic hybridisation (CGH). This allows the detection of DNA sequence 
copy number changes throughout the genome and can therefore identify regions where 
deleted TSG or amplified oncogenes may be harboured. Using CGH researchers have 
shown that locally recurrent hormone refractory prostate cancers contain almost four 
times as many alterations as untreated primary tumours (Nupponen & Visakorpi 1999). 
The early development of prostate cancer is associated with inactivation of TSG, 
whereas later progression, including the development of hormone refrac
CGH and Al (allelic imbalance) studies have demonstrated the most common 
chromosomal aberrations in prostate cancer are deletions in chromosome regions 3p, 6q, 
7q, 8p, 9p, lOq, 13q, 16q, 17q and 18q and gains in 7p, 7q, 8q and Xq (Alers et al. 2000; 
Cooney et al. 1996b; Elo & Visakorpi 2001; Latil et al. 1997; Li et al. 1999). 
Furthermore, the frequency of Al at several loci increases with higher grade (Hugel & 
Wemert 1999; Leube et al. 2002) and higher stage disease (Hugel & Wemert 1999; 
Perinchery et al. 1999).
associated with activation of oncogenes.
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1.11(c)!. Early prostate cancer
Genetic changes have been identified at all stages of prostate cancer development and 
progression. In this section we will examine the changes in chromosomal regions and 
genes identified in early, metastatic and hormone refractory prostate cancer (Bott et al. 
2005b).
8p
Two of the most common deletions found using Al and CGH are on 8p and 13q 
(Visakorpi et al. 1995b). Laboratory techniques including fluorescence in situ 
hybridisation (FISH) and Al have found that losses in these regions are frequently found 
in HGPIN (Emmert-Buck et al. 1995; Saric et al. 1999). It would appear that 
inactivation o f one or more as yet unidentified TSG in 8p and 13q is an early event in 
prostate cancer pathogenesis.
At least two regions of loss on 8p have been identified 8pl2-21 (Haggman et al. 1997b) 
and 8p22 (Cher et al. 1996; Emmert-Buck et al. 1995; Oba et al. 2001). Loss of 8 p l2-21 
is an early event in prostate carcinogenesis, occurring in HGPIN and early invasive 
disease, whereas loss of 8p22 is a late event, found more commonly in advanced 
cancers. The NKX3.1 gene (Brothman et al. 1999) at 8p 12-21, and FEZ1 (Ishii et al.
1999) at 8p22 have been implicated. In mice with a disrupted NKX3.1 gene, defects in 
prostate duct morphology and secretory fuction occur (Bhatia-Gaur et al. 1999). 
Furthermore NKX3.1 mutant mice develop lesions that closely resemble HGPIN 
(Bhatia-Gaur et al. 1999). Yet mutations in the coding region of NKX3.1 gene have not 
been identified (Voeller et al. 1997) nor is NKX3.1 mRNA lost in prostate cancer (Xu et 
al. 2000). Knock-out o f a single NKX3.1 allele may be sufficient to lead to the 
development of HGPIN, perhaps haploinsufficiency at 8p 12-21 accounts for the lack of
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mutations found in this region. NKX3.1 expression is found only in adult prostate 
(Bhatia-Gaur et al. 1999), whereas deletions of 8p are common in other malignancies 
including lung and colorectal tumours (Chang et al. 1994) suggesting the existence of 
other TSG in the 8p22 region.
FEZ1, at 8p22, codes for a leucine zipper protein and alterations in this gene have been 
reported in oesophageal and breast as well as a prostate cancer cell line (Ishii et al.
1999). There are no reports of alteration of this gene in radical prostatectomy 
specimens.
13q
Loss of chromosome 13q occurs in at least 50% of prostate tumours (Cooney et al. 
1996b; Li et al. 1998). TSGs on the long arm of chromosome 13 include the 
retinoblastoma gene RBI (13ql4), DBM  (13ql4) and the breast cancer susceptibility 
gene BRCA2 (13ql2-13). Mutations in the RB gene and loss of Rb protein has been 
reported in localised and advanced prostatic carcinomas (Ittmann & Wieczorek 1996). 
RB is thought to regulate apoptosis in prostatic cells, particularly in response to 
androgens (Bowen, Spiegel, & Gelmann 1998; Yeh et al.). Several studies have 
however failed to demonstrate mutations in the RB gene (Cooney et al. 1996b; Li et al. 
1998; Sarkar et al. 1992), so an alternative gene on 13q may be a significant gene in 
prostatic carcinogenesis.
GSTP1
Hypermethylation of the GSTP1 gene is seen in 70% of cases o f high-grade prostatic 
intraepithelial-neoplasia (HGPIN) and over 90% of prostate cancers, but is a rare event
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in benign prostate tissue (Brooks et al. 1998; Lee et al. 1997). The GSTP1 gene on 
l lq l3 , encodes for glutathione S-transferase which conjugates electrophilic and 
hydrophobic environmental carcinogens with glutathione and protects the cell 
(Mannervik et al. 1985). Hypermethylation of the CpG islands of the promoter region 
prevents the transcription of the gene, thus removing the cell’s in-built protection 
mechanism against potential environmental carcinogens, including dietary factors 
(Nelson & Wilding 2001).
GSTP1 inactivation occurs in the vast majority o f cases of HGPIN and prostate cancer 
early in the disease course, so may be used as a molecular marker (Lee et al. 1997). 
Indeed studies have already reported measurement of GSTP1 methylation in cells in the 
urine of men with prostate cancer (Cairns et al. 2001; Goessl et al. 2001). Cairns et a l 
detected GSTP1 methylation in the urine o f 27% of patients with GSTP1 methylation in 
their primary tumour (Cairns et al. 2001). Goessl et a l improved the sensitivity of this 
technique to 73% by looking at GSTP1 methylation in the urine sediment after prostatic 
massage. They found GSTPJ methylation in 1 (2%) of 45 patients with BPH, 2 (29%) 
of 7 patients with HGPIN, 15 (68%) o f 22 patients with localised prostate cancer and 14 
(78%) of 18 with locally advanced or disseminated disease (Goessl et al. 2001). In a 
study examining the methylation status o f GSTP1 in prostate biopsies (Harden et al. 
2003) the sensitivity o f cancer detection rate was 11% greater using GSPT1 methylation 
status compared with histology alone. Included in this study were men undergoing 
cystoprostatectomy for bladder cancer or radical prostatectomy for prostate cancer. 
After prostate resection sextant needle biopsies were taken and examined by an expert 
uropathologist. DNA was extracted from the needle cores and GSTP1 quantitative 
methylation specific PCR (QMSP) was undertaken. The whole prostate specimen 
underwent standard serial sectioning. Histological examination o f the biopsy tissue
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revealed tumour with a 64% sensitivity (95% Cl = 51 -76%), whereas the combination 
histology and QMSP with an assay threshold >10 detected cancer with 75% sensitivity 
(95% Cl = 63-86%). In men with GSTP1 methylation in biopsy material, but negative 
histology, early repeat extensive biopsy may be recommended.
Furthermore, GSTP1 methylation status in serum is related to biochemical outcome 
(Bastian et al. 2005). GSTP1 methylation was detected in 12% of men with clinically 
localised disease, 28% of men with metastatic cancer and in 15% of men who 
developed PSA recurrence after surgery. While both these studies demonstrated high 
specificity for GSTP1 methylation in prostate cancer, the overall sensitivity of the 
assays was low. Augmentation of GST activity, using pharmaceutical GST inducers, 
may in the future have a role in prostate cancer prevention (Wilkinson & Clapper 1997).
Cell cycle regulatory genes
In the normal prostatic epithelium the relatively low rate of cell proliferation is matched 
by the low rate o f apoptosis. In HGPIN and early invasive disease the cell proliferation 
rate increases by 7-10 fold. In advanced and metastatic prostate cancer the apoptotic rate 
is reduced by 60% (Abate-Shen & Shen 2000). Changes in the genes that code for the 
cell cycle regulatory proteins may be critical early events in the development and 
progression of prostate cancer.
The G l/S transition checkpoint in the cell cycle is an important point o f control as DNA 
damage can be repaired before replication occurs (Sherr 1996). Progression through this 
checkpoint is regulated by a family o f cyclin dependent kinases (CDKs), whose activity 
is in turn controlled by CDK inhibitors (CDKIs). CDKIs have been sub-classified into 
two classes on the basis of their structure and their CDK target (Sherr & Roberts 1999).
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The first class, the INK4 proteins, inhibit CDK4 and CDK6 and include p l6 INK4a and 
pl i^NK4b ( s errano> Hannon, & Beach 1993). The second class of CDKIs are the Cip/Kip 
family, which includes p27WAF1/CIPI and p27K,pl (Harper et al. 1993) and they regulate 
the cyclin D-, E-, and A-dependent kinases (Sherr & Roberts 1999).
p 2i WAFI cipi was identified simultaneously as a mediator of p53 induced growth arrest 
(Wild type p53-Activated Fragment 1) (el Deiry et al. 1993) and as a regulator of CDK 
(CDK-Interacting Protein) (Harper et al. 1993). p27WAF1/CIP1 has two binding sites for 
p53 and its transcription is activated by wild type p53, but not mutated p53 (el Deiry et 
al. 1993). Therefore, cancer cells expressing mutated p53 protein may be unable to 
induce expression of p21WAFI/CIPI. Factors including TGF-p (Datto et al. 1995), IFN-a, 
IFN-p, IFN-y (Chin et al. 1997; Gartel & Tyner 1999; Xu et al.), IL-6 (Bellido et al. 
1998) and EGF (Chin et al. 1997) have been shown to up-regulate />27WAF1/CIP1, via the 
JAK-STAT and other pathways, in a p53 independent manner (Gartel & Tyner 1999). 
p 2i WAFI/CIPI aiSo inhibits DNA replication directly, by binding to the proliferating 
nuclear antigen (PCNA), a subunit of DNA polymerase 8 (Li et al. 1994). In addition to 
its associations with CDKs and PCNA, p 2 ] WAF,/CIP1 has been found to participate in 
specific protein-to-protein interactions, acting both on other cell cycle regulators and as 
a modulator o f apoptosis (Dotto 2000).
Malignancy is characterised by the inability of cells to respond correctly to growth 
arrest signals, such as cell-to-cell contact. The various roles of p 2 iWAF,/CIPI and other 
CDKIs as inhibitors of the cell cycle and as a modulators of apoptosis and 
differentiation implies a tumour suppressor function (Toyoshima & Hunter 1994). 
Decreased levels of CDKIs like p2 1 WAFI/CIP/, or increased cyclin- CDK levels, may lead
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to inappropriate cell division. Alternatively, decreased levels of CDKIs may limit the 
cellular response to DNA damage.
Lack of p21WAhl/CIPI expression has been related to poor prognosis in several solid 
cancers including pancreatic (Jarrard et al. 1997a), gastric (Noda et al. 2001), bladder 
(Shariat et al. 2004) and non-small cell lung cancers (Shoji et al. 2002). A single 
nucleotide polymorphic region in p 2 lWAFIC,PI and in p27k,pI has been identified as a risk 
factor for developing advanced prostate cancer (Kibel et al. 2003), and in men with this 
polymorphism close screening is recommended. Immunohistochemical studies have 
shown reduced p21WAF1/CIPI protein expression in prostate cancer can be used to predict 
poor survival outcome (Cheng et al. 2000; Matsushima et al. 1998). Although decreased 
p21 WAFI CIPI expression is often detected in cancer cells, the mechanism of inactivation 
is not known, mutations and allelic loss o f p21WAFt C,PI are rarely found (Gartel & Tyner 
1999; Shiohara et al. 1994). In acute lymphoblastic leukaemia poor prognosis is 
associated with transcriptional silencing of the p 2 JWAFI C,PI gene by methylation o f the 
CpG islands in the promoter (Roman-Gomez et al. 2002).
The CDK4 inhibitor p27kipI is a cell cycle regulatory gene whose function is frequently 
lost in advanced prostate cancer (Kibel et al. 1998). Loss o fp27kipl expression, which is 
mapped to 12 p l2-13.1, is associated with increasing tumour grade and poor clinical 
outcome (Cote et al. 1998; Guo et al. 1997). This gene is rarely mutated, with lack of 
expression usually due to aberrant phosphorylation and/or ubiquitinylation (Loda et al. 
1997; Singh et al.; Tan et al.). In a recent study using a murine model, the p27kipI gene 
along with the PTEN  and NKX33.1 gene were reduced or eliminated (Gao et al. 2004). 
Mice that were heterozygous (p27+/-) displayed enhanced prostate carcinogenesis, 
whereas mice that were homozygous (p27-/-) showed inhibition of cancer progression.
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Moreover, expression profiling revealed that Cyclin D1 was up-regulated in 
heterozygotes, but was down-regulated in the homozygous mutants. This suggests that 
p27kipl possesses dosage-sensitive positive as well as negative modulatory roles in 
prostate cancer progression.
Another cell cycle regulatory gene is the CDKN2 {p i6) gene located on 9p21. CDKN2 
codes a cyclin-dependent kinase inhibitory protein, which controls passage through the 
G1 phase of the cell cycle. Inactivation o f the CDKN2 gene may facilitate progression 
through the cell cycle. Increased expression has been reported in proliferative 
inflammatory atrophy (PIA) a common histological finding that maybe associated with 
prostate cancer (Faith et al. 2005). Furthermore, increased expression has been reported 
in 83% of primary prostate tumours and was associated with higher grade and worse 
clinical outcome, whereas loss was seen more frequently in metastatic lesions (Jarrard et 
al. 2002).
Mutations in the p i  6 gene have been identified in advanced and metastatic prostate 
cancer but not in primary tumours. In primary prostate cancer it has been suggested that 
inactivation may occur by point deletion of one pi 6 allele and promoter methylation of 
the remaining allele (Jarrard et al. 1997b). Jarrard et al. reported 3 (13%) of 24 primary 
and 1 (8%) of 12 metastatic tumour samples had hypermethylation in the promoter 
region. Deletions near the CDKN2 gene were detected in 12 (20%) of 60 primary 
tumours and in 13 (46%) of metastatic lesions. Gu et a l looked at CDKN2 in early 
prostate cancers and could find no evidence of methylation, although deletions close to 
the gene were identified (Gu et al. 1998). Surprisingly, up-regulation of the p i 6 protein 
has been reported as a prognostic marker of disease recurrence in prostate cancer 
(Halvorsen et al. 2000; Lee, Warde, & Jewett 1999). Similarly, up-regulation of p i  6 has
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been reported in ovarian cancer and is associated with disease progression and 
unfavourable prognosis in this tumour (Dong et al. 1997). The reason for this anomaly 
is not clear, it may be that the up-regulated p i6 protein is abnormal and this confers a 
growth advantage, but there is no evidence for this theory.
Other cell cycle regulatory genes include cyclin D1, this gene is over-expressed in 
metastatic prostate cancer (Drobnjak et al. 2000) but not primary tumours (Gumbiner et 
al. 1999).
lOq
Up to 50% of prostate cancers have been found to harbour deletions on lOq detected by 
FISH, CGH, Al and cytogenetics (Carter et al. 1990; Macoska et al. 1993; 
Madersbacher et al. 1998; Sakr et al. 1994; Saric et al. 1999; Visakorpi et al. 1995b). 
Two commonly deleted regions have been identified, 10q23.1 and 10q24-5. Putative 
TSG in these regions include PTEN/MMAC1 (Phosphatase and Tensin homologue/ 
Mutated in Multiple Advanced Cancers) at 10q23.23 (Cairns et al. 1997) and MXI1 on 
10q25 (Di Cristofano & Pandolfi 2000; Schreiber-Agus et al. 1998), though their 
respective roles in prostate carcinogenesis is not fully established.
Germ line mutations are found in the autosomal dominant PTEN in cancer syndromes, 
such as Cowden’s disease (breast and thyroid cancer) (Liaw et al. 1997) and Bannayan- 
Zonana syndrome (multiple lipomas and haemangiomas) (Marsh et al. 1997). PTEN  
codes a lipid phosphatase, which induces p27k,pl expression. Loss of PTEN  activates 
PKB/AKT kinase resulting in enhanced cell proliferation, decreased apoptosis, and 
increased angiogenesis (Zhong et al.).
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PTEN  mutations have also been found in 5-27% of early and 30-58% of metastatic 
prostate cancers (Alers et al. 2000; Cairns et al. 1997; Dong et al. 1998; Feilotter et al. 
1998; Halvorsen, Haukaas, & Akslen 2003; Suzuki et al. 1998). In 104 radical 
prostatectomy specimens the expression of PTEN  and p27k,pl was examined in tissue 
microarrays using immunohistochemistry (Halvorsen, Haukaas, & Akslen 2003). PTEN 
was negative in 27%, and combined loss of PTEN  and p27kipl expression was seen in 
18% of tumours; combined loss was associated with adverse pathological features, as 
well as being an independent predictor o f time to biochemical failure and clinical 
recurrence.
Mice deficient in one PTEN  allele and both Cdknlb  alleles (which codes for p27kipl) all 
develop prostate cancer within 3 months of birth (Di Cristofano et al. 2001). 
Inactivation of one of the two PTEN  genes may be sufficient to allow the progression of 
tumour - haploinsufficiency. To demonstrate this PTEN  knock-out mice were bred with 
TRAMP mice (Transgenic Adenocarcinoma o f Mouse Prostate) (Kwabi-Addo et al. 
2001). All TRAMP mice develop prostate cancer, mice with one PTEN  gene knocked 
out developed larger more aggressive tumours and had a significantly reduced survival 
compared with mice with both PTEN  genes activated. Mice with both PTEN  genes 
knocked out had the same survival rate and had similar sized tumours to those with one 
PTEN gene knocked-out. Rapamycin, an immunosuppressive agent that acts on 
FRAP/mTOR protein kinase, a downstream effector protein of PTEN, reduces the 
volume of prostate cancer xenografts in PTEN  knock-out mice. Clinical trials are 
currently underway to see whether rapamycin has a similar affect in patients with 
prostate cancer that do not express PTEN  (Neshat et al.).
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MXI1, located at 10q24-q25, is implicated as a TSG as it codes for a MYC-binding 
protein (Eagle et al. 1995; Schreiber-Agus et al. 1998). The MYC gene has been 
implicated in a number of cancers, it is mapped on 8q, a region frequently amplified in 
prostate cancer (Bubendorf et al. 1999). Some studies have found a high mutation rate 
in MXI1 (Eagle et al. 1995) (Prochownik et al. 1998) others have failed to detect 
mutations in primary prostatic tumours (Kawamata et al. 1996).
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1.1 l(c)2. Metastatic prostate cancer
Metastasis requires a complex interrelated series of events including vascularisation, 
invasion, survival in blood or lymph, adhesion, extravasation and proliferation at a 
distant site (Fidler 1990). This requires several critical genetic changes and these 
changes may act as molecular markers and targets for therapeutic intervention.
16q
Several CGH and Al studies have shown losses of 16q in late stage prostate disease 
(Cher et al. 1998b; Latil et al. 1997; Li et al. 1999), though up to 68% of primary 
tumours may also harbour losses o f 16q (Harkonen et al. 2005). Loss of 16q23 and q24 
are associated with metastatic potential (Elo et al. 1999; Suzuki et al. 1996) and loss of 
16q24.3 with risk of disease recurrence and progression (Harkonen et al. 2005).
A candidate gene, CDH1 coding for the E-cadherin protein, is located on 16q22.1. 
Decreased expression of this gene is associated with high-grade prostate cancer (Dong 
et al. 1998; Elo et al. 1999; Feilotter et al. 1998; Latil et al. 1997; Pesche et al. 1998; 
Richmond et al. 1997; Suzuki et al. 1996), in addition decreased expression is 
associated with metastatic potential in the primary tumour (Umbas et al. 1994). 
Although no mutations have been described, hypermethylation of the CpG island has 
been reported in cell lines. E-cadherin is calcium dependent and is responsible for cell- 
to-cell recognition and adhesion (Takeichi 1991). a  and P-catenins form part of the 
same adhesion mechanism and decreased expression of a-catenin has been 
demonstrated in prostate cancers which have normal E-cadherin expression (Richmond 
et al. 1997). About 5% of prostate cancers contain mutations in P-catenin (Chesire et al. 
2000; Voeller, Truica, & Gelmann 1998). P-catenin has two known roles, firstly in cell 
adhesion with a-catenin and secondly as part o f the Wnt signalling pathway. Another
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potential TSG, located at 16q24.2-q24.3, is H-cadherin, which is associated with breast 
lung and colorectal tumours, though this gene has not been directly implicated in 
prostate cancer tumourigenesis.
17p
Mutations in the TSG p53 have been described in the majority of cancers including 
breast, colon and lung (Hollstein et al. 1991). Located at 17 p l3.1, p53 codes for a 
nuclear phosphoprotein that has a negative effect on cell growth. In the event o f DNA 
damage, the cell cycle is arrested or apoptosis is induced. I fp53 is inactivated and loses 
its function, damaged DNA may be transcribed (Ruijter et al. 1999). The frequency of 
p53 mutations in prostatic cancer ranges from 1-42% and a consistent finding is its 
association with high grade and high stage disease coupled with disease recurrence and 
poor prognosis (Aprikian et al. 1994; Brewster et al. 1999; Navone et al. 1993; Shi et al. 
1996; Stackhouse et al. 1999). The frequency of p53 mutations is relatively low in 
prostate compared with other cancers (Abate-Shen & Shen 2000). Prostate cancer 
occurs only rarely in the Li-Fraumeni cancer syndrome where patients carry a germline 
mutation in p53 (Kleihues et al. 1997), although this may be because patients die from 
other malignancies before they acquire prostate cancer.
The low mutation rate, particularly in early stage disease, precludes p53 from being an 
effective target for curative intervention in prostate cancer (Brooks et al. 1996; Stattin 
1997). p53 may however play a role as a molecular marker in radiotherapy resistance 
along with BCL, MYC and RAS. Radiotherapy induces apoptosis and may be less 
effective in patients who have defective apoptotic pathways as a result o f mutations in 
these genes (Prendergast et al. 1996). The p53 gene mutation predicts poorer overall 
survival for patients treated with antiandrogen therapy after radiotherapy (Grignon et al.
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1997). The presence of mutations in the p53  gene may therefore be used before 
radiotherapy and antiandrogen therapy to predict treatment failure (Huang et al. 1998; 
Prendergast et al. 1996).
The breast cancer susceptibility gene BRCA1 is also mapped to 17p. This gene is not 
deleted however in prostate cancer (Brooks et al. 1996).
18q
Loses of 18q have been reported to be associated with metastatic prostate cancer (Saric 
et al. 1999). Two TSGs implicated in cancer progression are located in this region, DCC 
(Deleted in Colon Cancer) and DPC4 (Deleted in Pancreatic Cancer), however no 
mutation in these genes have been found in prostate cancer (Gao, Porter, & Honn 1997; 
U edaetal. 1997).
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EZH2
The EZH2 gene, situated on 7q35-36, encodes the EZH2 protein, of which levels are 
significantly increased in prostate cancer compared with BPH tissue. EZH2 increases 
histone deacetylation, which is a repressor of transcription in prostate cancer 
(Varambally et al. 2002). Elevated levels of EZH2 mRNA and protein in clinically 
localised prostate cancer predicts poor prognosis (Varambally et al. 2002). In a separate 
immunohistochemistry study moderate or strong expression of EZH2 coupled with 
expression of ECAD was strongly associated with the recurrence after radical 
prostatectomy in 183 men even after adjusting tumour stage, Gleason score, and PSA 
level (Rhodes et al. 2003). This gene represents an exciting development both as a 
prognostic marker and also as a therapeutic target.
ERBB2
The ERBB2 gene is located on 17q21.1 and mutations have been widely reported in a 
number o f tumours including breast and ovarian. ERBB2 or HER-2/neu, codes for a 
transmembrane tyrosine kinase growth factor, which is involved in interleukin 6 (IL6) 
signalling through the MAP kinase pathway. IL6 induces phosphorylation in the ErbB2 
and ErbB3 receptors in prostate cancer cell lines (Qiu, Ravi, & Kung 1998). 
Phosphorylation inactivates the receptors resulting in inhibition of the MAP kinase 
pathway (Qiu, Ravi, & Kung 1998). The recent development of a monoclonal antibody 
to the epidermal growth factor receptor, anti-ERBB2 (Herceptin, Genetech Inc, South 
San Francisco, CA) for use in advanced breast cancer (Pegram & Slamon 1999) has led 
researchers to re-focus on the role o f this oncogene in prostate cancer. Trials on the use 
of Herceptin in prostate cancer are ongoing (Scher 2000), but it is clear that high level 
ERBB2 amplification does not occur in this disease (Kallioniemi & Visakorpi 1996).
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However, Herceptin does inhibit growth in prostate cancer cell lines, including LNCaP 
(Agus et al. 1999) and ERBB2 enhances androgen receptor signalling in the presence of 
low androgen levels (Craft et al. 1999).
KAI1
The KAIl gene (Kang Ai, Chinese for anticancer), found on 11 pi 1.2-13, encodes a 
2.4kb mRNA for a membrane glycoprotein belonging to the TM4 superfamily, 
suggesting a role in cell-to-cell interaction or cell-extracellular matrix binding (Yu et al.
1997). KAI-1 has been shown to suppress metastatic potential in highly metastatic 
Dunning rat tumour models (Behrens et al. 1989). In addition expression of this gene is 
reduced in metastatic prostate cancer cell lines (Gao et al. 1997), but no mutation in this 
gene has yet been found, suggesting epigenetic silencing may be the mechanism of 
down regulation.
The KAIl gene is in close proximity to CD44 (11 p i3), this latter gene codes for a 
membrane glycoprotein, which is also present on lymphocytes and participates in cell- 
to-cell interaction. Dong et al. transfected the CD44 gene into metastatic rat prostate 
cells and demonstrated suppression of metastatic potential, without suppression in vivo 
of growth rate or tumorigenicity (Dong et al. 1995). Moreover down regulation of CD44 
at a protein and mRNA level correlated with metastatic potential in the Dunning rat 
tumour model (Dong et al. 1995). Studies in patients have found an inverse correlation 
between prostate cancer histological grade and stage with CD44 expression (Noordzij et 
al. 1997). Immunohistochemical studies have shown CD44 expression is either 
negligible or non-existent in prostate cancer lymph node metastases.
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l .ll(c )3 . Hormone refractory prostate cancer 
The androgen receptor
During embryological development and puberty androgens play a key role in prostate 
development. Testosterone is converted to its more potent metabolite 
dihydrotestosterone by the enzyme 5 a-reductase. There are no reported cases of 
prostate cancer in men who have a congenital deficiency o f 5 a-reductase. This enzyme 
can be antagonised pharmacologically by finasteride (Proscar®) and this drug has 
recently undergoing a phase III trial in over 18.000 men to evaluate a possible role in 
prostate cancer chemoprevention (Feigl et al. 1995). Early reports suggest a reduction in 
the incidence o f prostate cancer in the treated arm, however there appears an increased 
risk of high-grade tumours in men receiving finasteride. Whether this is a genuine 
difference or a result of the difficulties in interpreting the glandular architecture in men 
receiving finasteride remains to be seen (Thompson et al. 2003).
Dihydrotestosterone and testosterone bind to the androgen receptor (AR), which 
initiates phosphorylation and dimerisation of the receptor. The AR binds to a specific 
DNA sequence, the androgen responsive element, located in the promoter region of 
androgen responsive genes. The AR complex, in collaboration with cofactor proteins, 
up or down regulates the transcriptional activity o f the androgen response genes (Figure 
1.6).
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Low androgen level: 
IGF-1, KGF, EGFAdrenal glandsTestes
prostate cell cytoplasm
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5a -reductase
prostate cell nucleus
DNA
Androgen responsive element
Figure 1.6 The androgen receptor ligands and androgen responsive element. (AR =
androgen receptor, DHT = dihydrotestosterone, IGF-1 = insulin-like growth factor-1, 
KGF = keratinocyte growth factor, EGF = epidermal growth factor)
The removal of androgens by surgical castration or therapeutic blockade initiates 
apoptosis in prostate cancer cells resulting in a clinical response in up to 95% of men 
for a median 18 months (Petricoin et al. 2002). However, some prostate cancer cells 
have the ability to grow even in low or absent androgen levels. These cells have a 
selective growth advantage over the androgen dependent cells following androgen 
withdrawal. Androgen independent cells are able to proliferate and typically have a 
highly aggressive phenotype.
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The androgen receptor is amplified in 20% o f hormone refractory prostate cancers, but 
in only 2% of the same untreated individuals (Edwards et al. 2003). This suggests AR 
gene amplification is selected following androgen withdrawal though is not solely 
responsible for androgen independence. Amplification is associated with over­
expression of the AR gene (Koivisto et al. 1997; Visakorpi et al. 1995a) and some 
hormone refractory tumours express AR protein highly even in the absence of AR gene 
amplification (Edwards et al. 2003; Linja et al. 2001). Over-expression allows even very 
low levels o f androgen (such as adrenal androgen levels after surgical or medical 
castration) to promote androgen dependent growth and therefore, patients with AR 
amplification may respond better to therapeutic maximum androgen blockade 
(Visakorpi et al. 1995a).
There is also evidence that growth factors including insulin-like growth factor 1 (IGF- 
1), keratinocyte growth factor (KGF) and epidermal growth factor (EGF) may be able to 
activate the AR either through a ligand dependent or independent pathway. For 
example, the cAMP, protein kinase A and protein kinase C pathway may be able to 
directly activate the androgen receptor (Ikonen et al. 1994).
As well as amplification of the AR  gene several hundred other AR gene mutations have 
been reported (www.mcgill.ca), although not all these reported mutations are associated 
with prostate cancer. These mutations may alter the AR function and ligand specificity 
allowing other steroid hormones to bind, overcoming the need for androgens to 
stimulate growth. Mutations are uncommon in untreated prostate cancer and in cases 
treated with surgical castration, though they are found in patients treated with the 
testosterone antagonist flutamide (Taplin et al. 1995; Wallen et al. 1999). 
Approximately one third o f patients treated with flutamide have specific mutations,
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which result in AR activation (Eeles et al. 1998). This mutation, T887A, found only in 
patients treated with flutamide, changes the AR response from an antagonist to an 
agonist. This may explain why a minority o f patients paradoxically, show a temporary 
clinical improvement when flutamide therapy is withdrawn.
Up to 10-15% of hormone refractory metastatic lesions express only low AR levels as a 
result o f methylation in the promoter regions (Kinoshita et al. 2000). Clearly, a number 
of genetic and epigenetic changes occur in relation to the androgen receptor in late stage 
prostate cancer, and AR amplification, overexpression and mutation are not the 
exclusive cause the development of androgen insensitivity.
The androgen receptor complex exerts its effect on the target gene in conjunction with 
various cofactor proteins. Several of these proteins have been cloned including SNURF, 
ARIP3, ARA54, 55, 70, 160 and ANPK. Their role in cancer progression in vivo 
remains unknown at present.
BCL2
Bcl2 over expression is a characteristic o f advanced and hormone refractory prostate 
cancer and it may account for the dramatic reduction in apoptosis that occurs at this late 
stage (McDonnell et al. 1997). Like p53, Bcl2 expression maybe used as a molecular 
marker that correlates with disease outcome (Mackey et al. 1998). Over-expression in 
prostate cell lines confers a resistance to chemotherapeutic agents (Tu et al. 1995) and 
in a clinical setting several studies are testing whether Bcl2 inactivation can be used to 
prevent tumour recurrence (Gleave et al. 1999; Miyake et al. 1999).
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8q
Several studies using CGH have shown that gain in 8q is a characteristic of hormone 
refractory disease (Cher et al. 1996; Visakorpi et al. 1995b). Almost 90% of samples of 
hormone refractory prostate cancer and distant metastases compared with 5% of 
untreated primary tumours contained gains o f the whole of 8q. Alers et al. found the 
number of individuals with 8q gains increases with advancing tumour stage (Alers et al.
2000). Furthermore, gain in 8q, as well as loss of 6q, is significantly less frequently 
encountered in regional lymph node metastases than in distant metastases (Alers et al.
2000). This implies differential genetic changes for haematogenous versus lymphatic 
spread (Alers et al. 2000).
Several sites within 8q have been suggested as containing critical oncogenes, 8q21 
(Cher et al. 1996) and 8q 23-q24 (Nupponen et al. 1998). MYC is located at 8q24, and 
codes for a nuclear phosphoprotein whose function is in the promotion of DNA 
replication, regulation of the cell cycle and control over cell differentiation (Yeh et al.). 
Amplification of this oncogene has been found in 8% of primary and up to 72% of 
hormone refractory or advanced prostate cancers (Bubendorf et al. 1999; Nupponen et 
al. 1998; Sato et al. 1999). Furthermore amplification o f this gene is associated with 
poorer prognosis in patients with locally advanced disease (Sato et al. 1999). In 
androgen dependent LNCaP cell lines, cells treated with the androgen antagonist 
bicalutamide underwent growth arrest, whereas cells over-expressing c-myc were able 
to grow in an androgen independent environment (Bernard et al. 2003). This did not 
occur as a result o f a change in AR activity, rather c-myc is a downstream target of AR 
and overexpression of c-myc may be an alternative mechanism of androgen 
independence.
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Other sites o f amplification on 8q include 8q23 and 8q24.2, which harbours the putative 
oncogenes EIF3S3 and PSCA (Reiter et al. 2000; Visakorpi et al. 1995a). Using FISH, 
Nupponen et a l  found EIF3S3 in 30% of cases o f hormone refractory prostate cancers. 
Moreover EIFS3S was frequently, but not exclusively, co-amplified with MYC 
(Visakorpi et al. 1995a). PSCA is often co-amplified with MYC , and over-expression of 
PSCA has been reported in high grade and metastatic prostate cancer (Reiter et al. 2000)
l.ll(c )4 . Telomerase activity
Ageing is one of the major risk factors for the development of prostate cancer. HGPIN 
has been found in prostate samples from men in their twenties and occurs with 
increasing frequency with advancing age. Invasive cancer generally manifests itself in 
the sixth and seventh decade. This is because the prostate epithelium has a low 
proliferation rate and so takes longer for transforming events to occur. In addition, it 
may be related to the ability of telomerase over time to overcome replicative senescence 
in cancer cells. Telomeres are the non-coding repeat base sequences found at the end of 
eukaryotic chromosomes. With each cell division the telomeric sequence is shortened as 
DNA polymerase starts at an RNA primer that is subsequently removed. The telomere 
thus protects the coding regions until it has been shortened to a critical length. Then, at 
a critical age, it is thought to act as a signal to initiate apoptosis. Telomerase is an 
enzyme that adds telomeric sequences to newly formed DNA, therefore compensating 
for loss of sequences as a result of replication. This prevents the telomere reaching its 
critical shortened length and allows unlimited cell division.
Telomerase activity has been examined in exfoliated epithelial cells in the urine 
(Botchkina et al. 2005). All 56 men with prostate cancer had high levels of telomerase 
activity, though it was also detected in 12% of men who were thought to have BPH, this
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represents a potentially exciting new non-invasive test. Telomerase activity has not been 
found in normal or benign prostate tissue, it has however been found in 172 (89%) of 
194 cases of prostate cancer where it is associated with a reduced telomere length 
(Sommerfeld et al. 1996; Zhang et al. 1998). Increased levels of telomerase activity 
correspond more frequently to poor tumour differentiation (Lin et al. 1997). 
Furthermore telomerase activity was found in HGPIN in 14 (74%) of 19 samples and 5 
(12%) of 42 samples of normal prostate tissue adjacent to prostate cancers (Zhang et al.
1998). This suggests ‘normal’ adjacent tissue may have genotype changes before 
malignant phenotype changes can be identified.
Attempts have been made to use telomerase activity in prostate fossa biopsies at radical 
prostatectomy to predict local recurrence. Increased telomerase activity was found in the 
prostatic fossa samples of 5 (10%) of 48 men with pT2 and 7 (15%) of 47 men with 
>pT2(Straub et al. 2001). Recurrence rates in these trials are awaited, although 
telomerase activity may enable more accurate molecular staging of prostate cancer.
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1.12 Molecular markers in cancer
Gold and Freedman were the first to observe the potential of molecular markers when 
they discovered carcinoembryonic antigen (CEA), a protein usually only found during 
fetal development, is expressed in some colorectal cancers (Gold & Freedman 1975). 
This work has been expanded upon, augmented by the discovery of the human genome 
sequence, such that now genetic and epigentic changes are being used as molecular 
markers. Identification of specific genetic changes already allows the subclassification 
of several malignancies according to prognosis, including B cell lymphoma (Alizadeh et 
al. 2000) malignant melanoma (Bittner et al. 2000), breast cancer (Iwao et al. 2002), 
lung adenocarcinoma (Beer et al. 2002) and Wilms’ tumours (Lu et al. 2002). 
Prognostic markers currently used in patients with prostate cancer are limited as they 
measure tumour differentiation and the extent o f malignant tissue rather than the 
underlying biological properties that drive tumour behaviour (Singh et al. 2002). 
Attempts to identify genetic changes associated with prostate cancer progression have 
yielded alterations in a number of candidate genes associated with cancer progression, 
including loss of p53 , amplification o f MYC, loss of p27  and loss of PTEN (Sellers & 
Sawyers 2001). However, presently no single genetic change has been identified in a 
sufficiently significant proportion o f prostate cancer specimens to have prognostic value 
which will warrant its use in everyday clinical practice (Singh et al. 2002).
Novel markers have several potential roles:
• Detect early disease before symptoms develop when cure is still possible.
• Allow the detection of metastases before they are clinically evident thus 
preventing unnecessary radical intervention when cure is not possible.
• Assess the possible effect o f a therapy on a tumour to facilitate treatment 
planning. For example, breast cancer cells that express high levels o f tyrosine
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receptor kinase (ERBB2 or HER2/neu) are more likely to respond to Herceptin 
treatment. Assays are used to measure tyrosine receptor kinase expression before 
treatment is initiated.
• Monitor the effects of treatment. PSA plays an important role in the follow-up of 
men after radical treatments for localised prostatic cancer, detecting disease 
relapse several years before symptoms develop. Newer therapies, for example 
agents that disrupt angiogenesis or tumour invasion, may produce more subtle 
changes in the tumour so markers may be used to monitor therapeutic response.
1.12(a) DNA markers and microarray technology
Several genetic changes have been identified in early cancer and include: oncogenic 
mutation, microsatellite instability and methylation of the promoter region. These 
genetic modifications were originally detected in biopsy specimens but have 
subsequently been identified in cells from bodily fluids including: serum -  TP53 in 
hepatocellular carcinoma, urine -  telomerase and GSTP1 in prostate cancer and 
telomerase and TP53 mutations in bladder cancer, saliva -  CDKN2A in head and neck 
cancer, sputum - RAS mutations in men with lung cancer and faeces- RAS mutations in 
colorectal cancer (Sidransky 2002).
Gene expression profiling using microarrays allows a large-scale analysis of gene 
expression and cancer characterisation. DNA microarrays consist of thousands of spots 
of DNA oligonucleotides on a ‘chip’ each coding for part of a known or unidentified 
gene. Radio or fluorescently labelled DNA or RNA is applied to the chip and hybridises 
where there is a complementary oligonucleotide sequence. The site on the chip and 
intensity of the radioactive or fluorescent signal is proportional to the amount of a
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particular DNA/RNA. Rather than studying individual genes this technique allows 
examination of as many as 25,000 genes at one time.
Microarray chips have been used in young women with node negative breast cancer to 
identify a gene expression signature that predicts poor prognosis (Veer et al. 2002). In 
this study 5,000 genes were either significantly up- or down-regulated, a group of 70 
genes could be used to accurately predict disease outcome in 83% of 78 patients. This 
had important clinical implications as patients with the good prognosis genetic signature 
could safely avoid adjuvant chemotherapy, which they would otherwise have received, 
saving unnecessary side effects and cost.
The signature derived included genes involved in regulating the cell cycle, invasion, 
metastases, cell signalling and angiogenesis (eg cyclin E2, MCM6, VEGF receptor 
FL1). In breast cancer, like prostate cancer, numerous studies have shown associations 
between individual gene expression and patient outcome (cyclin D2, ER-, HER2/neu 
and MYC) (Bieche & Lidereau 1995). In the microarray analysis none of these genes 
was included in the 70 marker genes. The authors concluded cancer occurs as a result o f 
a coordinated action of several genes, so genes looked at in isolation have only limited 
predictive power.
Dhanasekaran et al. were one of the first groups to report gene expression profiling in 
prostate cancer. Using a selection of normal tissue prostate, benign prostatic 
hyperplasia, primary cancer, metastatic cancer and cell lines they identified a number of 
genes with altered expression patterns depending on the stage of disease. A hierarchical 
clustering algorithm was used to group genes based on the similarities o f genes 
expressed. They found benign prostatic conditions clustered separately from malignant
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tissue or cell lines. Within the cancer cluster, metastatic and clinically localised cancers 
clustered into two succinct groups. Several genes already implicated in prostate cancer 
carcinogenesis had altered expression levels. PTEN  and CDH1 (E-cadherin) were 
down-regulated and MYC and the fatty acid synthase (FSAN) gene were up-regulated. In 
addition numerous genes not previously implicated in prostate cancer were identified. 
Notably, hepsin, a cell-surface serine protease, was up-regulated by 4.3 fold on 
microarray analysis and this was confirmed on Northern Blot studies. 
Immunohistochemistry showed hepsin was preferentially expressed by neoplastic and 
HGPIN samples over benign prostate. In 78 men with clinically localised disease, 
absent or low hepsin expression was significantly associated with PSA recurrence after 
radical prostatectomy (p=0.03). In multivariate analysis the association of weak (HR 2.9 
(p=0.0004)) or absent (HR1.65 (p= 0.037)) hepsin protein expression was similar to 
having high-grade disease in terms o f PSA outcome.
Microarrays have also been used to predict tissue identity and pathological outcome 
after radical prostatectomy (Singh et al. 2002). This study also examined gene 
expression in relation to clinical outcome after radical prostatectomy, albeit involving 
small patient numbers. Using RNA extracted from tumours and normal tissue of fresh 
radical prostatectomy specimens the authors were able to identify 317 genes highly 
expressed in the tumours and 139 genes more highly expressed in normal prostatic 
tissue. Using a 4- or 16-gene model they were able to predict tumour from normal tissue 
with an accuracy of 77% and 86%, respectively. When the gene expression patterns 
were compared with the clinico-pathological prognostic indicators only the Gleason 
score correlated with gene expression, not pathological stage, positive surgical margins 
or perineural invasion. Fifteen genes had expression positively correlated with Gleason 
score with 14 genes had expression negatively correlated with Gleason score. Most
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high-grade cancers expressed the positively correlated genes. Interestingly, a subset of 
intermediate grade tumours also expressed these genes, possibly identifying a subset of 
phenotypically intermediate grade tumours with a more aggressive genotype.
Singh et a l also examined the relationship between gene expression and tumour 
recurrence in 21 unmatched patients, 8 having relapsed and 13 having remained PSA 
free for at least 4 years. No single gene was statistically associated with recurrence, 
when a 5-gene model was used (including chromogranin A, platelet-derived growth 
factor receptor p, HOXC6, inositol triphosphate receptor 3 (ITPR3) and 
siayltransferase-1), 90% accuracy could be achieved in predicting recurrence. The 
Gleason score of tissue adjacent to the sample tissue was >8 in 4/8 relapse patients 
compared with 0/13 in the non-relapse group. In this small sample of unmatched 
patients it is not possible to draw meaningful conclusion about the gene expression 
patterns and clinical outcome. This study does however demonstrate that gene 
expression patterns can be used to distinguish benign from malignant prostatic tissue 
with 86-92% accuracy.
Microarray analysis was performed on the cRNA of 24 patients with clinically localised 
prostate cancer (Welsh et al. 2001). A large number of genes with expression specific to 
malignant cells including, hepsin and fatty acid synthase (FASN), were identified. The 
gene expression of malignant cells could be divided into two groups by the expression 
patterns of a group of ribosomal genes and patients with higher Gleason score disease 
had significantly lower ribosomal gene expression (p<0.01). The authors emphasised 
the potential for therapeutic targeting o f differentially expressed genes including FASN, 
hepsin and MIC-1, though no new evidence was presented in this study to support this 
(Welsh et al. 2001).
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The results of gene expression profiling across the cancer spectrum are promising, and 
classification of cancers according to their genetic expression are now possible 
(Alizadeh et al. 2000; Bittner et al. 2000; Blaveri et al. 2005; Eschrich et al. 2005; Perou 
et al. 2000; Yang et al. 2005). Tailoring cancer treatments according to gene expression 
patterns is already underway and therapeutic targets are being tested. Prostate cancer 
poses several difficulties. The heterogeneous nature of the disease means that while the 
expression pattern of one area of tumour may accurately predict prognosis for that 
tumour the other foci with different genetic make-up may behave differently to the 
index lesion. For the same reason therapeutic modulation of genes with altered 
expression patterns may select out those tumours which do not have altered expression 
of the particular gene, in the same way that antiandrogen treatment selects androgen 
independent prostate cancer cells. In prostate cancer, the results of prospective studies to 
examine gene expression and patient outcome take many years to mature. The studies to 
date are retrospective and have involved small patient numbers, larger scale trials are 
required to demonstrate the validity and reproducibility of these results before these 
experimental techniques are used in the prostate cancer clinic.
1.12(b) Allelic imbalance
The protein coding regions account for just 3% of the whole human genome. The 
remaining 97% is located either within genes, the introns, or between genes. Since these 
regions do not code proteins variation is tolerated resulting in genetic diversity. Much of 
this non-coding DNA consists of repeated nucleotide sequences or Variable Number 
Tandem Repeats (VNTR). These may be single tandom repeats (STRs), often a 
dinucleotide consisting of CA (cytosine and adenosine) on the sense strand and GT 
(guanine and thymidine) on the antisense strand. These 2-5 nucleotide repeat segments
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are called microsatellite regions. Microsatellite regions also occur within or close to 
tumour suppressor genes. If a cell develops a mutation o f one allele of a TSG and loss 
o f the other allele, loss o f heterozygosity (LOH), then tumourigenesis may occur. 
Detecting deletion of a microsatellite region may therefore implicate the coding 
sequence near to the polymorphic region in the initiation or progression of the disease.
In a normal cell the microsatellites o f the paternal and maternal alleles are usually of 
different length. In a PCR reaction a single pair of oligonucleotide primers 
(microsatellite markers) that surround such sequences produce variably sized DNA 
fragments depending on the number of repeats. If either the maternal or the paternal 
microsatellite region is lost during tumorigenesis (LOH) the product of only one of the 
alleles will be amplified -  this is allelic imbalance (Al) (Figure 1.7).
The role of Al as a molecular marker was first described in 1996 from urine samples of 
25 patients with bladder cancer (Mao et al. 1996). Al alterations that matched those in 
the tumour were detected in 95% of those with bladder cancer whereas urine cytology 
detected cancer in only 50% of samples. This study demonstrated the role of 
microsatellite markers in the screening o f cancer, subsequent studies have used Al 
analysis in monitoring the response o f bladder cancer to therapy.
The problem with this technique is that it is not very sensitive and so large quantities of 
cancer DNA is required. Furthermore a panel of microsatellite markers is required, 
perhaps 15-20, to reliably detect cancer.
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Figure 1.7. Demonstrates locus ‘a ’ in a normal cell and a malignant cell containing 
microsatellite instability and allelic imbalance (LOH).
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1.12(c) Microsatellite instability
Errors generated during DNA replication are usually corrected by DNA repair enzymes, 
such as those involved in nucleotide excision repair and mismatch repair. Short 
stretches o f mismatched base pairs occur in microsatellite regions during normal DNA 
replication, however these errors are not corrected if mismatch repair genes have been
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inactivated (Figure 1.7). Inactivating mutations of mismatch repair genes have been 
described in cancer. Errors in mismatch repair lead to instability at microsatellites and 
increased mutation rates causing differing lengths of microsatellite regions between the 
tumour and normal tissue o f the same individual. This is termed microsatellite 
instability (MSI) and is responsible for the development of hereditary nonpolyposis 
colon cancer (HNPCC).
Several mismatch repair genes have been identified, including hM LHl, hPM Sl, 
hPMS2, hMSH2. Using immunohistochemistry hMSH2 staining was minimal to low in 
normal glands (Velasco et al. 2002). In 32% of benign prostatic hyperplasia cases 
hMSH2 staining was increased, in 71% of cancer specimens moderate to high staining 
was reported. Microsatellite instability was detected in 60% of absent to low staining 
and 26% of moderate to high staining prostate carcinoma specimens. Independent of 
tumour grade and stage, decreased risk for PSA recurrence after radical prostatectomy 
correlated with absent to low hMSH2 staining. Some studies have shown extensive MSI 
is associated with high grade and more advanced tumours (Uchida et al. 1995) though 
others have failed to confirm this (Dahiya et al. 1997a). Mutations or epigenetic 
silencing of the mismatch repair genes may augment cancer progression by failing to 
correct potentially pro-carcinogenic DNA defects, identifying these changes may 
potentially provide prognostic and therapeutic targets.
1.12(d) Hypermethylation
Epigenetic changes are alterations in gene expression without change in DNA sequence.
The most common somatic alteration in prostate cancer is hypermethylation in the
regulatory region of certain genes, most commonly in GSTP1. Areas rich in the
cytosine-guanine motif (CpG islands) occur in the promoter region of some genes,
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including tumour suppressor genes. Methylation of these cytosine residues, which 
occurs in cancer as well as normal fetal development, inactivates the promoter and 
blocks transcription.
Inactivation of TSGs by methylation occurs in a number of cancers. To assess DNA 
methylation DNA is treated with sodium bisulphite. Sodium bisulphite converts 
unmethylated cytosines to uracil while the methylated cytosines are protected and 
remain as cytosine. Methylation specific PCR assays can be performed with great 
sensitivity, amplifying only methylated DNA and enabling the detection o f 1 cancer cell 
amongst 1000 normal cells in a body fluid. This technique is currently being used to 
assess the urine of men with prostate cancer, saliva in patients with oral cancer, 
bronchiolar lavage fluid in patients with lung cancer and the serum of people with lung, 
head and neck and colorectal cancers.
Efforts to quantify the degree o f methylation are being developed. Real-time-PCR 
involves the monitoring of fluorescent signals during DNA amplification. Cancer cells 
that have a high degree of methylation will amplify at a faster rate than benign cells 
with low or no methylation. Real-time-PCR has been used to assess the degree of 
methylation of cells obtained by prostatic massage (Goessl et al. 2001). GSTP1 
(glutathione-S-transferase) encodes for an enzyme that detoxifies potential carcinogens. 
This is inactivated, by promoter methylation, in 70% of patients with HGPIN and 90% 
of men with invasive prostate cancer (Brooks et al. 1998; Lee et al. 1997).
1.12(e) Mitochondrial DNA mutation
Mitochondrial DNA is more susceptible to damage by exogenous mutagens than
nuclear DNA and has less efficient repair mechanisms (Sidransky 2002). Several
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tumour specific mutations have been described in mitochondrial DNA initially in men 
with colorectal carcinoma and subsequently in bladder, breast, lung and head and neck 
cancers.
Mitochondrial DNA is significantly shorter than genomic DNA at 16000 base pairs. 
Furthermore mutations are most frequently found in a region probably involved in 
mitochondrial replication called the mitochondrial D-loop. While the detection of 
mutations in mitochondrial DNA may prove useful, methods are not yet available to 
carry out high volume analysis as required in the clinical setting.
1.12(f) Viral DNA
Viral DNA can be detected in a number o f tumours, including human papilloma virus 
(HPV) in cervical and head and neck squamous-cell-carcinomas and Epstein-Barr virus 
(EBV) in nasopharyngeal carcinoma. These viruses are strongly implicated in the 
aetiology of these diseases. While viruses are probably not aetiological factors in 
prostatic neoplasms, viral DNA may become a useful molecular marker in other 
carcinomas.
1.12(g) RNA markers
Genetic alterations lead to fundamental changes in the level of mRNA and this can be 
detected by the reverse transcriptase polymerase chain reaction (RT-PCR). This 
involves the conversion of RNA into a copy or cDNA, catalysed by the enzyme reverse 
transcriptase. This is then amplified by PCR to allow detection. This has been used to 
detect mRNA for tyrosinase to distinguish benign skin moles from melanoma. It has 
also been used to detect transcripts o f PSA and CEA in blood, lymph node and bone 
metastases to confirm detection.
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Quantitative RNA analysis may be required as altered gene expression may be present 
in normal as well as malignant cells. Quatitative RT-PCR is currently used to monitor 
treatment response in, for example mRNAs that encode thymidine phosphorylase in 
colon tumour samples in patients treated with 5-flourouracil (Salonga et al. 2000).
1.12(h) Protein markers
Several protein-based assays have been developed to detect malignant cells. Most use 
antibody based assays, although other approaches are being developed. These 
techniques either detect levels o f over-expressed protein or structurally altered protein 
in cancer cells. The measurement o f serum PSA involves a protein assay, other protein 
markers used to detect cancer or to diagnoses recurrent disease include human chorionic 
gonadotrophin (HCG) and a-fetoprotein (AFP) in testis and hepatocellular cancers, 
CEA in colorectal cancer and CA125 in ovarian carcinoma. Some newer markers, like 
CA15-3 in breast cancer or CA19-9 in pancreatic cancer are only found in a fraction of 
affected individuals (Canizares et al. 2001; Slesak et al. 2000). In addition all these 
markers lack specificity -  they may be elevated by other disease processes, which limits 
their role in cancer screening. PSA, CEA and CA125 are used to diagnose recurrent 
disease before radiological evidence or symptoms are apparent, enabling further 
treatment while the tumour burden is low.
As discussed, telomerase is required for cellular immortalisation and is therefore 
expressed in almost every cancer type. Telomerase has been detected in the urine of 
patients with bladder and prostate cancer and the saliva of people with oral 
malignancies (Califano et al. 1996; Yoshida et al. 1997). Several assays are available, 
including the telomerase repeat amplification protocol (TRAP). Lymphocytes also
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express low levels of telomerase, leading to false positive telomerase assays (Califano et 
al. 1996; Yoshida et al. 1997). A more quantitative telomerase assay may be more 
useful to determine the presence of cancer cells in a clinical sample.
Antibodies to aberrant proteins expressed by malignant cells may be detected in the 
serum of patients with certain cancers. For example, antibodies to p53 have been 
detected in the serum of patients with small cell lung carcinoma (Jassem et al. 2001).
Since the mapping of the human genome, attention has now focused to proteomics as a 
source of cancer markers. This is because post-translational protein modification may be 
cancer specific and cannot be determined at the genomic level. Proteomics is the 
analysis o f large number of proteins. It has already been used to compare normal and 
malignant prostate cells and this information was used to correctly identify unique 
proteins in the sera o f patients with prostate cancer (Paweletz, Liotta, & Petricoin, III 
2001). High throughput mass spectroscopy can be used to detect cancer in patient 
samples including blood and urine. Techniques including matrix-assisted-laser- 
desorption-ionisation time-of-flight (MALDI-TOF) mass spectroscopy or liquid- 
chromotography-ion-spray tandem mass spectroscopy (LC-MS) have revolutionised 
protein analysis. In these examples a patient sample, such as urine or serum, is 
fractionated and digested with proteolytic enzymes and separated using chromatography 
(Wall et al. 2000). The partially separated sample is then put into a mass 
spectrophotometer. While individual proteins are not identified a proteomic profile 
containing several thousand points is produced. The protein profile of normal and 
malignant cells differs and these techniques have been used in diagnosing ovarian and 
bladder cancers. A diagnostic sensitivity of 100% and a specificity of 95% was reported 
in one series examining ovarian cancer, including patients with early stage disease
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(Petricoin et al. 2002). These techniques have the potential to diagnose and detect 
disease relapse at an earlier stage without the need for a biopsy. Their role as prognostic 
markers has not yet been examined, though it is likely it may be extended to allow 
specific proteomic profiles to correlate with patient outcome in the future.
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1.13 Summary
The current clinico-pathological markers used in the management of men with clinically 
localised prostate cancer undergoing radical prostatectomy and their limitations have 
been reviewed. Inaccuracies in these markers results in a significant proportion of men 
developing recurrent disease after surgery, despite stage migration and modest 
improvements in staging techniques. The management options for men with recurrent 
disease are limited to radiotherapy for local control and androgen ablation as systemic 
therapy. Prospective data on these treatments in the setting of PSA only recurrence after 
radical prostatectomy is currently lacking.
The fact that specific molecular changes are associated with each step in the 
pathogenesis o f prostate cancer has been emphasised. By identifying these molecular 
changes it may be possible to use genetic biomarkers to predict the likelihood of relapse 
after surgery. In the future these changes may be identified in biopsy material to enable 
better patient selection for surgery, as well as directing treatment in the adjuvant and 
salvage setting. Ultimately genetic or epigenetic changes may act as targets for therapy.
This thesis aims to identify molecular changes in radical prostatectomy specimens in an 
attempt to identify genetic alterations that predict patient outcome after surgery. The 
patient selection, methods and results of this experiment will be described in chapters 
2,3 and 4 respectively. The experiments examining an epigenetic change in the 
promoter o f the p 2 iWAhI/CIPI gene are described in Chapter 5.
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CHAPTER 2 r u ;
Patient Selection
Aim
The aim of this study was to address the question: In two matched groups of men who
have undergone radical prostatectomy, can molecular markers be used to predict 
biochemical outcome? This chapter outlines the rationale for patient selection and how 
this process was undertaken.
2.1 Introduction
The increasing use o f serum PSA as a biomarker has led to more men being diagnosed 
with prostate cancer when it is still clinically organ-confined (Bott et al. 2005c; Han et 
al. 2001) (Figure 2.1). Early detection allows radical treatment with curative intent. 
However, 25-53% of men will develop prostate specific antigen (PSA) recurrence up to 
10 years after radical prostatectomy (Hull et al. 2002; Pound et al. 1997; Quinn et al. 
2001; Trapasso et al. 1994; Zincke et al. 1994), often as a result of micrometastatic 
disease present, but undetected, at the time of surgery (Roberts et al. 2001). Identifying 
markers that predict metastases would preclude some men from undergoing the 
procedure with its inherent risk of short and long-term side effects but without any 
evidence of a survival benefit.
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Figure 2.1 Pathological stage over time in the UCL Radical Prostatectomy 
database (Bott et al. 2005c).
From the Johns Hopkins series in the United States, over 90% of men with a rising PSA 
within 2 years of surgery have metastatic disease, presumably present but undetectable 
at the time of surgery (Pound et al. 1997). With the advent of highly sensitive PSA 
assays up to 90% of potential disease recurrences can be recognised within 3 years of 
radical surgery (Stamey et al. 2000). In the minority of men who relapse after 3 years, 
74% develop local recurrence, without distant metastases (Pound et al. 1997). To 
investigate whether molecular markers could be used to predict poor outcome after 
radical prostatectomy, two groups of patients were selected. One group had rapid 
disease progression likely to represent occult metastases at the time of surgery and the 
other group remained disease free for at least 3 years. Patients were matched for the
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most important clinical predictors of outcome after surgery: radical Gleason sum score, 
preoperative PSA and pathological tumour stage.
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2.2. Methods
2.2(a) The UCL Radical Prostatectomy Database
The radical prostatectomy database held at University College London contained the 
pathological details o f 1001 men who had undergone radical prostatectomy, between 
1988-2001. All specimens were examined by a single histopathologist, MCP, and there 
were 16 surgical contributors, operating at nine hospitals. The database was used to 
identify patients according to their pathological stage and once the study population was 
recruited the clinicopathologic-1 ----------------
In this series, the UICC 1997 TNM classification was used. Prostate cancer was 
reported as organ confined if  the tumour did not extend outside the smooth muscle 
limits of the gland and into the periprostatic fibroadipose tissue. If tumour was close to
designated as gland-confined (Epstein 1990; Epstein & Sauvageot 1997). 
Apical/urethral, base/bladder neck and vasal margins were assessed using the shave
aspects of the apical and basal blocks, respectively. Where cancer was present in the 
shave limit the margin was considered positive. If the bladder neck shave margin 
contained tumour the specimen was classified as margin positive and stage pT4. If the 
apical or vasal shave contained tumour these were reported as a positive margins but 
this did not impact the stage.
Positive circumferential margins (anterior, lateral and posterior) were classified as either 
extraprostatic where tumour was in contact with the inked specimen limits having 
spread beyond the gland or intraprostatic when the cancer was cut through inside the 
glandular area of the prostate due to inadvertent surgical incision of the periprostatic
the prostatic limit but separated by a few fibroblasts or smooth muscle cells it was still
technique (Figure 2.2). Thios involved taking a section from the inferior and superior
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fibroadipose tissue and prostate capsule. The term pTx was applied to tumours that 
could not be assessed for stage. This included specimens with an intraprostatic positive 
limit and no evidence of extraprostatic spread at any other site. Eighty-one patients in 
whom stage was indeterminate (pTx) were excluded.
Vasal
Bladder neck
Urethral
Figure 2.2 Assessment of margin status using the shave technique.
The Gleason score at radical prostatectomy consisted of the sum of the two Gleason 
grades, each 1-5, from the two largest areas of cancer. At biopsy the two highest 
Gleason grades were summated to give the overall biopsy Gleason score.
Tumour volume was assessed by identifying areas of tumour microscopically and 
outlining them in ink. A microscopic measurement grid was used to calculate the areas 
of all tumours, which were summated and multiplied by 0.5cm (the depth of each 
block).
Biochemical recurrence in this study was defined as a serum PSA level at least 0.2ng/ml 
and rising after radical prostatectomy (Pound et al. 1999; Salomon et al. 2003) or 
0.5ng/ml (Partin et al. 1993) if a less sensitive assay had been used.
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2.2(b) Consent
Consent for the radical prostatectomy database and for this project was obtained from 
the Joint UCL/UCLH Committees on the Ethics of Human Research (Study number 
01/0093), in compliance with the ICH GCP (International Committee on Harmonisation 
Good Clinical Practice - www.corec.org.uk). The committee stated retrospective patient 
consent was not required. From January 2000 individual patients were asked to consent 
for their clinicopathological details to be stored on the database and for tissue from their 
surgical specimen to be used in genetic research. Patients undergoing radical 
prostatectomy were provided with an information sheet and consent form to sign and 
return. The vast majority o f men gave their consent, where consent was refused patients 
were excluded from the database and laboratory based research. The database was 
registered under the Data Protection Act 1998.
2.2(c) Identifying two groups of patients 
2.2(c)l. Tumour stage
The findings from the whole radical prostatectomy database were collated. The most 
common pathological stage in the UCL database was pT2 i.e. pathologically organ- 
confined prostate cancer; of 1001 cases 435 had pT2 disease. However, in our series and 
from the literature an insufficient number of these patients develop biochemical 
recurrence for optimal matching (Babaian et al. 2001; Pound et al. 1997). The reported 
PSA free rate for men with pathologically organ confined disease is 81-85% at 7-10 
years (Babaian et al. 2001; Catalona, Ramos, & Carvalhal 1999; Pound et al. 1997). In 
the UCL series, one surgeon (RSK), from who PSA follow-up data was available, had 
operated on 196 men with a pT2 disease. After a median follow up of 25 months only
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14 (7%) o f these men developed a PSA rise >0.2ng/ml (Bott SRJ et al. 2002). Despite 
having 435 men with pT2 disease overall, there were an insufficient number of men 
who have relapsed to enable matching.
A total of 415 men had pT3 disease, the second most common pathological stage in the 
UCL database. The literature reports between 24-82% of men with stage pT3 prostatic 
cancer develop biochemical relapse after 7-10 years follow-up (Catalona, Ramos, & 
Carvalhal 1999; Hull et al. 2002; Pound et al. 1997). Data were available on the 
biochemical outcome of 143 men with pT3a from RSK, of who 49 (34%) developed 
biochemical recurrence after a median 25 months (range 2-89 months). It was estimated 
140 men with pT3 from the whole UCL radical prostatectromy database were predicted 
to relapse so this cohort was selected for further investigation.
2.2(c)2. Exclusion criteria
Lymph node metastases are one o f the most significant independent predictors of 
biochemical failure after radical prostatectomy (Epstein, Pizov, & Walsh 1993; Gervasi 
et al. 1989; Quinn et al. 2001; Stamey et al. 2000) and almost all patients with lymph 
node involvement develop biochemical relapse within 10 years of surgery (Epstein, 
Pizov, & Walsh 1993; Gervasi et al. 1989). Molecular markers are unlikely to add to the 
prognostic data from routine histological examination in cases with lymph node 
metastases, as their outcome is known. Patients with lymph node disease were excluded, 
leaving 401 men with pT3N0 disease.
Men who received antiandrogen therapy either preoperatively as neoadjuvant therapy, 
or as adjuvant treatment immediately postoperatively as a result o f the pathological 
findings, were excluded. Antiandrogen therapy causes apoptosis in the hormone
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sensitive prostatic epithelial cells and may result in down staging of the tumour, 
inaccurate Gleason scoring and a reduction in serum PSA concentration - all potentially 
leading to inappropriate matching. Men receiving finasteride, a 5a-reductase inhibitor 
used in the treatment o f benign prostatic hyperplasia, were also excluded as finasteride 
reduces PSA levels and may alter the glandular structure affecting Gleason grading. 
Men receiving antiandrogen therapy as salvage treatment, after a rising post-operative 
PSA, were included in the ‘relapse’ group if they fulfilled the other matching criteria.
Patients who received adjuvant radiotherapy based on adverse pathological features 
identified on the radical prostatectomy specimen were excluded from the non-relapse 
group. Men who received adjuvant radiotherapy and subsequently relapsed within 2 
years were included in the relapse group as these men were still likely to be harbouring 
micrometastases at the time of surgery.
Patients who receive primary radiotherapy and subsequently underwent salvage 
prostatectomy for cancer recurrence are a selected group of men with poor prognosis 
disease. Furthermore, radiotherapy leads to DNA damage, which may have adversely 
affected the study findings; consequently these men were excluded from this study. In 
total 83 men were excluded as they had received either radiotherapy or hormonal 
manipulation.
Tumours diagnosed on TURP are more likely to represent transition zone cancer which 
is commonly of lower Gleason score, higher tumour volume and has different gene 
expression patterns compared with tumours arising in the peripheral zone (Bott et al. 
2005c; Erbersdobler et al. 2002a; McNeal et al. 1988; Pavelic, Zeljko, & Bosnar 2003).
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Tumours diagnosed after TURP were excluded so all cancers included in this study 
were diagnosed by prostatic biopsy.
The UCL Radical Prostatectomy database has limited PSA follow-up uaia. num. 
patients who met the inclusion criteria could be identified, their biochemical outcome 
was not known. Furthermore, data on adjuvant and salvage treatments was required. 
The notes o f all 49 NHS patients were retrieved and their PSA follow-up and adjuvant 
therapy noted. NHS patients who were referred for surgery from another hospital were 
often followed up and had their PSA measured at their local hospital. In order to obtain 
their follow-up details, notes were retrieved and reviewed in the local hospital. If 
insufficient information was derived from these, the patient or their General Practitioner 
was contacted directly.
Private patient records were also examined in the case o f three consultants (RSK, NOD, 
JB). These cases were often referred from across the UK and overseas so these data 
were incomplete. A questionnaire was therefore devised and sent to all 440 private 
patients operated on by the most prolific private surgical contributor, RSK. This asked if 
patients had achieved a PSA nadir o f <0.2ng/ml within six weeks of surgery and 
whether the PSA had subsequently risen above 0.2ng/ml. Patients were asked whether 
they had received radiotherapy, hormonal manipulation or if they were taking the herbal 
remedy PC-SPES. As part o f a separate study addressing the impact o f radical 
prostatectomy on erectile dysfunction, continence and quality of life further questions 
derived from the Short Form 36, International Index of Erectile Function and 
International Continence Society-male questionnaires were included. If a response had 
not been received within 6 weeks, a further questionnaire was sent. A final response rate
2.2(c)3. Biochemical outcome
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of 81% (360) was achieved including 145 men had pT3N0 disease. Patients with pT3N0 
disease who did not respond to the questionnaire were contacted directly. The 
questionnaire results have been presented (Bott SRJ et al. 2002; Thomas K et al. 2002).
Once biochemical outcome and adjuvant therapy status was established patients were 
assigned to either a ‘relapse’ group or a ‘non-relapse’ group. The relapse group 
consisted of patients who developed biochemical relapse, defined as a PSA of 
>0.2ng/ml (Aus et al. 2003; Pound et al. 1999; Salomon et al. 2003) or >0.5ng/ml if a 
less sensitive assay was used (Partin et al. 1993), within two years of surgery. The non­
relapse group were defined as patients whose serum PSA level remained undetectable 
for at least 3 years after radical prostateetemy. Men who relapsed in the third 
postoperative year were excluded.
Gleason grade and pre-operative PSA. Pathological stage was split into pT3a and pT3b 
and men matched accordingly. The Gleason grade was divided into Gleason sum 5, 6, 7 
or 8. The two components o f the sum score were matched where possible. The 
preoperative PSA was grouped 4-9.9, 10-19.9 and 20ng/ml or above. This is in line with 
recognised inflection points for prognosis in pre-treatment PSA levels (Quinn et al.
To avoid bias once patients had been identified from the database they were given a 
randomisation number and the study investigators were blind which numbers were 
allocated to a particular patient until the final analysis.
The relapse and non-relapse groups were matched for pathological tumour stage, radical
2.2(c)4. Matching
2 0 0 1 ).
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Other possible prognostic factors examined but not included in the matching process 
included the surgical margin status, tumour volume and the presence of lymphovascular 
invasion.
A positive surgical margin implies incomplete tumour resection at the time of radical 
prostatectomy and most authors consider positive margins an independent predictor of 
disease outcome (Cheng et al. 1999; Epstein et al. 1996; Ohori et al. 1995). Positive 
margin status maybe sub-classified into intra or extra prostatic, focal or extensive - 
though a universally agreed definition of each of these has not been established 
(Bostwick et al. 2000). Furthermore, the site as well as the extent and multifocality of 
positive margins all affect PSA outcomes (Blute et al. 1997; Obek et al. 1999). Due to 
the complexity surrounding positive margins and the lack of agreed definitions patients 
were not matched for surgical margin status. Statistical analysis was undertaken to 
examine whether differences existed with respect to margin status between the two 
groups.
Tumour volume as a prognostic indicator has been extensively studied but its 
importance remains to be validated in statistically robust trials (Bostwick et al. 2000; 
Epstein et al. 1993; Stamey et al. 1993). Tumour volume was not included in the 
matching criteria although statistical analysis was undertaken to examine any 
association with biochemical outcome in this cohort.
Some authors have found the presence of lymphovascular invasion is an independent 
prognostic predictor after radical prostatectomy (Stamey et al. 1999), though this is not 
universally accepted (Bostwick et al. 2000). Differences between the two groups with
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respect to lymphovascular invasion were examined statistically but were not included in 
the matching criteria.
2.2(d) Statistical Analysis
Matching two groups o f patients for the main prognostic features limits the impact of 
confounding variables and increases statistical power. For this reason, in a matched 
study the sample size required to show statically significant differences is smaller than a 
comparable randomised study. The disadvantages of using matched groups for this 
study include:
• between participant difference still exists (e.g. PSA levels not identical in 
matched pairs)
• uninformative locus in one individual results in the loss of a pair of subjects
• additional potential prognostic variables are not included in matching (e.g. 
tumour volume or lymphovascular invasion).
The outcome variable for the allelic imbalance experiments was qualitative binary - 
either the patient has or does not have allelic imbalance at an informative locus. Where 
an individual was homozygous or uninformative they were not included in the statistical 
analysis for that locus. The McNemar test is used for paired or matched samples in 
which the outcome variable is binary. A significance level of 5% (p=0.05) was set and a 
power calculation of at least 80% required. The power is the probability of finding a 
difference if one truly exists (Appendix 1).
To establish the minimum sample size a realistic expectation of what difference in 
allelic imbalance between case and control was set at 40%. The statistical power 
increases with greater subject numbers. For example, if  20 paired cases are matched a 
power value o f >80% cannot be achieved. If 30-paired cases are matched and 70% of
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test cases and 30% of controls (a difference o f 40%) have allelic imbalance at a locus 
the power value is 86%. If the same 30-paired cases have allelic imbalance at a single 
locus in 70% of test cases and 40% of controls (a difference of 30%) then the power 
value is 62% and a significant difference between the test and control groups is not 
evident. To demonstrate a significant power difference between the two groups a 
sample size o f at least 30 matched pairs was required using the McNemar test. This 
statistical test was selected at the outset and before patient matching was undertaken.
From 413 men with pT3a prostate cancer two groups of only 31 men could be 
identified. Men with an uninformative locus or in who a result was unobtainable for j
/
experimental reasons could not be included such that the 30 matched pairs required for 
the McNemar test could not be achieved for any locus. ^
y  c O z .
Fisher's exact test is a statistical test used to determine if there are non-random 
associations between two categorical variables. It has the advantage that it does not 
make any approximations, and so is suitable for small sample sizes (expected frequency 
in any of the cells is <5). However, it assumes both groups are independent (unmatched) 
and so the increased statistical power gained by paired matching in this series was lost. 
Fisher’s exact test was used to assess differences in allelic imbalance between the two 
study groups. The Fisher’s exact test allowed all results to be analysed irrespective of 
whether the matched pair was informative.
Chi square test is a method to assess statistical significance for bivariate tabular analysis 
and provides the degree of confidence in accepting or rejecting a hypothesis from non- 
parametric data (e.g. lymphovascular invasion). The paired /-test is a parametric test to 
compare means and determines whether two matched groups differ from each other in a 
significant way under the assumptions that the paired differences are independent and 
normally distributed (e.g. patient age). The Wilcoxon Signed Ranks is non-parametric
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alternative to the paired t test and compares medians, as it is a non-parametric test 
ordinal data may be analysed (e.g. preoperative PSA).
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2.3 Results
2.3(a) The Radical Prostatectomy Database
The radical prostatectomy database contains clinicopathological features of 1001 men 
who have undergone radical prostatectomy between 1988-2001 (Bott et al. 2005c). The 
surgeons contributed the following number o f radical prostatectomy specimens each: 44 
MB, 31 JB, 3 AC, 42 ME, 510 RK, 201 NOD, 1 CO, 1 AP, 1 JP, 38 JS, 122 PS, 7 PW. 
Seven hundred and forty two radical prostatectomies were performed in the private 
sector and 259 in the National Health Service. The selection criteria (preoperative PSA 
and biopsy Gleason grade) and pathological outcome (pT stage, radical Gleason score 
and tumour volume) did not differ significantly between the NHS and private sectors. 
Although the mean age at surgery did show a statistically significant difference, 63 
years (NHS) and 61 years (private sector) (paired t test, p < 0.01) this was not of major 
clinical importance.
The preoperative features and pathological variables of the whole UCL database are 
shown in Table 2.1 and the incidence and site o f positive surgical margins is 
summarised in Table 2.2.
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Table 2.1 Preoperative and pathological features of the UCL Radical 
Prostatectomy database.
Age (years) Mean
SD
62
6
Pre-op PSA (ng/ml) Minimum 0.10
Median 8.00
Maximum 146.00
Biopsy Gleason sum Minimum TSTG
score Median 6.00
Maximum 10.00
Tumour volume (mis) Minimum TSTM
Median 1.40
Maximum 30.60
Pathological stage pTO 3 (<1%)
/ pT2a 94 (9%)
pT2b 341 (34%)
V pT3a 311 (31%)
pT3b 104 (10%)
pT4 67 (7%)
pTX 81 (8%)
Number of patients =1001, TSTG = too small to grade,r 'STM = too small to measure
Table 2.2 The number and site of positive surgical margins from The UCL Radical 
Prostatectomy database.
All m argins -ve 465 (48%)
1 margin +ve 336 (35%)
Apical 215 (22%)
Circumf-CIP 71 (7%)
Circumf - CEP 31 (3%)
Circumf- CIP+CEP 5 (<1%)
Bladder neck 10 (1%)
Vasal 4 (<1%)
2 m argins +ve 135(14%)
CIP + Apical 69 (7%)
CEP + Apical 34 (4%)
Others 32 (3%)
3 m argins +ve 26 (3%)
4 m argins +ve 5(1%)
CIP = Circumferential intraprostatic margin 
CEP = Circumferential extraprostatic margin
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2.3(b) Patient matching
Four hundred and fifteen patients had pT3 disease o f which 14 had lymph node 
metastases and were excluded. Eighty-three patients who received preoperative 
treatment with antiandrogens, finasteride or radiotherapy were also excluded. O f the 
remaining 307 patients, 17 relapsed in their third postoperative year and so were 
ineligible for either the relapse or non-relapse groups. O f the remaining contactable men 
there were 91 men with adequate follow-up. Forty-four men had developed PSA 
recurrence within 24 months o f surgery and 47 had remained PSA free for at least 36 
months without receiving adjuvant therapy. These patients were matched for stage 
(pT3a or pT3b), Gleason sum score (5,6,7,8) and the constituent scores where possible, 
and PSA (4.1-10, 10.1-20 ng/ml). Two groups o f 31 patients were matched (Table 2.3); 
all had been diagnosed with prostate cancer as a result of prostatic biopsy.
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Table 2.3 Patient matching
J t e i a p ^
'
7
......
* Reiapao  ^ni. vJUbuljb
1 32 3+4=7 3+4=7 14.2 11.3 pT3a pT3a 9 40
6 10 4+3=7 4+3=7 16.7 18.5 pT3a pT3a 6 44
4 26 4+3=7 4+3=7 10.1 12 pT3a pT3a 18 47
2 49 4+3=7 4+3=7 12 10 pT3a .._ pT3a 13 60
3 54 4+3=7 3+4=7 18 11 pT3a pT3a 4 53
55 56 4+3=7 3+4=7 14 16.6 pT3a pT3a 7 49
42 21 4+4=8 4+4=8 15.7 16.3 pT3a pT3a 19 47
16 30 4+3=7 3+4=7 8 8.8 pT3a DT3a 17 39
25 13 4+3=7 3+4=7 8.6 5.9 PT3a pT3a 11 64
58 57 4+3=7 3+4=7 16 10.5 pT3a pT3a 21 48
59 9 3+4=7 3+4=7 8 8 pT3a pT3a 6 56
27 12 4+3=7 4+3=7 7.5 8.8 pT3a pT3a 16 66
60 5 4+3=7 3+4=7 8.7 7.9 pT3a pT3a 3 42
52 29 4+3=7 3+4=7 5.9 7.4 pT3a PT3a 5 37
11 62 3+3=6 3+3=6 4.3 9.3 pT3a pT3a 3 70
38 48 2+4=6 4+2=6 10.2 12.9 pT3a pT3a 12 62
18 33 3+2=5 3+2=5 18.6 16 pT3a PT3a 18 70
7 23 2+3=5 2+3=5 14.7 17.8 PT3a pT3a 9 60
79 77 3+5=8 4+4=8 9.7 7.5 pT3a pT3a 12 46
22 28 2+3=5 2+3=5 8.6 7 PT3a pT3a 16 87
15 17 2+4=6 3+3=6 9.1 5.1 pT3a pT3a 20 62
24 19 4+3=7 3+4=7 16 8.3 pT3a pT3a 21 71
43 44 4+3=7 3+4=7 5.2 5.5 pT3a pT3a 3 53
45 20 3+4=7 3+4=7 9.8 6.4 pT3a pT3a 8 59
64 61 5+3=8 4+4=8 14.4 15.1 pT3a pT3a 11 48
75 37 4+3=7 3+4=7 15.8 13 pT3a pT3a 5 45
74 31 3+4=7 3+4=7 9.9 9.7 pT3a pT3a 3 36
50 51 4+3=7 3+4=7 15.7 17 pT3a pT3a 15 36
35 34 3+2=5 2+3=5 5.1 9 pT3b pT3b 3 36
78 53 4+3=7 4+3=7 12.4 16.6 pT3b .  ......... 5____________ 57
39 36 4+3=7 4+3*7 18 13.4 pT3b pT3b 6 55
Median 10.2 
(range 5.1-18.6)
Median 10.0 
(range 5.1-17.8)
Median 9 
(range3-21)
Median 53 
(range 36-87)
2.3(c) Comparison between the groups
The complete clinicopathological details of the matched groups are in Appendix 3. The 
mean age at the time of surgery was 59.6 (SD 6.1) years in the relapse group and 64
(SD 6.2) years in the non-relapse group (paired t test, p<0.01). Patients
for pathological stage and Gleason sum score. It was not always possible to match 
patients exactly for their constituent Gleason grades. Fifteen (48%) were matched 
exactly. In 12 matched pairs the constituent scores were the same but the relapse group 
had the higher grade in the predominant tumour (4+3 vrs 3+4 in 11, 3+2 vrs 2+3 in 1), 
in one matched couple the constituent scores were the same but the predominant 
Gleason pattern was higher in the non-relapse group (4+2 vrs 2+4). In the remaining 3 
patients, the relapse group vrs the non-relapse were 3+5 vrs 4+4, 2+4 vrs 3+3 and 5+3 
vrs 4+4, respectively.
The median preoperative PSA was 10.2ng/ml (range 5.1-18.6) in the relapse group and 
lO.Ong/ml (range 5.1-17.8) in the non-relapse group. There was no significant 
difference between the two groups with respect to PSA (Wilcoxon Signed Ranks test
The median PSA free follow-up for the non-relapse group was 53 months (range 36- 
87), most men were PSA free for well in excess o f the stipulated 36months. The median 
time to PSA recurrence in the relapse group was 9 months (range 3-21).
Surgical margin status was not included in the matching criteria; 20 patients in the 
recurrence free group and 21 patients in the relapse group had at least one positive 
margin. Statistical analysis showed neither the site (apical, C-IP or C-EP - Table 2.4)
p=0.39).
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nor the number o f positive surgical margins (negative, solitary or multiple margins - 
Table 2.5) was significantly different between the two groups (Wilcoxon Signed Ranks 
test p=0.11 and p=1.0, respectively).
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Table 2.4 The site of solitary positive surgical margins
(Wilcoxon Signed Ranks test, p=0.11)
Site of solitary positive 
margin
Non-relapse Relapse
Margin negative
11 10
Urethral/Apical only (U) 14 9
Circumferential- 
intraprostatic (C-1P)
1 1
Circumferential- 
extraprostatic (C-EP)
1 3
Table 2.5 Patients with 0 ,1  or >1 positive surgical margins
(Wilcoxon Signed Ranks test, p=1.0)_________________
Number of positive 
margins
No recurrence Recurrence
Margin negative
11 10
Solitary (U or C-EP) 15 12
Multiple (U and C-EP) 1 5
C-IP (excluded) 4 4
Total 31 31
In this matched series, 2 patients had lymphovascular invasion in the non-relapse group 
compared with 9 in the relapse group - the relapse group were significantly more likely 
to have lymphovascular invasion (Chi square, p=0.02). Most large series do not report 
the prognostic significance of lymphovascular invasion, while two found vascular 
invasion to be a significant but not independent predictor of outcome (Babaian et al. 
2001; Stamey et al. 2000).
The median tumour volume was 3.0mls (range 0.5-10.5) in the relapse group and 1.8mls 
(range 0.8-8.4) in the non-relapse group. There was significant difference between the 
tumour volumes of men with disease relapse versus men without PSA recurrence 
(Wilcoxon Signed Ranks test p=0.01).
While both lymphovascular invasion and tumour volume are not proven to be 
prognostic factors, in this small series there is a significant difference between these 
factors in the relapse and the non-relapse groups. In univariate analysis, tumour volume 
was not an independent predictor o f PSA relapse within two years of surgery (p=0.063), 
but lymphovascular invasion was (p<0.05). The clinical significance o f this finding in 
this series in not known.
2.3(d) The unmatched patients
The remaining unmatched patients tended to have either lower stage, grade and 
preoperative PSA if they had not relapsed or and a higher stage, grade and preoperative 
PSA in they had relapsed (Table 6).
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Table 2.6. The stage, grade and preoperative PSA group for the unmatched 
patients (PSA group A=4-10ng/ml, B=10.1-20ng/ml and C= >20ng/ml)
U nm atched non -relap se group
Pathological stage Gleason grade Preoperative PSA
pT3a 3+4=7 A
pT3a 3+4=7 A
pT3a 3+2=5 A
pT3a 3+2=5 A
pT3a 2+3=5 B
pT3a 2+3=5 B
pT3a 3+3=6 A
pT3a 3+3=6 A
pT3a 3+3=6 B
pT3a 3+3=6 A
pT3a 3+2=5 A
pT3a 3+3=6 A
pT3a 3+3=6 B
pT3a 4+3=7 A
pT3a 2+4=6 A
pT3a 3+3=6 A
U nm atched relap se group
Pathological stage Gleason grade Preoperative PSA
pT3b 4+4=8 B
pT3b 3+4=7 B
PT3b 4+5=9 B
pT3b 4+3=7 B
pT3b 4+3=7 C
pT3b 4+3=7 B
pT3a 4+3=7 B
pT3b 4+3=7 A
PT3b 4+3=7 A
pT3b 4+5=9 A
pT3b 4+5=9 B
pT3b 3+4=7 B
pT3b 3+4=7 A
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The Radical Prostatectomy Database at UCL identified men by stage and full 
pathological details with respect to the biopsy and radical prostatectomy findings were 
available. However, without adequate PSA follow-up or details of adjuvant therapy the 
biochemical outcomes could not be ascertained. A self-completed questionnaire was 
sent to all patients operated on by the highest volume surgeon, clinical notes were 
reviewed and patients or their General Practitioners were contacted directly. Using this 
data two groups were matched for the molecular study.
It may be surprising that from a large series of over a thousand patients more men could 
not be included in the study. There are several reasons why this was not the case. 
Firstly, during the first six years (1988-1993) less than 20 radical prostatectomies were 
performed per year. From 1994 the number of operations performed and submitted to 
the database rose dramatically. In 1995 forty-one were submitted, in 1996 ninety-six, 
1999 one hundred and fifty one and in 2001 just over two hundred. While the total 
number in the database represents a large series the number with 3-year follow-up was 
limited.
Secondly there was a propensity for men with poor prognosis tumours, based on the 
pathology report, to be treated with adjuvant therapy. Indications for adjuvant therapy 
are variable (Bott & Kirby 2002), though positive surgical margins frequently triggered 
adjuvant radiotherapy. From the UCL Radical Prostatectomy database 465 (52%) men 
had positive surgical margins. A significant proportion of these men had adjuvant 
radiotherapy and were excluded.
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Pre-operative androgen ablation was shown in the mid 1990’s to reduce the incidence of 
positive margins and extracapsular disease after radical prostatectomy (Goldenberg et 
al. 1996; Soloway et al. 1995; Van Poppel et al. 1995; Witjes, Schulman, & Debruyne 
1997). At the time these findings were reported, the proportion of men in this series 
receiving androgen ablation was at its highest (24% in 1996). More recently, series 
with longer follow-up have reported no benefit in terms of overall survival (Goldenberg 
& et al 1997; Lee, Warde, & Jewett 1999; Soloway & et al 1997). The use of these 
agents in the UCL series mirrored these findings and declined in the latter years, 
however the patients treated with neoadjuvant therapy tended to be the men who had the 
longer follow up.
Half the patients in the series were operated on by one surgeon in the private sector. 
Many o f these men were referred from across the UK, Europe and the Middle East. 
After their radical prostatectomy, their PSA follow-up was performed locally. While 
some were traced many were lost to follow-up.
The matching criteria were based on the most widely accepted features that predict 
progression after radical prostatectomy (Bostwick et al. 2000). Patients were grouped 
according to accepted inflection points for prognosis with respect to PSA (4-9.9, 10- 
19.9 or 20ng/ml), Gleason sum (5, 6, 7 or 8) and pathological stage (pT3a or pT3b). As 
these are strong predictors of biochemical outcome, identifying men with poor 
prognostic features who had not relapsed and vice versa proved difficult.
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2.5 Summary
The UCL radical prostatectomy database is the largest of its kind in the UK, with 
complete clinicopathological details on over 1000 men who had undergone radical 
prostatectomy. Despite this the cohort size was insufficient to allow matching of the 
required number o f relapse and non-relpase pairs for this study, because of insufficient 
length of follow-up and exclusion of patients who had nodal metastases and treatments 
that might affect the matching features. Future studies may enable more patient 
matching as the duration of follow-up becomes longer and the strict matching criteria 
could be broadened to include a wider range of relapse and non-relapse men.
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CHAPTER 3
Materials and Methods
Aim
This chapter will outline how the study DNA was extracted and amplified and the 
genotyping technique.
3.1 The pathological specimen and tumour dissection
The radical prostatectomy specimen was received by MCP in 10% formal saline. The 
specimen was weighed and laterality indicated by different coloured inks. The prostate 
was sliced between parallel glass rods of 5 mm diameter, producing a series of 4-6 
coronal sections and embedded in paraffin (Figure 3.1a). A 5 pm ‘wholemounf section 
was taken from each coronal slice, stained and examined by MCP.
The existence of allelic imbalance (AI) in tumour tissue may be masked if DNA from 
normal cells contaminates the cancer DNA. Areas of tumour within a radical 
prostatectomy wholemount also contain areas o f normal stromal tissue (fibroblasts and 
smooth muscle cells) and benign prostatic glands. The wholemount containing the most 
tumour was selected and the largest area containing at least 70% malignant cells was 
marked on the cover-slip by MCP (Figure 3.1b). Other authors have used areas 
containing 50-70% cancer by area (Cunningham et al. 1996; Macoska et al. 1995; 
Pesche et al. 1998; Uchida et al. 1999; Wang, Parsons, & Ittmann 1998; Wu et al. 
2001), 70% was used in this study to maximise the proportion of tumour DNA. The 
paraffin block corresponding to the slide was retrieved together with the lymph node 
paraffin block. In cases where a lymphadenectomy had not been performed or no 
lymphoid tissue was identified in the ‘lymph node’ specimen, seminal vesicle tissue was
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used (patients 6, 27 and 37) -  in these three cases the seminal vesicles were free from 
tumour involvement.
Once the block containing the tumour and control tissue had been identified a further 
four to six 5pm sections were taken using a microtome (Figure 3.1.c) and floated on 
water at 40°C. A microscope slide partially submerged at an angle of 45° was used to 
lift the section from the water and left to dry. The slide and section was placed in an 
incubation oven at 60°C for 20min to attach the specimen to the slide. The specimens 
were dewaxed in 100% xylene, rehydrated in ethanol and stained with haemotoxylin 
and eosin (Appendix 5.)- Slides were passed through an ethanol series and left to dry 
overnight.
The cover-slipped master slide was placed over the sample slide so that the 
wholemounts were aligned. The H&E staining facilitated this alignment in the prostate 
sections (malignant areas stained strongly with the nuclear staining haematoxylin) as 
well as identifying nodal tissue from adipose tissue in the lymph node sections. Both 
nodal and adipose tissues contain ‘normal’ DNA. The DNA yield is significantly greater 
from lymph nodes as lymphocytes have a high nuclear to cytoplasmic ratio.
The areas of cancer marked on the master slide were then transcribed by marking the 
underside of each sample slide with a fibre-tip pen. Areas of cancer of >0.5cm2 were 
scraped off using a number 20 scalpel blade within the region marked. The scrapings 
were prone to ‘blow-away’ or their static charge adhered them to the scalpel blade. 
Therefore, for ease of handling, a drop of 100% ethanol was added before samples were 
scraped. The scalpel blade was changed between each patient and between tumour and
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control slides to avoid contamination. The dissected sample was placed in a labelled 
Eppendorf™ tube and placed at 37°C for 15 mins to allow the ethanol to evaporate.
Figure 3.1 a) Coronal block of prostate embedded in paraffin, b) master slide with 
area of prostate containing at least 70% malignant cells marked, c) 10pm section 
unstained, d) section stained, tum our area m arked and excised with scalpel blade.
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Where the tumour area was small (<0.5cm2) the malignant tissue was obtained by laser 
capture microdissection (LCM, Arcturus) (patients 12 and 28). For LCM sections were 
soaked in 70% xylene for 3 mins followed by 100% xylene for 3 minutes to facilitate 
transfer. The area of tumour was marked (Figure 3.2a) and a polymerising film 
attached to an Eppendorf™ cap was applied to the section. The section was viewed 
microscopically and the cells of interest orientated to the centre of the field of vision. A 
45mW pulsed laser beam was activated and produced a 30pm diameter spot on the 
transfer film immediately above the cells of interest. At this precise location the laser 
heated and focally polymerised the film, thus fusing the film with the underlying cells 
(Figure 3.2b). The transfer film, fused with the selected cells, was lifted off the tissue 
section. This technique allows malignant acini and even individual malignant cells to be 
dissected from the section.
Figure 3.2 Laser capture microdissection 
a) Area of tum our marked
b) Tum our captured on polymerised film
c) Defect left on slide
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3.2 DNA extraction
DNA extraction was performed using the Qiagen DNeasy™ kit. This involved: lysis of 
the cells, binding o f DNA to a silicone membrane, removal of proteins and divalent 
cations and the elution o f DNA, in fragments of 50-30kb. The protocol was as follows:
1. To each o f the tumour and control samples 180pl of buffer ATL and 20pl of 
proteinase K was added. Buffer ATL was an enzymatic buffer and also 
contained the detergent sodium dodecyl sulphate. Together these performed an 
enzymatic and chemical digestion to lyse the connective tissue between cells and 
the cell membrane. Lysis occurred over 16-20 hours at 55°C and the samples 
were vortexed intermittently.
2. To the samples 200pl o f buffer AL was added. This solution was votexed and 
incubated at 70°C in a water bath for 10 mins. Buffer AL was a chaotrophic salt, 
which dehydrated the DNA and exposed the negatively charged phosphate 
backbone to optimise binding to the column. It also inactivated proteins and 
carbohydrates in the solution.
3. 200jnl of ethanol (96-100%) was added, to further dehydrate the DNA and 
expose the phosphate backbone
4. The solution was pipetted onto the spin columns provided and centrifuged at 
8000rpm for 1 minute. The spin column contained a positively charged silicone 
membrane that bound to the negatively charged phosphate backbone of the 
DNA.
5. Two wash steps were performed. 500pl of buffer AW1 (a dilute chaotrophic salt 
solution removed residual protein and carbohydrate) was added and the column 
centrifuged at 8000rpm for one minute and the eluate was discarded. 500pl of
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buffer AW2 (dilute ethanol solution) was added and the column centrifuged at 
8000rpm for 3 minutes to dry the silica membrane.
6. The column was placed in a clean labelled collecting tube and the DNA was 
eluted by adding lOOpl o f buffer AE and centrifuging at 8000rpm for one 
minute. This step was repeated. Buffer AE is a simple alkaline buffer (pH 8-9) 
which bound to the acidic DNA.
7. The sample DNA was stored at -20--30°C.
When the DNA from all 124 tumour and control samples had been extracted, aliquots of 
50pl of DNA were placed in an ABgene DNA block 96 plate and sealed with the 
corresponding Cap mat™ and Parafilm™ (Appendix 6).
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3.3 DNA amplification
3.3(a) Principles of the polymerase chain reaction
The polymorphic regions o f DNA to be studied were amplified using the polymerase 
chain reaction (PCR), to increase the quantity of study DNA. This is a cyclical process 
of heating and cooling to denature, anneal and enzymatically amplify DNA. Specific 
DNA sequences can be multiplied exponentially using a system that combines a 
computerized thermal cycler with a heat stable enzyme (Taq polymerase). The standard 
reaction uses two oligonucleotide primers that are complementary to and hybridize with 
opposite DNA strands flanking the region of interest in the target DNA. The primers are 
generally around 20-30 nucleotides in length and sufficiently long to be unique within 
the genome. The reaction consists of the following steps:
template denaturation at 90-94°C for 30-120 seconds - this separates the two DNA 
strands
primer annealing at 50-60°C for 30-60 seconds - the primers anneal to the template 
extension at 72°C for 30-120 seconds; from the sense and antisense primer on 
complementary DNA strands, nucleotides in solution bind to their complementary 
base, catalysed by the enzyme Taq polymerase.
These steps are repeated 20-60 times depending on the quality and length of the DNA to 
be amplified and the efficiency o f primer annealling. The cycling means that the newly 
synthesized DNA strands can themselves act as templates for further rounds of DNA 
synthesis in the subsequent cycles o f the reaction. The DNA is therefore amplified 
exponentially, theoretically 2" times where n is the number of cycles, although in 
practice the efficiency is not 100%. Typically, 30-40 cycles are performed and, although
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it is easier to amplify small fragments of a few hundred base pairs, up to lOkb can be 
amplified.
In this project, DNA was extracted from formalin fixed paraffin sections. DNA from 
archival tissue is fragmented, consequently the primers were designed such that the 
product length was kept below 275 base pairs.
3.3(b) Microsatellite marker selection
PubMed and MedLine searches were performed and 184 papers were identified relating 
to ‘prostatic neoplasia’ and ‘loss o f heterozygosity’ or ‘allelic imbalance’. These papers 
were reviewed and the most frequent sites of Al in prostate cancer noted. Al is the most 
frequently found genetic alteration in prostate cancer (Dahiya et al. 1997c) and is 
reported consistently on chromosomes lq, 3p, 5q, 6q, 7q, 8p, 9p, lOp, lOq, l ip , l lq , 
12p, 13q, 16q, 17p, 17q, 18q and 21q (Carter et al. 1990; Cooney et al. 1996a; Dahiya et 
al. 1997b; Dahiya et al. 1997c; Elo et al. 1999; Emmert-Buck et al. 1995; Fromont et al. 
2003; Gao et al. 1995; Hugel & Wemert 1999; Kawana et al. 1997; Macoska et al. 
1995; Narla et al. 2001; Saric et al. 1999; Smith et al. 1996). The sites most frequently 
lost in somatic cancers include 8p, lOq, 13q, 16q and 18q (Carter et al. 1990; Elo et al. 
1999; Emmert-Buck et al. 1995; Fromont et al. 2003; Hugel & Wemert 1999; Macoska 
et al. 1995; Saric et al. 1999) and losses on lq are associated with hereditary prostate 
cancer (Smith et al. 1996). Some losses, such as those on 8p and 13q, are associated 
with early prostate cancer (Emmert-Buck et al. 1995; Fromont et al. 2003; Macoska et 
al. 1995; Saric et al. 1999). Others, such as those on 1 lp  and 16q (Carter et al. 1990; Elo 
et al. 1999; Kawana et al. 1997; Saric et al. 1999; Suzuki et al. 1996), are more frequent 
in advanced disease.
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Fluorescently labelled microsatellite markers for the most common polymorphic regions 
that are lost in all stages o f prostate cancer were identified (Appendix 7) and obtained 
and are shown in Table 3.1. Markers were selected where a heterozygosity rate of 
>70% was reported. Several markers were obtained which despite attempts over a range 
of conditions failed to generate a PCR product. These included D8S549 on 8p22, 
D9S2136 on 9p (p i6), D16S413 on 16q, D17S855 on 17q, D17S960 on 17p, KLF6M1 
and KLF6M2 on lOp.
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Table 3.1 Details o f m icrosatellite markers
Marker Sequence Size Het Locus
D1S158 GGGCCTT CTT AT ATT GCTT C 137-163 0.89 1q25.2-31.1
GGAAAGACT GGACCAAAGAG
D1S422 CAT GGGGTAT AGC AACAG AC 160 0.76 1q31.2-42.3
T GATTT CCTGCAAACATTTT
D1S305 CCAGNCT CGGT AT GTTTTT ACT A 156-176 0.8 1q21.1-21.2
CT GAAACCTCTGTCCAAGCC
D1S414 GCACAGTTCAACATCCATT 195 0.78 1q31.3-32.3
T CT CT GT CATTTT AGGT CT ATTT CT
D2S222 ACAAAT GCAG AAAAAGC AT AT G 118-138 0.9 2q23.1
CT GT CAGGCT G AGG AAATTT
D5S500 ACCTATTCGACCTAATGACTAAAGA 213 0.84 5q31.1
ATCGGT G AAAT GCAACT ACTT
D5S656 GCT AAG AAAAT ACG ACAACT AAAT G 189 0.75 5q21.3
CAT AAT AAACT G ATGTT G AC AC AC
D6S501 GCT GGAAACT GAT AAGGGCT 173 0.75 6q16.3-21
GCCACCCT GGCT AAGTT ACT
06S314 AAAAT GACTT CTTT GGGTGGGC 243-259 0.81 6q16.3-27
GTGGGT AGCAACACT GTGGC
D7S523 CT GATT CAT AGCAGCACTT G 224-240 0.81 7q31.1-31.33
AAAACATTT CCATT ACCACT G
D7S480 CTT GGGGACT G AACC AT CTT 189-206 0.87 7q31.31
AGCTACCATAGGGCTGGAGG
D8S1991 GT GAAGGAGGGCAGTCAT 200-220 0.71 8p22
CAGGGTT GAAGCAAT CT G
D8S136 GCCC AAAGAGG AGAAT AAA 71-89 0.88 8p12-21
CT GTTT CCACACCGAAGC
NEFL GCAGT AGT GCCGCAGTTT C A 137-147 0.81 8p21.3
T GCAATT CAT CTT CCTTT CT
01OS1246 CT ACGGACT CATT G AAG ACT AGG 219 0.8 10q25.1
AGCGTTTT CT AT AGCT CT G ACG
D10S587 CCCAG ATT CAT GGCTTT C 172-186 0.8 10q25.3
TT CT GCT GACACGGGC
D10S211 CT CCT GGT CT CAT GCG 195-211 0.84 10p12.1
CAGGCT CCT ACT ACCGT C
D11S902 CCCGGCT GT G AAT AT ACTT AAT GC 145-163 0.8 11 p15.1
CCCAACAGCAAT GGGAAGTT
D11S916 CAGACTATTCTCATT GCTGC 135-153 0.73 11q14.1
GG ACTT CT AAGCCT CCAT AA
D11S2000 AGT AGAGAACAAAACACTGTGGC 213 0.87 11q22.3
TTT GAAGATCTGT GAAATGTGC
D12S89 ATTT GAGAGCAGCGT GTTTT 254-288 0.79 12p13.1 -13.31
CCATT ATGGGGAGTAGGGGT
D12S1697 CAT CTT GGCCCAGT CAAT 218-234 0.83 12p12.3
CCTT CT GTTT AT AGC AAT GGGA
D13S269 T GT CTT CCAGCAGGGC 116-134 0.71 13q21
CAAAGT GGTT CAT CTT GGT CT
D13S171 CCT ACCATTGACACT CT CAG 227-241 0.71 13q12.3
T AGGGCCAT CCATT CT
D13S263 CCT GGCCT GTT AGTTTTTATT GTTA 149 0.84 13q14
CCCAGT CTT GGGT AT GTTTTT A
D15S1232 CC AG AG AG AT CTTT CCCCAT 289 0.84 15q13.1
TT GCT CCACT GTTTT CT CAC
D16S413 ACT CCAGCCCGAGTAA 131-149 0.85 16q24.3
GGT CACAGGT GGGTT C
D18S541 CT CCCAAAT AT GG AAT GG AA 275 0.75 18q21.1-21.3
T GAGCT GAGAT CAT AT CAATGC
D19S223 CAAAAT CG AGGT GC AT AGAA 228-246 0.82 19q13.2
ACCAT GACT GGCT AATT GT G
D21S156 GT CAACAT AGT G AG ACCCCA 77-107 0.84 21q22.3
ATCCAGCCT GT AACACATT C
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3.3(c) PCR optimisation
The PCR reaction consists of the following reagents:
• lOx reaction buffer - a commercially available solution containing 750mM Tris- 
HC1 (pH 8.8), provides optimal pH to prevent dNTP hydrolysis.
• dNTP -  dinucleotide triphosphates (A,T,G and C)
• MgCb - required for efficient enzymatic activity of Taq
• sense primer (forward microsatellite marker)
• antisense primer (reverse microsatellite marker)
• Distilled water 18Q
• DNA
• Taq -  A heat stable DNA polymerase enzyme derived from Thermus aquaticus 
bacterium.
The concentration of lOx buffer, dNTP and Taq is standard, however the concentration 
of the other components and the PCR conditions was optimised for 3 sample markers - 
D10S211 (200bp), D16S413 (140bp), D21S156 (lOObp) of varying size.
3.3(c)l. DNA concentration
The total quantity of patient DNA available was limited. The minimum volume of DNA 
required for PCR was checked at several DNA dilutions (1, 0.5 and 0.25pl per 15pl 
reaction mix, respectively). A DNA volume of 0.5pl per 15pl reaction mix yielded 
sufficient product, a lower concentration did not. All 124 samples were tested, where 
there was inadequate product on two or more occasions the sample was replaced, either 
by repeating the DNA extraction process if sufficient tissue was available or by using 
another appropriately matched patient’s DNA. These replacement samples were also 
tested.
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3.3(c)2. M arker concentration
The markers supplied were diluted to a concentration of 5mM and the optimal 
microsatellite marker concentration for five microsatellite markers (D7S523, D10S211, 
D8S549, D11S916, D13S263) was evaluated using 2.5, 5, 8 and 12 picomoles per 15pl 
reaction (0.5, 1.0, 1.6 and 2.4pl of 5mM microsatellite marker) for each of the sense 
and the antisense markers (Figure 3.3). Above 8 picomoles per reaction there was 
considerable marker dimerisation, indicating an inefficient reaction, below this 
concentration the product yield was impaired. Eight picomoles per 15pl was therefore 
used in subsequent reactions.
Figure 3.3 Agarose gel of prim er D7S523 at 2.5, 5 and 8 picomoles per 15pl 
reaction in DNA from unm atched patients.
8 picomoles D7S523
The optimal microsatellite marker annealing temperature is affected by the proportion 
and number of guanine-cytosine (3 hydrogen bonds) and thymine-adenine (2 hydrogen 
bonds) bonds formed. An annealing temperature of 55, 58, 60 and 62°C was tested; 
58°C yielded the greatest product (Figure 3.4).
3.3(c)3. Magnesium chloride concentration
Using the three test microsatellite markers and unmatched patient DNA, the optimum 
magnesium chloride concentration was established using 22.5, 30, 37.5 and
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45micromoles per 15pl reaction. The optimal concentration was 37.5 micromoles (1.5pl 
of 25mM MgCb per 15pl reaction or 2.5mM) (Figure 3.3).
Figure 3.4 Agarose gel showing optimisation with DNA from 8 unmatched patients 
at m arker D10S211. M gCh concentration 22.5, 30, 37.5 and 45 pmoles per 15pl 
reaction and annealing tem peratures of 55, 58, 60 and 62°C were tested. The 
optimal concentration of M gCh was 37.5 pmoles and maximum annealing 
occurred at 58°C.
55°C
MgCh 22.5 
* m  m  m  f t
•MgCI' 45
30
no DNA
M M
60°C
62°C
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Once the optimal conditions were established all 124 samples were amplified, using a 
‘cold start’ and 37 microsatellite markers. The PCR reaction conditions and master mix 
were as follows:
PCR reaction mix
1 Ox buffer 1.5pl
dNTP (2mM) 1.5pl
MgCl2 (25mM) 1.5|il
Sense primer (5pM) 1.6pl
Antisense primer (5pM) 1.6pl
Water 6.65pl
Taq 0.15pl
DNA 0.5pl
Total reaction mix 15^1
PCR conditions
DNA denaturation/7tf</ activation 15 mins 95°C
DNA denaturation 45 secs 95°C
Primer annealing 45 secs 53-58°C
Extension 45 secs 72°C
Final extension 10 min 72°C
Throughout the PCR stages and the genotyping two controls were used, the first where 
DNA was replaced by water and the second where DNA was replaced by reaction mix.
163
3.4 Genotyping
A random selection o f 8 PCR products from each 96 well plate was run on a 1.5% 
agarose gel to check sufficient product o f the correct size had been generated. This also 
enabled a ‘by eye’ estimate o f the quantity o f product for the next stage.
Panels o f markers were designed so that PCR products could be pooled and genotyped 
simultaneously. Products o f similar size but with a different fluorescent label (FAM, 
HEX or TET) could be placed in the same panel. A gap of at least 20 base pairs was 
required for products with the same fluorescent label to be in the same panel. Forty 
microlitres of di-iodinised water was added to a 96 well plate and to this 2-4pl of PCR 
product was added depending on the yield as assessed on the agarose gel. The plate was 
sealed, vortexed and centrifuged for 10 secs.
In a 1.5ml Eppendorf™ tube, 1 ml o f HiDi was added to 15pl of 400 Genescan® High 
Density ROX size standard. ROX is an internal lane size standard and allows high run- 
to-run precision in sizing DNA fragments by electrophoresis. It consists of 21 single 
stranded fragments of 50-400bp range. Each fragment is labelled by a single 
fluorophore, which results in a single peak when run on a polyacrylamide gel in the ABI 
A3700.
The HiDi/ROX solution was mixed by vortexing and lOpl aliquots were pipetted into a 
MicroAmp Optical 96® well reaction plate. To this lpl of pooled PCR mix was added, 
the 96 well plate was sealed and centrifuged briefly.
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The reaction mix was heated at 95°C for 5 minutes. This results in the tangled DNA 
fragments straightening and the HiDi becoming incorporated within the DNA to 
maintain its new shape.
The ABI A3 700 software allows each of the 96 lanes to be labelled with a sample name. 
The PCR products were therefore arranged in the 96 well plate so that the fluorescent 
electropherogram generated from the radical prostatectomy DNA could be compared 
directly with its corresponding lymph node control (Appendix 6).
The ABI A3700 is a high voltage electrophoresis circuit. The machine loads the Hi/Di, 
ROX and PCR product mix into a well containing buffer and the cathode. Over a period 
of 50 seconds this reaction mix is injected into a capillary containing polyacrylamide 
gel. After the samples have been injected into the capillaries the injection wells are 
washed and re-filled with buffer. A 1000V potential difference is applied between a 
loading bar, the cathode, and an electrode, the anode, at the back of the cuvette 
assembly (Figure 3.4).
Electrode
Capillary containing array-fill polymer Cuvette (anode) (+)
DNA fragments
Sheath-flow polymer
HIGH VOLTAGE
Loading bar Injection well containing buffer 
(cathode) (-)
Figure 3.4 The electrophoresis circuit
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The potential difference results in a current carried by the DNA, buffer and polymer 
ions. The negatively charged DNA fragments move through the polymer within the 
capillary towards the anode at varying speeds according primarily to their mass (number 
o f base pairs in the product), but also their charge. When the fragments reach the end of 
the detection-ends tips, they are moved through a laser light path by the flow of the 
sheath flow-polymer, which in turn carries the current to the anode and so completes the 
circuit. As the fluorescently labelled fragments pass through the laser they emit a blue 
(FAM), green (TET or HEX) or red (ROX) light that is detected by a camera. The 
amount of light detected is proportional to the quantity of product and so the amplitude 
of the curve on the fluorescent electropherogram.
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3.5 Analysing the data
Preceding the allelic peaks are ‘stutter peaks’ which represent slippage of the Taq 
polymerase during PCR (Gray et al. 1995) (Figure 3.5). The allelic peak is the highest 
peak after the stutter peaks. The first allelic peak is usually higher than the second as it 
is made up of its own product as well as a stutter peak of the second, larger allele. The 
ABI A3700 software was set so that the highest peak within the predicted size range, 
preceded by stutter peaks was labelled (size, amplitude and area under the curve). The 
next highest peak where present and preceded by stutter peaks was also labelled by the 
software (Figure 3.5).
The definition of allelic imbalance is based on the relative ratio difference between the 
two alleles from the control sample and the two alleles from the cancer sample. 
However, the ratio that constitutes loss varies in the literature. One of the first 
definitions o f Al using fluorescent electrophoresis was given by Canzian et al. (Canzian 
et al. 1996). They used the amplitude of the peaks in the equation below
xAI = (At2 x A n l) /  (A tl x  An2)
Where A=amplitude, t=tumour, n=normal, 1 =shorter allele, 2=longer allele.
A ratio o f <0.6 or >1.67 equates to an allelic loss of more than 40% and was classified 
as Al.
More recently Narla et al. used a similar equation; for each heterozygous locus, the ratio 
between the smaller peak (usually the second or larger allele) and larger peak (usually 
the first or smaller allele) in the tumour DNA was compared to the same ratio in the 
normal DNA.
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XAI= ([T1/T2]/[N1/N2])
In this way, the Xai varies between 0 (complete allele loss) and 1 (no loss). Narla et al. 
used an XAi value of <0.7 to define Al in this study (Narla et al. 2001).
In a study in colorectal carcinoma Barratt et al. used the same calculation as above, 
however, a cut off <0.5 was used to classify Al (Barratt et al. 2002). Other workers have 
used a lower cut-off, Gray et al. defined Al as a relative amplitude loss of >20% (Gray 
et al. 1995)
If a sample constitutes pure cancer DNA and one allele has undergone loss of 
heterozygosity, because of the clonal nature o f cancer, all daughter cancer cells would 
also have Al at this site and so there should be no peak on electropherogram for the lost 
allele. Contamination by normal benign cells or other cancer clones during the 
extraction process will result in some normal DNA, without Al, also being amplified 
during PCR. While there is less normal than cancer DNA to be amplified there may be 
sufficient quantities to produce a peak on the electropherogram. The cut-off for what 
defines Al therefore reflects the purity o f the cancer DNA. In this study, the majority of 
samples were not laser microdissected as large quantities of DNA were needed. The 
master wholemount slides were marked with areas containing at least 70% malignant 
cells, it is inevitable that some contamination with normal DNA occurred. The cut-off 
for this project was put at an XAi score of 0.7 to reflect the predicted degree of 
contamination. This correlates with an allele loss of approximately 40% (Figure 3.5).
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Figure 3.5 Allelic imbalance is present where the amplitude of the smaller cancer 
peak divided by the larger cancer peak over the amplitude of the smaller control 
peak divided by the larger control peak is 0.7 or less.
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Two researchers both blind to the patient outcome examined each electropherogram 
independently. The results from both were collated, where discrepancies occurred the 
electropherograms were examined together and agreed. Where Al occurred in less than 
10% of informative cases this was considered background losses and therefore not 
significant (Dong, Boyd, & Frierson, Jr. 2001; Macoska et al. 1995; Saric et al. 1999).
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CHAPTER 4
Results
Aim
This chapter will present the results of the allelic imbalance experiments ancf discuss the
findings in relation to the literature.
r
x 4.1 Allelic Imbalance
Maternal and paternal alleles have naturally occurring sites of two or more nucleotide 
repeats, usually outside the coding regions of genes, called microsatellite 
polymorphisms. Over 18,000 microsatellite polymorphisms have been identified and are 
listed on the Genome database (www.gdb.org). The polymorphic regions of the 
maternal and paternal alleles are usually of different lengths, rendering the individual 
heterozygous at that locus. Deletion or amplification, which occur during the initiation 
and progression of cancer, may be detected by the loss or gain o f one o f these 
polymorphic regions; this is allelic imbalance (Al). Deletions are far more common than 
amplification in early prostate cancer accounting for most cases of Al in this study. The 
deleted region may contain a tumour suppressor gene and deletion in one allele is 
usually preceded by a point mutation in the other allele so that the deletion represents 
the second hit of the Knudson’s hypothesis.
If the maternal and paternal microsatellite regions at a particular locus in normal tissue 
are of the same length, Al is not detectable and this locus is termed uninformative. 
Hence, a normal tissue control is required to evaluate if an individual is heterozygous, 
therefore informative at the loci of interest.
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Allelic imbalance has prognostic and therapeutic implications and has resulted in its use 
clinically for certain tumours (Barratt et al. 2002; Bell et al. 1993; Jen et al. 1994). In 
patients with Dukes B colorectal carcinoma, allelic imbalance in the region of the DCC 
gene (D18S61, 8q22.3) indicated a prognosis similar to a Dukes C lesion (40% 5-year 
survival) (Barratt et al. 2002). Conversely, heterozygosity at this locus conferred a 
better prognosis (70% 5-year survival). Furthermore, benefit from the chemotherapeutic 
agent fluorouracil was significantly greater in patients retaining heterozygosity (Barratt 
et al. 2002).
Allelic imbalance in prostate cancer has been consistently reported at several 
chromosomal arms, including 7q, 8p, lOq, 12p, 13q, 16q, 18q and 21 q (Gray et al. 1995; 
Harkonen et al. 2005; Hugel & Wemert 1999; Kibel et al. 2000; Latil et al. 1995; Latil 
et al. 1997; Latil et al. 1999; Leube et al. 2002; Oba et al. 2001; Prasad et al. 1998; Yin 
et al. 2001). Several studies have reported an association of Al at certain loci with 
histopathological features o f the radical prostatectomy specimen, including advanced 
stage (Gray et al. 1995; Hugel & Wemert 1999; Kibel et al. 2000; Leube et al. 2002), 
higher Gleason score (Hugel & Wemert 1999; Leube et al. 2002) and perineural 
invasion (Fromont et al. 2003). However, the frequency of Al differs widely among 
studies as tissue from a small number of patients with a range of clinical stages has been 
used. Most studies have employed tissue from advanced metastatic tumours so the 
association of Al with prognosis in localised prostate cancer remains controversial.
/W h a t this study aims to do is to identify microsatellite markers that can be used to 
predict biochemical outcome in men undergoing radical prostatectomy.
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4.2 Results
4.2(a) Interpreting electropherograms
Thirty fluorescently labelled microsatellite markers for prostate cancer associated loci 
on chromosome arms lq, 2q, 5q, 6q, 7q, 8p, lOp, lOq, l ip , 1 lq, 12p, 13q, 15q, 16q, 
18q, 19q and 21 q were used. The DNA from the prostate cancer and the lymph node 
control of the relapse group was amplified in parallel with the DNA from the non­
relapse group who were matched for grade, stage and pre-operative PSA. PCR products 
were run on a polymer gel and the fluorescent electropherogram assessed by two 
workers independently. In 79% of cases both workers scored the electropherograms the 
same (heterozygote, allelic imbalance, homozygote, microsatellite instability or 
unreadable). Where there was a discrepancy the electropherograms were examined 
together and an overall score given.
Some examples are shown in Figure 4.1 (See also Figure 3.5 for explanation of 
figure). Each marker produced a characteristic electropherogram due to ‘stutter peaks’, 
which precede the allelic peaks. In Figures 4.1a, b and c there is a smaller peak one or 
two base pairs after the allelic peak, this is as a result of adenine adhering to the PCR 
product. Adenine does not bind to the sense strand if the complementary nucleotide on 
the antisense strand is cytosine, guanine or adenine residue. Consequently a peak after 
the allelic peak is not always seen (Figure 4.Id).
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Figure 4.1. Shows characteristic cancer and control electropherograms for 5 
markers, demonstrating stutter peaks preceding the allelic peak in a., b. and c., 
heterozygotes in a. and c., a homozygote (uninformative) in b., allelic imbalance in
d, and microsatellite instability in e.
cancer cancer
1227 87 1 1238.021
1405S|16475|
control control
184.031[227.781
Figure 4.1a. D7S523 
Patient 12 - Heterozygote
Figure 4.1b. D5S656 
Patient 12 - Homozygote
cancer cancer
12 7 1 .6 7 1 
151501|2208| 
190291
146551
[626941
control control
1256.271 
172071
1271.631 
136511[876]
[74721
Figure 4.1c. D16S413 
Patient 33 - Heterozygote
Figure 4.1d.D15S123
Patient 33 - Allelic imbalance
cancer
Figure 4.1e. D6S314 
Patient 2 -
Microsatellite instability Extra peak in cancer Allelic peaks
control
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The appearance of the electropherogram from a homozygote individual or from a 
heterozygous individual whose maternal and paternal alleles were of significantly 
different length was used to aid analysis of other electropherograms where the stutter 
and allelic peaks overlapped (Figure 4.2).
cancercancer
1158.18| |
11160|| 1321]
110612)
1160.121
1 5 6 .1 4
4 1 6 6
3 8 1 7 2
12472
controlcontrol
1 5 6 .1 7
158.11
3 0 6 4
2 8 2 1 0
160.06
112944|
Figure 4.2a. D13S263 
Patient 39 -  Homozygote
Figure 4.2b. D13S263 
Patient 32 -  Allelic imbalance
Figure 4.2a and b. Electropherograms from patients 39 and 32. Patient 39 is
homozygous at the D13S263 locus. Two stutter peaks precede the alleles. This 
appearance can be used to confirm that patient 32 is heterozygous at this location 
as there are four peaks, and the cancer sample shows allelic imbalance.
The heterozygosity rate of each marker was similar in this series to the reported ‘hef 
rate (Table 3.1) ranging between 52-94%. At all loci a mean of 36 (58%) of 62 patient 
cancer samples were informative i.e. were heterozygotes or had allelic imbalance.
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For all patients the cumulative allelic imbalance rate for informative cases at all 30 
markers was 23%. The cumulative allelic imbalance frequency was greater in the 
relapse group compared with the non-relapse group, 24% of informative cases in the 
relapse group and 21% of informative cases in the non-relapse group (Chi square, 
p>0.05). The results are summarised in Tables 4.1, 4.2, 4.3 and 4.4.
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4.2(b) Allelic imbalance and PSA outcome
One marker D10S211 at 1 Op 12.1 demonstrated significantly greater allelic imbalance in 
the relapse patients than in the non-relapse patients (35% vrs 5%, respectively, Fisher's 
exact test p=0.03). Several loci showed a marked increase in allelic imbalance in the 
relapse compared with the non-relapse groups. These included D2S222 (29 vrs 8%), 
D6S314 (25 vrs 11%), D8S136 (50 vrs 29%), NEFL (71 vrs 55%), D12S1697 (31% vrs 
17%), D13S269 (19 vrs 4%), D15S1232 (38 vrs 18%) and D18S541 (25% vrs 0%) in 
the relapse and non-relapse groups, respectively. Some loci demonstrated an increased 
rate o f allelic imbalance in the non-relapse group. These were: D1S158 (14 vrs 35%), 
D1S422 (17 vrs 27%), D5S500 (13 vrs 23%), D11S2000 (6 vrs 31%), D12S89 (14 vrs 
29%) and D16S413 (13 vrs 24%) in the relapse and non-relapse groups, respectively. 
These differences were not statistically significant.
All the primers gave satisfactory electropherograms for some DNA samples, and all the 
DNA samples produced satisfactory electropherograms for some primers. Allelic 
imbalance was seen in 57 (92%) o f the 62 patients. Five patients who did not show 
allelic imbalance included 3 relapse patients (24, 25, 64) and 2 non-relapse individuals 
(30, 61) (Table 4.5).
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Table 4.1. OVERALL RESULTS - ALL PATIENTS
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Table 4.2. OVERALL RESULTS - RELAPSE GROUP
Table 4.3. OVERALL RESULTS - NON-RELAPSE GROUP
/ y y y y < y y y y < $ ^ ^/ o / o / o / o  /  < y /  <> /  v  /  o  /  < r /  o  /  < y /  < r /  < r /  o  /
Al 7 4 6 0 2 6 3 7 1 4 1 10 6 11 4
Heterozygotes 13 11 15 20 23 20 10 8 8 12 17 12 15 9 16
Informative loci 20 15 21 20 25 26 13 15 9 16 18 22 21 20 19
% Al 35% 27% 29% 0% 8% 23% 23% 47% 11% 25% 6% 45% 29% 55% 25%
MSI 2 0 1 2 1 1 1 0 3 3 1 0 2 0 0
Homozygous 5 3 6 2 2 1 15 10 4 4 3 1 6 10 8
Unreadable 4 13 3 7 3 3 2 6 15 8 9 8 2 1 3
/  <A / & / & / & / & / c s  /  •& / £ >  / V s / £ >  / < & / &  / <v? /< &  /  
/  / / $ *  / / / $  / / &  / r*& / / V  / / / V / / S* / rfV/ r*? /
/  <& /  &  /  £> /  &  /  &  /  < & / (fr /  *& /  r& /  /  <& /  C V >  /  &  /  O? /  K? //  /  &  /  K* /  v /  »*s /  nV /  *y /  &  /  *v>/  Nr /  *? /  * ? / ' & / ' & /  <V //  < y /  < y /  <y/ < y /  < y /  0 / < y /  < $ /  < y /  <y/ < y /  < y /  0  /  0  /  <5V/
Al 2 1 0 5 5 6 3 1 4 5 3 6 0 1 5
Heterozygotes 18 18 16 11 11 15 15 24 8 13 14 19 11 18 21
Informative loci 20 19 16 16 16 21 18 25 12 18 17 25 11 19 26
% Al 10% 5% 0% 31% 31% 29% 17% 4% 33% 28% 18% 24% 0% 5% 19%
MSI 0 1 1 1 5 2 1 2 2 0 1 0 0 1 2
Homozygous 3 2 5 8 3 2 3 1 6 4 8 1 6 1 1
Unreadable 8 9 9 6 9 6 9 3 11 9 5 5 14 10 2
Table 4.4 SUMMARY: RATE OF Al IN RELAPSE AND NON-RELAPSE GROUPS
RELAPSE 25% 40% 29%14% 17% 35% 5% 29% 13% 25% 6% 50% 50% 71% 19%
NON-RELAPSE 35% 27% 29% 0% 8% 23% 23% 47% 1 1 % 25% 6% 29% 25%45% 55%
'Significance, p= 0.39 0.45 0.49 0.07 0.57 0 730.12 0.30 0.63 0.48 0.41 0.53 0.13 0.26 0.63
RELAPSE 21%6% 35% 5% 6% 14% 31% 19% 25% 28% 38% 13% 25% 0%
NON-RELAPSE 5% 19%0% 31% 31% 29% 17% 4% 33% 28% 18% 24% 0%10% 5%
'Significance, p= 0.540.56 0.55 0.09 0.29 028 0.5 0.31 0.19 0 25 0.16 0460.56 0.03
* = Fisher’s Exact test
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Table 4.5 Status of 30 microsatellite loci in 31 matched pairs of radical 
prostatectom y patients w ith pT3N0 stage disease.
Non-relapse group
I uni nterpretable heterozygous |allelic Imbalance microsatellite instabilityhomozygous
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Microsatellite instability was evident in 25 patients, 13 in the relapse group and 12 in 
the non-relapse group. There was no significant difference in the rate of microsatellite 
instability between the relapse and non-relapse groups at any of the 30 markers (Table 
4.6).
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Table 5. INCIDENCE OF MICROSATELLITE INSTABILITY IN THE RELAPSE AND NON-RELPASE GROUPS
RELAPSE
NON-RELAPSE
0.52 0.73 0.48 0.47Significance, p= 0.49 0.52 0.440.50 0.26 0.750.51
RELAPSE
NON-RELAPSE
0.670.550.26 0.710.480.52 0.470.29 0.590.570.48 0.470.51Significance, p=
* = Fisher’s  Exact test
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4.3(a) Discussion
Many sites o f allelic imbalance have been identified in prostate cancer though their 
prognostic significance remains unresolved. The aim of this study was to identify 
microsatellite markers, which could be used to predict biochemical relapse after radical 
prostatectomy. Allelic imbalance was seen more frequently in patients who had 
developed biochemical recurrence within two years of undergoing radical prostatectomy 
(24%) compared with patients who were PSA free for at least 3 years after surgery
f ■(21%), this was not significantly different. \ , N i-  IL d-
Allelic loss occurred at one locus on chromosome 10, 1 Op 12.1 (D10S211), significantly 
more in the relapse group (6 (35%) o f 17 informative cases) than the non-relapse cohort 
(1 (5%) of 19 informative cases, p= 0.03). Allelic imbalance at 10q25.3 (D10S587) did 
not exceed 10% in either group and therefore represents background losses (Dong, 
Boyd, & Frierson, Jr. 2001; Macoska et al. 1995; Saric et al. 1999). Losses at 10q25.1 
(D10S1246), though greater than background did not reach significance between the 
groups.
Allelic imbalance on chromosome 10 is a common event in several solid tumours, 
including renal cell cancer (Morita et al. 1991), glioblastoma (Karlbom et al. 1993), 
meningioma (Rempel et al. 1993), malignant melanoma (Herbst et al. 1994) and 
endometrial cancer (Peiffer et al. 1995). Loss of 10q22-24, the site of at least two 
putative tumour suppressor genes -  PTEN  and MXI1, is the most commonly reported 
site of deletion on chromosome 10, with rates of 20-50% of informative cases described 
(Bergerheim et al. 1991; Macoska et al. 1993; Phillips et al. 1994; Sakr et al. 1994). 
Two other sites on chromosome 10, lOp and 10q26, are also deleted in association with 
or independent o f 10q22-24 losses (Ittmann 1996; Karlbom et al. 1993; Komiya et al.
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1996; Trybus et al. 1996). Trybus et al. examined allelic imbalance in chromosome 10 
using 12 markers in 35 radical prostatectomy specimens (Trybus et al. 1996). Overall, 6 
(17%) tumours demonstrated loss of lOp loci only, 5 (14%) showed losses of lOq loci 
only and 14 (40%) were characterised by loses of both lOp and lOq loci. Six (18%) 
showed loss at D10S211, which is similar to the current series where 7 (19%) of 36 
informative demonstrated allelic imbalance at this locus. Trybus et al. found no 
significant association with 1 Op loses and tumour grade and stage, though patients with 
localised tumours had higher frequencies of lOp loss compared to men with 
extraprostatic tumours and those involving the seminal vesicles or lymph nodes (Trybus 
et al. 1996).
In a study of 64 clinically localised prostate cancers allelic loss was found in 9 cases in 
one or more of 12 microsatellite regions examined on chromosome 10 (Ittmann 1996). 
Of these 9 cases 6 were informative for D10S211 and 2 (33%) had allelic imbalance at 
this locus. In this study the incidence of allelic loss was higher than than our series 
because the subset of nine individuals who had confirmed Al in chromosome 10 were 
selected for analysis.
In a study of 48 Japanese men undergoing either radical prostatectomy or autopsy with 
stage B-D prostate cancer, losses on chromosome 10 were reported significantly more 
frequently in advanced compared to localised cases (Komiya et al. 1996). In these 
studies, unlike our series, tumours from a broad range of cancer stages (T2N0M0- 
T4N1M1) were utilised. These studies concluded deletions of chromosome 10 are more 
common with higher stage disease. The incidence of Al and biochemical outcome in 
patients undergoing radical prostatectomy was not correlated in these studies.
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Several loci demonstrated marked, though not statistically significant differences, 
between the relapse and non-relapse groups. Differences in the region of 2q23.1 
(D2S222) approached significance (p=0.07), 6 (29%) of 21 relapse patients and 2 (8%) 
o f 25 non-relapse patients region showed allelic imbalance. This region has not been 
extensively studied in prostate cancer. Saric et al. reported 1 (6%) of 17 men undergoing 
radical prostatectomy for clinically localised disease and 4 (23%) of 23 metastases 
samples from autopsy specimens had Al at this locus. Other studies confirm deletion of 
2q is associated with metastatic disease in non-small-cell lung carcinoma (Lu et al. 
1996). The current study suggests an association with poor outcome after surgery 
though further studies are required to confirm these findings.
In the current study 3 (25%) of 12 informative relapse patients and 1 (11%) of 9 
informative non-relapse patients demonstrated allelic imbalance at 6q 16.3-27 (marker 
D6S314). Cooney et al. have shown that this region is commonly deleted in radical 
prostatectomy specimens (Cooney et al. 1996a). However, no association was found 
between patients who developed PSA relapse and 6q losses, though only 10 patients 
relapsed over a short follow-up of 8 months in this series. In a study using using CGH 
analysis, 22% of primary prostate cancers and 44% of recurrent tumours had 6q losses 
(Visakorpi et al. 1995b). The region 6 q l6.3-21 has been implicated in hereditary mixed 
polyposis syndrome (HMPS), an autosomal dominant disorder predisposing to colonic 
polyps and carcinomas (Thomas et al. 1996). A tumour suppressor gene has not yet 
been isolated, though several may exist as patients with HMPS do not have increased 
risk of prostate cancer development.
Allelic imbalance occurred in 5 (19%) o f 26 relapse patients and 1 (4%) of 25 non­
relapse patients in the region 13q21 (marker D13S269). Deletions of 13q are frequently
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reported in prostate cancer and the region 13q21 is believed to harbour an as yet 
unidentified TSG important in prostate cancer progression. Studies examining this 
region have reported deletion in this region is associated with poorly differentiated or 
metastatic disease (Dong et al. 2000). The results from the current study support these 
findings; losses at 13q21 appear to be associated with increased risk of biochemical 
relapse after radical prostatectomy.
The chromosomal region 12 p l2-13 contains the TSG p27/kipl and deletion of this 
region is associated with metastatic potential in prostate cancer (Kibel et al. 2000). 
Kibel et al. identified Al in 23% of 60 primary tumours from radical prostatectomy 
specimens compared with 47% of 19 metastatic lesions from autopsy specimens using 
polymorphic markers spanning this region, including the marker D12S1697. Of eleven 
patients undergoing autopsy with multiple metastases, 7 demonstrated Al in this region 
and the pattern was identical in all the metastases examined from each individual patient 
as well as in the primary tumour. This study did not examine how many of the patients 
with 12pl 2-13 losses in the primary tumours at radical prostatectomy went on to 
develop biochemical relapse or metastases. However, this data suggests genetic 
inactivation of this region occurs in primary tumours prior to distant spread and may be 
a critical step in prostate cancer metastasis. In the current study 31% of the relapse 
patients compared with 17% of the non-relapse men had allelic imbalance at 12pl2.3 
(marker D12S1697). This difference was not statistically significant, a larger study may 
demonstrate allelic imbalance in this region is a predictor of biochemical failure after 
radical prostatectomy.
Studies looking at allelic imbalance on chromosome 15 in lung, colorectal, renal and 
ovarian carcinomas have found a low incidence of allelic imbalance in informative
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cases. However, in breast cancer region 15ql4 was reported to harbour a TSG which 
plays an important role in the development o f metastasis (Wick et al. 1996). There are 
no reported series looking at chromosome 15q in a significant number of patients with 
prostate cancer. The current series demonstrated 6 (38%) of 16 informative relapse men 
and 3 (18%) of 17 informative non-relapse patients had allelic imbalance at 15q 13.1 
(D15S1232). Though this is not statistically significant a TSG important in prostate 
cancer progression may exist in this region.
Several sites o f allelic loss are consistently associated with prostate cancer metastases. It 
might be feasible to identify patients harbouring metastases, before they are clinically 
detectable, by examining known deletion patterns associated with metastatic spread. 
Three sites frequently deleted in metastatic prostate cancer were evaluated. The tumour 
suppressor gene KAI1 gene is located at 1 lp l 1, close to marker D11S902. Deletion of 
this region is associated with metastatic prostate cancer (Kawana et al. 1997; Saric et al. 
1999) and the KAI1 gene has been shown in metastatic rat models to reduce metastatic 
potential (Behrens et al. 1989). Only 1 (3%) of 36 informative cases had allelic 
imbalance at this locus, though the patient (79) who had allelic imbalance at this locus 
relapsed soon after surgery (by 12 months).
Locus 18q 21.1 (marker D18S541) is also associated with metastatic potential in 
prostate cancer (Saric et al. 1999; Ueda et al. 1997). Similar to 11 pi 5, the overall 
incidence o f allelic imbalance at this locus was low, 2 (10%) of 19 cases, however both 
patients with allelic imbalance at this locus developed biochemical relapse, one at 13 
months (patient 2) and one at 3 months (patient 43). Patient 43 had good pathological 
features after surgery - Gleason 7 disease, specimen confined, surgical margin negative 
disease and a preoperative PSA of 5.2ng/ml, and yet developed a rising PSA rapidly,
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following a PSA nadir, after surgery. Using conventional criteria patient 43 would be 
expected to have a PSA free survival of over 80% at 5 years (Catalona, Ramos, & 
Carvalhal 1999; Pound et al. 1997). The microsatellite marker D18S541 successfully 
predicted poor biochemical outcome in this individual demonstrating the potentially 
superior predictive role of molecular markers over conventional phenotypic changes, 
though this needs to be shown in larger numbers to confirm this does not represent 
background losses.
Losses at 16q24 are associated with metastatic potential in prostate cancer (Elo et al. 
1999; Harkonen et al. 2005; Saric et al. 1999; Suzuki et al. 1996). Al was found in 17% 
of 18 primary cancers from radical prostatectomy specimens (Saric et al. 1999), which 
is consistent with an overall allelic imbalance rate of 18% at marker D16S413 in the 
current series. In metastatic samples Saric et al. noted this rate more than doubled, the 
rates between the relapse and non-relapse groups in the current series were similar. 
Likewise, Al at D16S413 was identified in 27% of 22 primary tumours, in 45% of 22 
recurrent prostate cancers and 44% of 9 metastatic lesions (Harkonen et al. 2005). 
Furthermore, the incidence of Al at 16q24.3 (marker D16S520) was greater in the 
recurrent than in the metastatic samples indicating an association with recurrent tumour 
after androgen withdrawl, rather than metastatic potential.
Losses at 8p play a key role in initiation and progression of prostate cancer and the three 
markers on the short arm o f chromosome 8 had some of the highest rate of allelic 
imbalance of all 30 markers in this study. At least, two distinct regions of loss have 
been reported (MacGrogan et al. 1994; Trapman et al. 1994). Loss of 8 p l2-21 is an 
early event in prostate carcinogenesis, occurring in HGPIN and early invasive disease, 
whereas loss of 8p22 is a late event, found more commonly in advanced cancers (Abate- 
Shen & Shen 2000). Marker D8S136 on 8pl2-22 demonstrated allelic imbalance in
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39% of informative patients, marker NEFL at 8p21.3 62 % and marker D8S1991 at 
8p22 47%. Vocke et a l found 72% Al at D8S136 and 64% at NEFL in the 
microdissected prostate cancer o f 97 patients with T2a-T3cNl disease. Microdissection 
increases the yield of tumour cells compared with normal stromal cells. By reducing the 
contamination of the cancer sample, allelic imbalance, when present, will be more 
apparent because the amplitude o f the deleted allele is less. This together with the 
higher number of more advanced cases explains why the Al rates were higher compared 
with the current series. In the current series three markers demonstrated a higher rate of 
allelic imbalance in the relapse patients than the non-relapse individuals. Macoska et al. 
attempted to examine the relationship between Al and PSA outcome after radical 
prostatectomy. They looked at 8p deletions in 78 of 135 men. No significant differences 
were seen in fractional allelic loss or total 8p loss between those patients with PSA 
recurrence (Macoska et al. 1995). Together with the current study there is currently no 
evidence of a link between 8p loses and biochemical outcome after radical 
prostatectomy (Macoska et al. 1995; Sato et al. 1999). \
4.4 Study Limitations
There are several reasons why with a large cohort of men and a large number of 
microsatellite markers more loci were predictive of biochemical outcome. Firstly the 
patient factors outlined in Chapter 2 meant that an insufficient number of men could be 
matched. To establish the minimum sample size a realistic expectation of what
difference in allelic imbalance between case and control was set at 40%. If either of the
\
matched relapse or non-relapse individuals were uninformative or uninterpretable both 
would be excluded for matched comparsion. The heterozygosity rate for markers 
selected was set at >0.7. The total number o f paired matched cases to give 30 
informative pairs, assuming a het rate on 0.7, is 62. So a radical prostatectomy cohort of
approximately twice the size of ours (ab^ut 2000 cases) would be needed to achieve 
sufficient patient numbers using this method.
Apart from the difficulty o f finding sufficient numbers, the other major limitation of this 
study was the relatively poor quality of the archival DNA recovered from the samples. 
This may be in part due to the relatively slow fixation achieved in the large radical 
prostatectomy specimens during immersion in formalin. However, all the primers gave 
satisfactory electropherograms for some DNA samples, and all the DNA samples 
produced satisfactory electropherograms for some primers. Perhaps by optimising the 
PCR conditions for each set of primers and each DNA sample, it would have been 
possible to increase the success rate, but given the exceptionally large scale of the study 
and the limited amount of DNA, this approach was not feasible. Recently, improving 
technology has meant more of the techniques used in this study can now be done using 
automated robots and large-scale PCR and genotyping machines. Tailoring the PCR 
conditions for each marker and increasing the number of markers and patients becomes 
more feasible using this more up-to-date equipment.
Tumours were selected based on their size and Gleason score. Samples were then 
scraped in the majority o f cases using a scalpel blade. Although this technique has been 
described in the literature it does not provide a pure clone of cancer cells. Prostate 
cancer is a genetically heterogeneous disease and so scraping large areas of tumour may 
incorporate several genetically different tumours. Al in one area o f tumour may be 
different from Al in another tumour area. DNA containing several different tumours 
may not reveal prognostic Al found only in one tumour. Furthermore benign stroma 
cells will be incorporated (Leube et al. 2002), particularly in the lower grade cancers 
where the stromaP.epithelial ratio is higher. The presence o f normal DNA contaminating
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cancer DNA diminishes the chance of detecting Al. This problem can be circumvented 
to a certain extent by laser capture microdissection (LCM) (Emmert-Buck et al. 1995; 
Leube et al. 2002; Narla et al. 2001). However with LCM a small area of tumour is 
extracted for analysis and this may not represent the index or clinically important 
tumour. Secondly, the DNA yield from LCM is substantially smaller and large 
quantities o f DNA were needed to perform genotyping with 30 markers in the current 
study. A i i
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This study involved selecting markers reported by others to show loses in prostate 
cancer. It is not clear from these studies whether these loses are critical in the 
pathogenesis o f prostate cancer and in particular the transition between extracapsular 
extension and the developent o f metastases. Loses may occur in tumour progression 
without any change in the cancer behaviour. Similarly prostate cancer progression may 
occur via many different genetic pathways. Identifying a patient as having a ‘good 
prognosis’ by demonstrating heterozygosity at a particular locus does not exclude allelic 
imbalance at another locus, which may represent worse prognosis. Results obtained in 
this study need to be confirmed in a separate patient cohort.
4.5 Conclusions
Allelic imbalance studies have been used to identify regions of loss, containing critical 
genes, important in the multi-step process of cancer development and progression. 
Identification of specific losses may be used to predict prognosis and treatment response 
in a number o f malignancies. This study demonstrated specific losses on chromosome 
1 Op 12.1 were associated with biochemical progression after radical prostatectomy. 
Several other loci approached significance and maybe statistically significant in a larger 
sample. The small number o f patients with allelic imbalance at l l p l l  and 18q21.1 all
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developed biochemical relapse, despite in some case favourable pathological prognostic 
features. For the minority of individuals with these deletions adjuvant therapy after 
radical prostatectomy may be o f benefit.
This study also illustrates some of the difficulties encountered relating genetic changes 
in formalin-fixed tissue to clinical outcome. Confirming the Al findings identified in 
the radical prostatectomy specimen are also present in the diagnostic needle biopsy 
may, in the future, enable treatment to be tailored to the individual patient.
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CHAPTER 5
The p21WAF1/clpI gene is inactivated in metastatic 
prostatic cancer cell lines by promoter methylation.
metastatic prostate cancer cell lines was examined and a mechanism of inactivation in 
prostate cancer is proposed (Bott et al. 2005a).
5.1 Introduction
The Gl /S transition checkpoint in the cell cycle is an important point of control as DNA 
damage can be repaired before replication occurs (Sherr 1996). Progression through the 
Gl/S checkpoint in the cell cycle is controlled by cyclin dependent kinases, whose 
activity in turn is controlled by cyclin dependent kinase inhibitors, including 
p21liAFI C,PI. The role o f p 2 ] WAFI/CIPI ancj its association with carcinogenesis has been 
described in section In brief, normally as a cyclin dependent kinase inhibitor
p 2 i ^ A F i  c i p i  a meciiator o f p53 induced growth arrest as a modulator of apoptosis. 
Inactivation of p21nAF1 CIP1 during prostate cancer development may allow unchecked 
passage through the cell cycle and p 2 iWAF,/CIPI has been related to several solid 
malignancies including prostate cancer.
Hypermethylation is the most frequent somatic epigenetic alteration in prostate cancer 
and may result in changes in gene expression (see section 1.11(d)). It involves the 
addition of a methyl group to the carbon-5 position o f cytosine residues (Figure 5.1),
The aim of this chapter was to describe the role of p21 in cell cycle progression
and its potential role as a tumour suppressor gene. The expression of p 2JWAFI CIPI in
W A F 1  C I P I
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and occurs almost exclusively at cytosine residues that are immediately followed by 
guanine (CpG dinucleotides). Isolated CpG dinucleotides are relatively rare and are 
nearly always methylated. In contrast small stretches of DNA rich in CpG 
dinucleotides, the CpG islands, are usually free of methylation in normal tissue. These 
CpG islands are frequently found in the promoter region of human genes and abnormal 
methylation within the islands has been associated with transcriptional inactivation of 
the corresponding gene. Alteration in DNA methylation in the promoter region of 
tumour suppressor genes may be pivotal to the development of cancer (Strathdee &
Brown 2002).
NH
Cytosine
SAM-CH
—  DNMT
SAM
5-Methylcytosine
Figure 5.1.
Mechanism of DNA methylation
DNMT = DNA methyltransferase 1,3a or 3b 
SAM = S-adenosylmethionine
The aim o f this study was to examine the expression of p 2 iWAFI/CIPl in metastatic 
prostate cancer cell lines and to assess the methylation status of the promoter.
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5.2 Materials and Methods
5.2(a) Cell culture and treatment
Human metastatic prostate cancer cell lines PC3, LNCaP, DU 145 and 1542 NP were 
obtained from the originators, RD a rhabdomyosarcoma cell line and 1542NP normal 
prostate epithelial cells were obtained from ATCC (American Type Culture Collection, 
VA, USA). LNCaP cells have a slower replication rate than the other cell lines. 
500,000 PC3, DU 145, 1542NP, RD cells and 106 cell LNCaP cell were plated in flasks 
containing standard growth medium, namely RPMI-1640 (Roswell Park Memorial 
Institute-1640, Gibco BRL), 10% Foetal Calf Serum (FCS) and 1% of L-Glutamine (G) 
and cultured in a humidified incubator in 5% carbon dioxide at 37°C. After 16 hours, 
500nM of the demethylating agent 5-Aza-2 deoxycytidine (5-Aza-CdR)(Sigma 
Chemical Co: A 3656 C8H 12N4O4) in 15pl o f phosphate buffer solution (PBS) was 
added to the test flasks and 15pl PBS was added to the control flasks. 5AzaCdR 
sequesters the enzyme DNA methyltransferase and thus prevents DNA methylation 
during DNA replication. After treatment for 24 hours the test and control media was 
replaced with standard growth medium. The media was changed every 72 hours.
After 5 days the cells were harvested. The medium was removed and 2mls of trypsin 
was added and distributed over the monolayer of cells and the flask returned to the 
incubator for 5 minutes. Trypsin is a proteolytic enzyme that releases the cells adhering 
to the flask. Once the cells were detached 8 mls of RPMI and FCS was added to 
neutralise the enzyme. The suspension was mixed and a sample taken for counting. The 
remaining cell suspension was alliquoted into a 20ml Universal tube and centrifuged at 
1250rpm for 10 minutes at 4°C. The cell pellet was resuspended and washed in 5mls 
PBS and centrifuged again. This wash step was repeated. After the second wash step the
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PBS was aspirated, the cell pellet snap frozen in liquid nitrogen and stored at -80°C. 
Cell culture was performed in triplicate.
5.2(b) Cell counting
200pl o f the well-mixed single cell suspension from each T80 flask was alliquoted into 
an Eppendorf ™ tube containing 0.2 ml trypan blue (0.1% solution) and mixed. Trypan 
blue is a viability stain and is only taken up by dead cells, these can be excluded from 
the count. A few microlitres of cell suspension mix was applied to the haemocytometer.
Cells were counted using the lOx microscope objective in at least four squares in both 
of the two chambers on the haemocytometer so that a minimum of 100 cells was 
counted. An average number o f cells was calculated by summing the number of cells in 
all squares counted and dividing by the number of squares examined. The volume of 
each square was lO^mls (1mm2 x 0.1mm in depth). The cells were diluted 1:1 with 
trypan blue, so the cell count was multiplied by 2. This is summarised below:
The cell number/ml o f  suspension =mean number o f  cells per square x 2xl04
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5.2(c) p 2 J WAFI/c,pl gene expression 
5.2(c) 1. RNA extraction
RNA from cell lines was extracted using RNeasy® mini kit (QIAGEN®).
•  600 (xl o f buffer RLT was added to the cell pellet and vortexed, buffer RLT 
contained p-mercaptoethanol and causes the cell wall disruption and release 
RNA.
• The lysate was pipetted onto a QIAshredder spin column, placed in a 2ml 
collecting tube and centrifuged for 2mins at 13,000rpm. This homogenisation 
step shears the high molecular weight genomic DNA and other high molecular 
weight cellular components.
• 600pl o f 70% ethanol was added to the homogenised lysate to expose the 
phosphate backbone for binding.
• This solution was placed in a RNeasy mini column and centrifuged for 15secs at 
13,000rpm, the flow-through was discarded. The spin columns contain a 
positively charged silicone membrane that binds to the negatively charged 
phosphate backbone of the RNA.
• 700pl o f washing buffer RW1 was added to the column and the tube was 
centrifuged at 13,000rpm for 15 secs. The wash-through was discarded.
• 500pl washing buffer RPE was added to the column and the tube was 
centrifuged at 13,000rpm for 15 secs. The wash-through was discarded.
• 500pl washing buffer RPE was added to the column and the tube was 
centrifuged at 13,000rpm for 120 secs to wash and dry the silica-membrane.
• To elute the RNA the column was placed in a 2ml collecting tube and 30pl of 
RNase-free water was added to the membrane and centrifuged at 13,000rpm for 
60 secs.
• RNA was snap frozen in liquid nitrogen and stored at -70°C.
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5.2(c)2. cDNA
Single stranded RNA was made into copy DNA (cDNA), as follows. Into a 200pl tube, 
lpg o f RNA made up to 11 pi with 0.1% diethylpyrocarbonate (DEPC) water was 
alliquoted. The DEPC destroys contaminating RNAses. lpl of oligo(dT) was added, the 
tube was vortexed and placed in a water bath at 70°C for 10 mins. Oligo(dT) is a primer 
consisting solely o f deoxythymine residues. At 70°C the RNA looses its secondary 
structure and oligo(dT) anneals to the polyadenylated 3' tail found on most mRNAs.
The tubes were removed and put on ice. To each tube 4 pi buffer, 2 pi deoxythymine 
triphosphate (DTT) and lp l dNTP (the single nucleotides A,T,G,C) was added. The 
tubes were placed in a PCR machine at 42°C for 50 minutes. After 2minutes, lpl of 
Superscript II reverse transcriptase (RT) was added to all tubes except the ‘no RT’ 
control. RT hybridises the single nucleotides (dNTP) to their complimentary base 
sequentially from the oligodT primer, forming cDNA. The tubes were heated to 70°C 
for 1 Omins to inactivate the RT and placed on ice.
5.2(c)3. Primer design
Primers are complementary to and hybridise with opposite DNA strands either side of 
the region of interest. The following were applied in primer design.
1. Primers were usually 20-30 base pairs long to allow a reasonably high annealing 
temperature, longer than 30 does not improve primer specificity.
2. Primer annealing was helped by having Guanine or Cytosine at the 3’ end, as the 
three H+ bond formed by G to C are stronger than the two formed between A 
and T.
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3. Primers were designed so that a total of 50 or more hydrogen bonds form when 
the primers anneal and were made up of approximately equal numbers of purines 
(A and G) and pyrimidines (T and C).
4. Repetitive sequences and stretches of more than 3 of the same base were 
avoided to ensure specificity. Complimentary sequences either within a primer 
or between a primer pair were minimised to prevent the formation of primer 
dimmers - an artifact where the primer itself acts as a template resulting in a 
short length product.
5. The distance between the sense and the antisense primer i.e. the length of 
desired product did not exceed 10 kilobases, the polymerase enzyme was less 
effective at amplifying the cDNA after 3kb.
6. When performing an RT-PCR there was a risk of cDNA contamination by 
genomic DNA. This was overcome by designing primers in adjacent exons 
where there was a significant length o f intron in between. The genomic DNA 
segment including the intron would be too large to amplify. However, the intron 
is removed in the formation o f mRNA so the cDNA can be amplified.
Intragenic primers for p21 and GAPDH  were designed and are summarised in 
Table 5.1.
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Table 5.1 Intragenic primers forp21 WAF,/CIP1 an(j GAPDH
Primer Sequence Annealing
temperature
Product 
size (bp)
p21 sense tgaccctgaagtgagcacagcc
60°C 834
p21 anti sense gccgagagaaaacagtccaggc
GAPDH  sense aaccaccactttgtcaagctc
60°C 210
GAPDH  
anti sense
gtccaggggtcttactccttg
5.2(c)4. Reverse Transcription -  Polymerase Chain Reaction (RT-PCR)
The reaction mix used in these experiments is shown in Table 5.2.
Table 5.2 PCR master mix for lx  50pl reaction
5 pi 1 Ox buffer 
5 pi dNTP (2mM)
3 pi MgCl2 (25mM)
2 pi sense primer (lOpmol/pl)
2 pi antisense primer (lOpmol/pl)
29.5 pi H2O (variable)
0.5 pi Taq enzyme
cDNA was amplified using intragenic primers at p 2 1 WAF1/CIP\  spanning a region -990
to -67 relative to the transcription start site and to GAPDH. Reactions were performed
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in a Perkin Elmer-Gene Amp 2400 thermal cycler (Perkin Elmer Ltd., UK), at 94°C for 
150 s, then 34 cycles at 94°C for 45 s, 60°C for 45 s and 72°C for 45 s, followed by an 
extension step at 72°C for 5 mins. The PCR products were electrophoresed through a 
1.5% agarose gel
5.2(c)5. Agarose gel electrophoresis
Agarose gel electrophoresis was used to separate DNA fragments according to their size 
and charge. 1.5g o f agarose was added to lOOmls of lxTAE buffer (Tris acetate 
electrophoresis buffer) and heated until the agarose had completely dissolved. 5pi of 
ethidium bromide (at 5mg/ml) was added per lOOmls of gel solution and mixed. 
Ethidium bromide incorporates into DNA strands and is photosensitive. The agarose 
was poured into a gel tray containing a gel comb and allowed to set.
A stock lx  solution of gel loading buffer was used and 6pl added and pipette mixed 
with 25pi o f PCR product. 20pl o f PCR product/gel loading buffer mix was loaded 
along with 4pl size standard 1Kb ladder (mixed 3:2 by volume with gel loading buffer), 
to ensure correct product size.
A potential difference o f 135V was placed across the gel tank. Migration across the gel 
was observed using the movement of the blue gel-loading buffer until the products had 
separated sufficiently when an image under ultraviolet light was recorded.
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5.2(d) Promoter sequencing 
5.2(d)l. DNA extraction
The frozen cell pellet was thawed on ice and re-suspended in PBS. DNA extraction was 
performed using the DNeasy Tissue kit ™ and the extraction process for cultured cells 
is similar to that of paraffin embedded sections described in Chapter 3.
The DNA content of the eluate was measured by diluting 2pl in 498pl water and using 
optical densometry (OD). Final DNA concentrations were 259-1500ng/ml.
The sample DNA was stored at -25°C.
5.2(d)2. Sodium bisulphite modification
Sodium bisulphite deaminates cytosine, removing the NH2 group from carbon-4 
(Figure 5.2) converting cytosine to uracil, unless the cytosine is methylated in the 
carbon-5 position. Metastatic prostate cancer cell line, RD (positive control), and NP 
(negative control) DNA was treated with sodium bisulphite.
Figure 5.2. Sodium bisulphite treatment of unmethylated and methylated DNA
M MM
5’ggg gcg gac cgc
|
5’ggg gcg
| |
gac cgc
NaBiSO, NaBiSO,
1r r
5’ggg gug gau ugu 5’ggg gcg
1
gau cgc
1 1
M MM
Unmethylated region Methylated region
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The modification protocol requires 0.001-lpg o f DNA. The CgGenome™ DNA 
modification kit was used. In a screw-cap 2ml centrifuge tube, 7pl of 3M sodium 
hydroxide was added to Ipg o f PC3, DU145, LNCaP, RD, and 1542NP DNA dissolved 
in lOOpl o f sterile water, mixed and placed in a water bath at 37°C, for lOmins. The 
NaOH renders the DNA single stranded. 550pl of Modification Reagent I was added 
and the sample vortexed. The samples were incubated at 50°C for 18 hours in a water 
bath. Reagent I contains sodium bisulphite, which is acidic, the pH was titrated to 5.0 by 
the addition o f 3M NaOH.
To purify the modified DNA, 750pl o f reagent II and 5pl of reagent III was added and 
left at room temperature for 10 minutes. The samples were centrifuged at 8000rpm for 
lOsecs and the supernatant discarded. The pellets were washed using 1ml of 70% 
ethanol, the sample vortexed and centrifuged at 8000 rpm for 10 seconds, the 
supernatant was discarded. This was repeated twice. A final wash step using 1ml 90% 
ethanol was performed and the supernatant removed. 25 pi of buffer TE was added to 
the sample pellet, the tube vortexed and incubated in a water bath for 15mins at 55°C.
The tube was centrifuged at 8,000 rpm for 3mins and the supernatant, containing the 
modified DNA drawn off. The DNA was stored at -20°C.
5.2(d)3. PCR
Primers for the promoter region o f p 2 ; WAF1/api Were designed as outlined above. 
‘Modified’ primers were designed assuming cytosine was converted to uracil and 
‘Unmodified’ primers were also designed assuming cytosine has not been deaminated. 
Primers were designed so they did not anneal over a CpG dinucleotide. Primers yielded 
product containing the CpG site at -692 - the SIE-1 STAT binding site.
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Table 5.3 p21 WAF1/CIPI primers
Primer
Primer sequence Annealing
temp
p21 M l-sense TTT GTT GT AT G ATTT G AGTT AG
60°C
p21 M l-antisense TAATCCCTCACTAAATCACCTC
p21 M2-sense GTTTT GTT GGGGT GTT AGGT G
60°C
p21 M2-antisense CACACCTCAACTAACACAACT
p21 U1 -sense ATCATTCTGGCCTCAAGATGC
62°C
p21 U1-antisense CGGCTCCACAAGGAACTGAC
Primers 1 and 2 denote different sites in the promoter region in cell, M = primers for 
modified DNA, U = primers for unmodified DNA.
PCR was performed on PC3, DU 145, LNCaP using primers M l, M2, and U1 in a 
Perkin Elmer-Gene Amp 2400 thermal cycler (Perkin Elmer Ltd., UK), at 95°C for 
150s, then 36 cycles at 95°C for 45 s, 60-62°C for 30 s and 72°C for 45 s, followed by 
an extension step at 72°C for 10 mins. The PCR products were electrophoresed on a 
1.5% agarose gel. Product was cut out from the gel using a number 11 scalpel blade and 
placed in a 1.5ml Eppendorf™ tube and weighed.
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5.2(d)4. DNA extraction from agarose gel
A 3x volume o f buffer QC to gel was added to the section cut out from agarose gel. For 
example if 50mg o f gel was cut out 150ml of buffer QC was added. The tube was 
placed at 50°C for 10 mins and vortexed every 3 mins until fully dissolved.
A lx volume 100% isopropanol was added and the sample vortexed (if 50mg of gel, 
then 50ml of isopropanol was added). The sample was pipetted onto a QIAspin column 
and centrifuged at 13,000rpm for lm in and the eluate discarded. DNA binds to the 
silicone membrane of the column. 500pl buffer QG was added and the sample 
centrifuged at 13,000rpm for lmin. Buffer QG was a wash buffer.
The sample was washed by adding 750pl o f buffer PE and centrifuged at 13,000rpm for 
1 min. The washing buffer was discarded and the column spun for a further 3minutes to 
dry the sample. The column was placed in an Eppendorf™ and 30pl buffer EB was 
added and left for lmin. Buffer EB alters the charge distribution of DNA so that the 
DNA no longer adheres to the silicone membrane. The sample was centrifuged at 
8,000rpm so that the eluate contained the extracted DNA. 3pl of DNA mixed with 2pl 
of lx  gel loading buffer was run on a 1.5% agarose gel to check DNA extraction and to 
estimate DNA concentration for sequencing.
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5.2(d)5. Sequencing reaction
The protocol for a sequence reaction was the same as a PCR reaction except 1) in 
addition to standard NTP, fluorescently labelled dideoxy NTPs are added (A-green, C- 
blue, G-black and T-red), these emitted a specific wavelength of light when excited by a 
laser. The dideoxyNTPs prevent binding o f further NTPs and so stop further elongation 
of the DNA strand 2) only the sense or the antisense primer is included.
The sequence reaction involves a primer annealing to the sense strand of the DNA 
fragment and NTPs elongating from the primer. When a dideoxy NTP binds the 
elongation phase is stopped. The result is many copies of parts of the sense strand 
ranging form lbp to the product size length e.g.220bp, each with a fluorescently 
labelled dinucleotide at the 3’ end. To confirm the results the same technique can be 
performed using an antisense primer, which will generate product with a labelled 5’end. 
The reaction was set up as follows.
The DNA yield from the gel extraction process was classified very dim to bright and 
was added to DEPC water in a 200pl tube as below:
Gel appearance Volume DNA (pi) Volume water (pi)
Bright 3 11
Moderate 5 9
Dim 7 7
Very dim 10 4
lpl of sense primer at 4pmol//jal and 5 pi o f solution containing NTP, ddNTP and 
polymerase enzyme was added (Terminator Ready Reaction Mix from the ABI 
PRISM® dRhodamine Terminator Cycle Sequencing Ready Reaction Kit) and the
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sample mixed. Oil was added to prevent evaporation during heating. The solution was 
then placed in a Perkin Elmer-Gene Amp 2400 thermal cycler (Perkin Elmer Ltd., UK) 
and programmed as below:
96°C lmin
96°C 30secs
50°C 15secs
60°C 4mins
4°C hold
The oil was removed and the sample transferred to 500pl tube containing 2pl of 3M 
sodium acetate and 50pl of 95% ethanol, mixed by vortexing and placed on ice for 15 
mins.
Precipitation of PCR products was subsequently performed by incubating with a 
mixture of 50pl o f 95% ethanol and 2pl o f 3M sodium acetate on ice for 15 minutes. 
The sample was centrifuged for 25minutes at 13,000rpm and the supernatant discarded. 
The remaining DNA pellet was washed with 70% ethanol (lOOpl). The pellet was stored 
in the dark. Automated sequencing was performed by running the fluorescently labelled 
DNA fragments on the ABI PRISM® 377 DNA Sequencer. The PCR products were 
loaded into the top of a polyacrylamide gel with product separating into distinct bands 
according to size and charge. Near the base o f the gel the bands passed through the 
beam of a constantly scanning laser, which excited the fluorescent label attached to 
DNA bands. The wavelengths o f the resulting light emissions were identified and the 
signal quantitated. Thus the wavelengh identified the terminal base characteristic of 
each band, and the quantitation o f each band’s fluorescent signal gave the relative 
number of fragments within each band. In addition to nucleotide sequence text files the 
automated sequencer also provided trace diagrams.
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5.3 Results
5.3(a) Cell Culture
The results o f the cell counting after 5-Aza-CdR treatment are shown below.
Figure 5.3 The number of cells harvested after treatment with 5- 
Aza-CdR or PBS (control)
Number of cells
PC3 LNCaP DU145 RD NP
Cell line 
□  5-Aza-CdR ■  PBS
Both Figures 5.3 and 5.4 demonstrate treatment with 5-Aza-CdR has a profound effect 
on the rate of cell division in the tumour cells. The rate of cell turnover is 1.9x in PC3, 
1.8x in LNCaP, 1.3x in Du 145 and 21x in RD greater in the untreated cells. There was 
also a dramatic difference in the size and morphology of the cells treated with 5-Aza- 
CdR as shown in PC3 cells in Figures 5.4a and 5.4b.
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Figure 5.4a PC3 ceils after 24 hours treatm ent with 5-Aza-CdR and 5 days growth 
in standard  media (xlO objective).
Figure 5.4b PC3 cells after 24 hours treatm ent with PBS and 5 days growth in 
standard media (xlO objective).
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5.3(b) RT-PCR
RT-PCR was performed on cDNA derived in triplicate from RNA of the treated and 
untreated cell lines. In all three metastatic prostate cancer cell lines p21WAFi/CIPI 
expression was either low or undetectable in the untreated populations. In the prostate 
cancer cell lines treated with 5-Aza-CdR, p 2 l WAF1/CIPI PCR product of 834 base pairs 
was seen (Figure 5.5). This implies 5-Aza-CdR treatment results in the re-expression of 
p2 JHAFI ( irl gene, which is otherwise inactivated in these prostate cancer cell lines. In 
the untreated RD cell line p21WAFI CIPI was expressed at a low level, following 5-Aza- 
CdR treatment gene expression increased. In the 1542NP cells p 2 l WAFI/CIP1 expression 
was present in untreated and treated cells. The GAPDH positive control confirmed 
equivalent quantities o f cDNA in the treated and untreated pairs. No product was seen 
in the ‘no cDNA’ control.
Figure 5.5 Agarose gel showing RT-PCR of 5-Aza-CdR treated (+) and untreated 
(-) cell line DNA.
a )p21w‘mm
I ■ o  TtwiH
b) GAPDH gene
■■■
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5.3(c) Sequencing the p21 WAF,/C,P1 promoter
To provide further evidence that inactivation of p21WAFIC,pl in the prostate cancer cell 
lines was due to methylation in the promoter, cell line DNA was modified by sodium 
bisulphite treatment and sequenced. In all three prostate cancer cell lines (PC3, LNCaP, 
DU 145) cytosine was conserved following sodium bisulphite treatment at positions - 
896, -856 and -692 in the p21WAFI/CIPI promoter, confirming methylation at these sites 
(Figure 5.6). In the RD cell line, a positive control, cytosine was also conserved at the 
same positions (-896, -856 and -692) (Figure 5.7a). indicating that these sites are 
methylated, in agreement with previous studies (Chen et al. 2000) (Table 5.4).
Figure 5.6 shows part of the p21nAFI/CIPI prom oter region in modified PC3 cells.
The cytosine residue is conserved at position -896 (a), -856 (b) and at the SIE-1
binding site at -692 (c), the la tter shown here using the antisense primer.
Figure 5.6a Figure 5.6b Figure 5.6c
SIE-1
-896 r Q'j-ovz
A C G G G T C C G A
The cytosine nucleotide within the SIE-1 site is shown more clearly in Figure 5.6c, 
where the antisense primer was used. This confirms the cytosine is conserved in the 
SIE-1 binding site, suggesting it is methylated in the C-5 position. Similar findings were
212
observed in LNCaP and DU 145 cell lines, cytosine was conserved in the -896, -856 and 
-692 (SIE binding site) positions.
In contrast, DNA from the normal prostate epithelial cell line, 1542NP, used as a 
negative control, was not methylated at the positions -896 and -856. This suggests that 
methylation at these sites is cancer specific and not an artefact due to cell culture.
Figure 5.7 Positive and negative controls: a) Preservation of the cytosine residue in 
RD at -896 and b) conversion to thymine in NP.
Figure 5.7a RD positive 
control at -896
Figure 5.7b NP negative 
control at -896
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Table 5.4 Results o fp 2 l WAFI/CIP1 promoter sequencing after sodium bisulphite DNA
DNA Site 5’-3’
-896 -856 -692 -471 -377 -278-78
PC3 M M M ND ND ND
LNCaP M M M M M U
DU145 M M M M M U
RD M M M ND ND ND
1542NP U U ND ND ND ND
Binding site cap SIE-1 cap
modification.
(M=methylated, U=unmethylated, M/U=partial methylation, ND=not determined)
In all samples, the cytosine residues that were not part of a CG site were converted to 
thymine by sodium bisulphite modification, confirming successful modification. 
Cytosine methylation was also seen at two other sites (-471 and -377) in LNCaP and 
DU 145. The sequence for PC3 DNA at these sites could not be reliably interpreted.
There is a CpG island in the p 2 l WAF,/C,PI gene promoter downstream of the sites 
discussed. The following sites were sequenced in LNCaP and DU 145 cell line DNA 
after modification and were not methylated: - 278, -259, -251, -245, -206, -192, -172, - 
152, -149, -123, -114, -108, -104, -101, -99, -91, -87 and -78.
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5.4 Discussion
The pivotal role o f CDKIs and in particular p 2 ] HAF1/CIPI in control of the cell cycle as 
well as modulators of apoptosis and differentiation implies a tumour suppressor 
function (Hirama & Koeffler 1995; Toyoshima & Hunter 1994). The aim of this study 
was to assess the expression o f p21WAFI/CIPl in metastatic prostatic cell lines and to 
determine if the low levels of expression observed result from methylation of the p21 
promoter. \ /
\]
f e j W A F i  c i p i  gene eXpressjon was iow or undetectable using RT-PCR in the metastatic 
prostate cancer cell lines and RD control but was highly expressed in normal prostate 
epithelial cell lines (1542NP). Following treatment with the demethylating agent 5-Aza- 
CdR, p21l*AFI'CIP1 was re-expressed in the metastatic prostate cancer cell lines. This 
suggests p 2 7 WAF,/C1P1 is inactivated by methylation. Low levels of expression were 
present in PC3, LNCaP and RD untreated cells presumably because either methylation 
is incomplete or because methylation does not completely inhibit gene expression.
SIE-1 (Sis-inducible-element-1) sites (TTCNNNGAA) are found at -692, -2557 and -  
4232 (SIE-1, SIE-2 and SIE-3, respectively), in the p21 WAFI/CIPI promoter. STAT1, a 
cytoplasmic protein which binds to SIE sites (Darnell, Jr. 1997), is an essential 
component of the IFN-y signal transduction pathway (Xu et al.). Activation of STAT1 
in response to IFN-y results in up-regulation of the p 2 J lj'Abl/CIP] gene and inhibition of 
cell growth (Xu et al.). Methylation at the SIE-1 binding site (-692) inhibits binding of 
STAT1 and decreases p 2 l WAFl/CIP1 gene expression (Chen et al. 2000). The SIE site at -  
692 was methylated in all 3 prostate cancer cell lines. Inhibition of ST AT binding by 
methylation may be the mechanism by which the p 2 i WAbI/CIPI gene is silenced in 
prostate cancer cell lines.
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CG sites at -896, and -856 were methylated in all three prostate cancer cell lines but not 
in the normal prostate epithelial cell line, suggesting that methylation at these sites is 
cancer specific. The CG site at -896 is not a recognised transcription factor binding site 
(TFSEARCH: Searching Transcription Factor Binding Sites (ver 1.3) 2004). A myeloid 
zinc finger protein MZF1 does bind 7 base pairs downstream at -889 (TFSEARCH: 
Searching Transcription Factor Binding Sites (ver 1.3) 2004). MZF-1 is a transcription 
factor of the Kruppel family o f zinc finger proteins (Gaboli et al. 2001). In in vitro 
transient transfection experiments, MZF-1 can alter transcription in haemopoietic and 
non-haemopoietic cells (Hromas et al. 1996; Morris et al.). It is feasible that 
methylation close to the MZF-1 binding site alters the structure of the binding domain 
affecting transcription. Another Kruppel-like transcription factor, KLF6, is mutated in 
prostate cancer (Narla et al. 2001). Up regulation of wild type KLF6 increases 
expression of the p 2 i WAF,/CIPI gene fivefold and significantly reduces cell proliferation. 
Unlike the wild type mutant KLF6 does not up-regulate p 2 i WAF,/C,PI gene, suggesting 
KLF6 is a tumour suppressor gene in prostate cancer. A germline KLF6 single 
nucleotide polymorphism is significantly associated with an increased relative risk of 
prostate cancer in men, regardless o f family history o f disease (Narla et al. 2005). KLF6 
interacts with DNA through a GC box promoter element, not in the regions examined in 
this study (Narla et al. 2001). The work by Narla et al. on KLF6 does however confirm 
a role for Krupel-like factors in the development and progression of prostate cancer.
Site -856 of the p 2 l WAFI/c,PI gene promoter was methylated in all three cancer cell lines 
and is a transcription factor binding site (TFSEARCH: Searching Transcription Factor 
Binding Sites (ver 1.3) 2004). The transcription factor ‘cap’ binds to sequence 
TCACTCGT and triggers transcription initiation (Bucher 1990). The CG at -377 was
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methylated in LNCaP and DU 145 cancer cells and is also a cap binding site (Bucher 
1990), in this instance binding to TCAGCGGT. Little is known about cap in normal or 
malignant cells.
The 18 CpG sites downstream of the area studied were unmethylated in two cell lines; 
this implies the p2J^AFFCIPl promoter is not inactivated by methylation at these sites. 
p2J liAF, c,PI is one of many cell cycle regulators and fits into the complex pathways of 
cell cycle control. It may be inactivated in several ways during tumourigenesis and 
methylation of upstream transcription factors may account for the reactivation of 
p 2]UAf-iciPi gene following treatment with 5-Aza-CdR. However sequencing 
experiments confirmed several sites on the p 2 JWAFIC,PI promoter were methylated and 
this suggests inactivation by methylation maybe the mechanism of p 2 j M'AFIC,PI 
inactivation in the cell lines examined.
Further studies are required to examine whether these findings are present in human 
prostate cancer samples. Results from several preclinical studies have demonstrated that 
decitabine (5-AzaCdR) effectively demethylated and reactivated different tumour 
suppressor genes in cell-lines from breast cancer, mesothelioma, lung, gastric, colorectal 
cancer and haematological malignancies. The role of decitabine in prostate cancer is 
under evaluation (NCI-T95-0070). Re-activation of tumour suppressor genes including 
p21WAFI C,PI by demethylation may play a role in prostate cancer therapy in the future.
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5.5 Conclusions
The p 2 i HAF1 ap/ gene product has a number of roles involving cell cycle control and 
apoptosis. With this in mind it is unsurprising that this gene has been implicated as a 
tumour suppressor gene in a variety o f solid and haematological malignancies. This 
study demonstrates p 2 l WAFI/C,PI is poorly expressed in metastatic prostate cancer cell 
lines and sequestration of the DNA methyltransferase enzyme results in re-expression. 
Furthermore, several cytosine residues in the promoter region are methylated, in 
particular the site o f ST ATI and cap binding. The inhibition of the STAT1 signalling 
pathway by methylation of the p21 promoter may inactivate the p21WAFI:C,PI tumour 
suppressor gene in prostate cancer.
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Chapter 6
Conclusions and Future Directions
The natural history of prostate cancer is so variable that reliable predictors of disease 
outcome are desperately needed to target patients who need radical and adjuvant 
treatment to prevent disease progression while avoiding unnecessary treatment in those 
with indolent disease. Current clinico-pathological markers, including Gleason grade, 
stage, pre-operative PSA and margin status are inadequate at predicting biochemical 
outcome in all men. In this thesis we have used a battery of markers to try and identify 
critical areas o f allelic imbalance, which may be used to predict PSA failure after 
radical prostatectomy.
Markers were selected from across the spectrum of prostate cancer biology, ranging 
from 8p 12-21 deletions found in high-grade prostatic intra-epithelial neoplasia and early 
invasive tumours to l ip  and 18q21 losses seen in metastatic and hormone refractory 
disease. To predict PSA outcome after radical prostatectomy, patients were matched for 
the best current markers of disease progression. One area of deletion at 1 Op 12.1 was 
significantly more common in patients who developed biochemical relapse. Markers 
associated with metastatic disease on 1 lp  and 18q21 were more commonly seen in men 
who relapsed, though this did not reach significance a larger study may demonstrate 
these to be important, albeit infrequent, predictors of PSA failure.
Future studies could repeat the allelic imbalance experiments on a larger cohort of 
patients focussing on markers, including D10S211, which showed the greatest 
differences between the two groups. Alternatively a prospective study could be 
undertaken using a select group of these markers to examine the allelic imbalance of
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men at the time of their radical prostatectomy in an attempt to predict which men 
develop PSA recurrence.
Ultimately the goal of molecular staging is to identify patients who will benefit from 
radical treatment before they undergo that treatment and which patients would be better 
managed by less invasive techniques. Comparing the genetic changes in radical 
prostatectomy specimens with the corresponding prostate biopsies will demonstrate how 
reliably genetic changes can be identified in biopsy tissue. As prostate cancer is a 
multifocal heterogeneous tumour the biopsy findings may not mirror the tumour 
characteristics of the whole prostate. The disparity between biopsy and radical Gleason 
scores demonstrates this variability. This disparity may be further exacerbated, as there 
appears to be greater genetic variation than Gleason variation within one radical 
prostatectomy specimen. Future studies could compare the allelic imbalance findings of 
the radical prostatectomy specimen with the Al in the pre-operative biopsy tissue. If 
markers are readily identified in both biopsy and radical prostate tissue this would have 
an important impact in directing appropriate radical treatment.
In clinical practice there is a pressing need for new therapeutic agents to treat hormone 
relapse disease, as there is a lack of treatment options and the prognosis for a man with 
androgen independent prostate cancer is less than a year. Improving our understanding 
of how a prostate cancer clone develops androgen independence will allow the 
development of such agents. Meanwhile targeting genome wide aberrant methylation 
with agents such as decitabine may improve the outcome of men with metastatic 
prostate cancer.
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Despite some knowledge of the genetic alterations found in prostate cancer the 
molecular mechanisms leading to the initiation and progression of the disease is poorly 
understood. In colorectal cancer a model of tumorigenesis in which specific genetic 
changes result in the stepwise progression from benign to malignant epithelium was 
reported over a decade ago. Prostate cancer appears much more complicated in its 
aetiology and pathogenesis. Only a small number of mutations have been identified, 
and no mutations have been reported in early stage disease. This is because only a tiny 
fraction of the 30,000 human genes have so far been screened for prostate cancer 
mutations. The Sanger Institute’s Cancer Genome Project is systematically screening 
for mutations in a number of malignancies, including prostate, and this should shed 
more light on these changes in prostate cancer. Another difficulty in determining the 
pathogenesis of prostate cancer is the critical changes may occur outside the coding 
sequence and it is difficult to predict the consequences of sequence variation in these 
regions. Furthermore genetic variation other than sequence variation may affect the 
oncogenes and tumour suppressor genes. Hypermethylation is proposed in this thesis as 
the mechanism of inactivation of the tumour suppressor gene p 2 l WAFI C,PI. Finally the 
loss of one tumour suppressor gene may be sufficient for tumour suppressor gene 
inactivation -  haploinsufficiency, as reported in NKX3.1 and PTEN. The difficulty is 
we do not know how common haploinsufficiency is and so how important the loss of a 
single gene may be in prostate cancer development.
Although molecular staging of radical prostatectomy patients has been under study for 
more than a decade, all techniques remain research tools. Still, this area holds great 
promise for improving the accuracy o f staging, providing a more accurate prognosis and 
tailoring treatment for the individual man with clinically localised prostate cancer. 
Likewise identifying critical genetic or epigenetic changes will allow the development 
of novel therapeutic tools in the treatment o f all stages of prostate cancer.
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APPENDICES
Appendix 1. Power calculation: based on the McNemar test.
Assuming a significance level of 5% (p=0.05)
Number of c a se s Number of controls Proportion with category Power (%)Case (%) Control (%)
20 20
70 40 44
70 30 68
60 30 44
60 20 69
40 20 26
40 10 55
30 10 33
20 5 28
20 40
70 40 56
70 30 81
60 30 56
60 20 83
40 20 34
40 10 69
30 10 42
20 5 36
30 30
70 40 62
70 30 86
60 30 62
60 20 87
40 20 37
40 10 74
30 10 47
20 5 40
30 60
70 40 75
70 30 95
60 30 75
60 20 95
40 20 47
40 10 86
30 10 59
20 5 51
40 40
70 40 75
70 30 95
60 30 75
60 20 95
40 20 48
40 10 86
30 10 59
20 5 51
40 80
70 40 87
70 30 99
60 30 87
60 20 99
40 20 60
40 10 95
30 10 72
20 5 63
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Appendix 2. Preoperative features of matched patients
R andom
num ber Age (yrs)
PreO p
PSA
Bx No of 
c o re s
Bx No of 
positive  
co res
Bx L ongest 
length  
involved 
(mm)
Bx H ighest 
% in co re
Biopsy
G leason
grad e
Random
nu m b er Age (yrs)
PreO p
PSA
Bx No of 
c o re s
Bx No of 
positive  
co res
Bx L o ngest 
length  
involved 
(mm)
Bx H ighest 
% in co re
Biopsy
G leason
grade
1 62 14.2 9 6 4+3 5 72 7.9 6 4 6 50 3+3
2 58 12 2 2 8 40 3+3 9 63 8 NA
3 59 18 6 3 16.1 95 4+4 10 73 16.7 6 2 2 15 3+4
4 69 10.1 NA 12 55 8.8 5 4 9 30 3+3
6 63 16.7 6 1 10 50 3+4 13 59 5.9 NA
7 55 14.7 4 1 14 100 3+3 17 65 5.1 5 2 8 100 2+3
11 54 4.3 6 1 12 75 3+3 19 59 8.3 3 2 7 15 3+3
15 68 9.1 NA 20 63 6.4 6 3 9 55 3+4
16 61 8 6 6 14 100 3+5 21 59 16.3 4 1 15 100 4+3
18 57 18.6 4 4 9 100 3+3 23 68 17.8 NA
22 57 8.6 3 1 8 44 3+5 26 61 12 6 3 13 65 3+4
24 60 16 6 6 18 100 4+3 28 57 7 NA
25 59 8.6 NA 29 59 7.4 NA
27 53 7.5 8 3 30 69 8.8 6 2 6 30 3+3
35 65 5.1 6 4 10 90 4+3 31 63 9.7 7 1 16 80 4+3
38 62 10.2 3 2 6 70 2+4 32 71 11.3 NA
39 49 18 NA 33 61 16 6 2 2 13 2+3
42 53 15.7 6 1 1 8 4+4 34 66 9 6 2 8 15 2+3
43 56 5.2 6 3 6 60 4+4 36 67 13.4 6 3 5 50 3+4
45 51 9.8 NA 37 70 13 NA
50 70 15.7 6 2 20 100 4+3 44 60 5.5 6 2 5 15 3+3
52 72 5.9 6 4 15 100 4+4 48 68 12.9 NA
55 56 14 6 2 12 65 5+4 49 73 10 NA
58 56 16 NA 51 52 17 6 4 1.3 100 3+4
59 58 8 7 6 3 20 5+3 53 62 16.6 4 4 3+3
60 57 8.7 NA 54 57 11 NA
64 54 14.4 6 4 10 50 4+3 56 65 16.6 50
74 54 9.9 1 4 4+? 57 65 10.5 NA
75 66 15.8 NA 61 66 15.1 NA
78 71 12.4 6 3 20 100 3+3 62 53 9.3 4 2 10 100 3+3
79 62 9.7 11 4 5 35 3+5 77 71 7.5 6 5 6 33 3+3
Mean 59.6 
(sd6.1)
Mean 64
(sd 6.2)
Appendix 3. Radical prostatectomy pathological findings of in matched patients (Relapse)
Randomism Radical PATHOLOGICAL OUTCOME - RELAPSELym pho /
ation
number
1 12-Jan-98 3+4 7 4 32 0 CIP 0 0 0 0 1 0 0
2 03-Feb-98 4+3 7 3.6 25 0 0 0 1 0 0 1 0 0
3 13-May-98 4+3 7 2.8 37 0 0 0 1 0 0 1 0 0
4 01-Apr-98 4+3 7 2 149 0 0 0 1 0 0 1 0 0
6 10-Dec-97 4+3 7 1.8 48 0 0 0 1 0 0 1 0 0
7 04-Jul-94 2+3 5 2.3 52 0 CEP 0 0 0 0 1 0 0
11 17-Oct-97 3+3 6 1.2 29 0 CEP 0 0 0 0 0 0 0
15 27-Nov-95 2+4 6 1.7 52 0 0 0 1 0 0 0 0 0
16 23-Mar-99 4+3 7 3.2 46 0 0 0 1 0 0 1 0 0
18 13-Jan-95 3+2 5 2.2 29 0 CEP 0 0 0 0 1 0 0
22 02-May-95 2+3 5 2.8 57 0 CIP 0 0 ? 0 1 0 0
24 16-Sep-98 4+3 7 4 32 1 0 0 1 0 0 1 0 0
25 08-Jul-98 4+3 7 5.1 54 0 CEP 0 0 0 0 1 0 0
27 21-Jul-97 4+3 7 2.6 40 1 CEP 0 0 0 0 1 0 0
35 09-Sep-96 3+2 5 5.7 48 0 CIP 0 0 0 0 1 0 0
38 18-Oct-94 2+4 6 10 92 1 CEP 0 0 0 0 1 0 0
39 09-Sep-96 4+3 7 2.1 29 0 CEP 0 0 0 0 0 1 0
42 31-Dec-97 4 + 4 8 1.5 32 1 0 0 1 0 0 0 0 0
43 21-Sep-98 4+3 7 5.2 31 1 0 0 1 0 0 0 0 0
45 05-Aug-96 3+4 7 1.6 28 0 CEP 0 0 0 0 0 0
50 28-Oct-97 4+3 7 3.5 27 0 0 0 1 0 0 0 0 0
52 09-Sep-98 4+3 7 5.5 30 1 0 0 1 0 0 0 NS 0
55 19-Jan-98 4+3 7 5.6 49 0 0 0 1 0 0 1 0 0
58 17-Oct-95 4+3 7 5.8 36 0 0 0 1 0 0 0 — c 0
59 26-Jul-00 4+3 7 1.9 35 1 0 0 1 0 0 1 ...  .0...... 0
60 15-Nov-00 4+3 7 0.5 38 1 0 0 1 0 0 0 0 0
64 13-Sep-00 5+3 8 10.5 104 1 0 0 1 0 0 1 0 0
74 01-Jun-94 3+4 7 3.7 53 0 0 0 1 0 0 0 0 0
75 17-Jul-96 4+3 7 3 24 0 CIP 0 0 0 1 0 0
78 15-Dec-99
A I I - , ,
4+3
O . C
7
o
3.9
A A
49
QQ
0
n
0 0fi
1
1
0
n
0
o
0
o
1
o
0
o79 10-May-00 3+5 8
Mean 6.74 
(sd 0.8)
1.4
Median
3
(0.5-10.5)
o o
Median 38 
(24-149)
u U u 1 V
CEP = Transverse extraprostatic positive margin, CIP = Transverse intraprostatic positive margin, NS -  Not Submitted 225
Appendix 3. Radical prostatectomy pathological findings in matched patients (Non-relapse)
Randomis
ation
num ber
5 04-Feb-98 3+4 7 2.5 62 0 0 0 1 0 0 1 0 0
9 14-Dec-95 3+4 7 2.3 45 0 0 0 1 0 0 1 0 0
10 02-Dec-97 4+3 7 2.8 82 0 CEP 0 0 0 1 0 0
12 29-Feb-96 4+3 7 1.3 52 0 0 0 1 0 0 0 0 0
13 04-Aug-97 3+4 7 1.2 48 0 0 0 1 0 0 0 0 0
17 11-Mar-97 3+3 6 0.9 45 0 0 0 1 0 0 1 0 0
19 02-Apr-96 3+4 7 3.4 47 0 0 0 0 0 1 0 0
20 31-Oct-95 3+4 7 2.2 48 0 0 0 1 0 0 0 0 0
21 10-Dec-97 4+4 8 1.7 37 0 0 0 1 0 0 0 0 0
23 02-Oct-96 2+3 5 8.4 50 0 0 0 1 0 0 1 0 0
26 22-Jan-97 4+3 7 5.4 41 0 0 0 1 0 0 1 0 0
28 27-Sep-93 2+3 5 3 39 0 CIP 0 0 0 1 1 0
29 27-Jan-98 3+4 7 1.6 50 0 0 0 1 0 0 0 0 0
30 21-Apr-98 3+4 7 1.1 39 0 0 0 1 0 0 0 0 0
31 22-Sep-98 3+4 7 0.9 17 0 0 0 1 0 0 0 0 0
32 27-Apr-98 3+4 7 2.6 27 0 0 0 1 0 0 1 0 0
33 09-Oct-95 3+2 5 1.5 57 0 0 0 1 0 0 1 0 0
34 12-NOV-96 3+2 5 1.7 59 0 0 0 1 0 0 1 1 0
36 14-0ct-97 4+3 7 3.2 64 1 0 0 1 0 0 1 1 0
37 10-Dec-91 3+4 7 1.7 NA 1 0 0 1 0 0 0 0 NS
44 09-Feb-98 3+4 7 1.1 NA 0 CIP 0 0 0 0 0 0
48 24-Apr-96 4+2 6 1 62 0 0 0 1 0 0 1 0 0
49 08-Sep-97 4+3 7 5.6 37 0 CEP 0 0 0 0 0 0
51 28-Jul-98 3+4 7 2.2 38 0 0 0 1 0 0 1 0 0
53 18-Sep-95 4+3 7 5 6 47 0 0 0 1 0 0 1 1 0
54 20-May-98 3+4 7 0.6 60 0 0 0 1 0 0 0 0 0
56 06-May-97 3+4 7 1.1 32 0 0 0 1 0 0 0 0 0
57 20-Aug-97 3+4 7 4.1 25 0 CIP 0 0 0 1 0 0
61 21-Aug-96 4+4 8 1.7 83 0 CIP 0 0 0 1 0 0
62 22-Aug-95 3+3 6 1.9 33 0 0 0 1 0 0 0 0 0
77 12-Nov-97 4+4 8 0.8 38 0 0 0 1 0 0 0 0 0
Mean 6.74 
(sd 0.8)
Median 1.8 
(0.8-8.4)
Median 47 
(27-83)
CEP = Transverse extraprostatic positive margin, CIP = Transverse intraprostatic positive margin, NS -  Not Submitted 226
Appendix 4. PSA follow-up in matched patients - Relapse
Random
number
Date of 
Surgery
Post
PSA1
Post PSA 1 
Date
Post PSA 
2
Post PSA 2 
Date
Post PSA 
3
Post PSA 3 
Date
Post PSA 
4
Post P§a 7  
Date
Post PSA 
5
Post PSA 5 
Date
1 09-Jan-98 0.5 20-Jan-98 0.1 27-Feb-98 0.1 02-Mar-98 0.1 03-Jun-98 0.3 17-Sep-98
2 03-Feb-98 0.2 13-Feb-98 0.05 03-Apr-98 0.05 14-May-98 0.1 17-Oct-98 0.1 16-Nov-98
3 13-May-98 0.4 31-May-98 0.1 01-Jul-98 0.4 01-Sep-98 0.1 05-Nov-98 0.2 01-Dec-98
4 01-Apr-98 0.2 14-Apr-98 0.1 26-May-98 0.1 03-Sep-98 0.1 09-Oct-98 0.2 12-Apr-99
6 10-Dec-97 0.3 22-Dec-97 0.1 17-Mar-98 1.2 29-Jun-98 1.3 AA 01-Jul-98 0.3 DXR 08-Jan-99
7 04-Jul-94 <0.5 03-Oct-94 <0.5 16-Jan-95 0.4 13-Apr-95 0.8 01-Nov-95 1.1 26-Jan-96
11 17-Oct-97 0.2 30-Oct-97 0.1 25-Nov-97 0.5 30-Jan-98 0.1 10-Feb-98 0.2 08-Apr-98
15 27-Nov-95 0.1 01-May-96 0.3 19-Jan-98 0.4 06-Aug-98 0.6 12-Nov-98 0.6 09-Feb-99
16 23-Mar-99 0.1 13-May-99 0.1 14-Jun-99 0.1 09-Aug-99 0.1 10-Nov-99 0.2 21-Feb-00
18 13-Jan-95 0.3 31-Jan-95 1.4 01-Jan-97 AA/DXR 23-May-00 0.04 13-Sep-01
22 02-May-95 1.3 01-Jul-96 0.9 20-Apr-99 0.8 21-Oct-99 0.8 03-Apr-00 0.8 05-Jan-01
24 16-Sep-98 0.4 29-Sep-98 0.1 22-Oct-98 0.1 27-Jan-99 0.1 27-Apr-99 0.1 09-Sep-99
25 08-Jul-98 0.1 20-Jul-98 0.1 04-Sep-98 0.1 26-Nov-98 0.2 01-Mar-99 0.4 07-Jun-99
27 21-Jul-97 0.3 31-Jul-97 0.1 01-Oct-97 0.1 01-Jan-98 0.1 01-Apr-98 0.4 14-Nov-98
35 09-Sep-96 0.2 01-Dec-96 0.5 01-Mar-97 0.6 01-Jun-97 0.9 01-Sep-97 1 29-Jun-98
38 18-Oct-94 0.5 01-Jan-95 0.5 01-May-95 0.7 01-Oct-95 0.7 01-Feb-96 1 01-Jul-96
39 09-Sep-96 0.2 09-Dec-96 0.4 18-Mar-97 0.5 04-Apr-97 0.6 02-Sep-97 0.6 09-Dec-97
42 31-Dec-97 0.2 01-Mar-98 0.1 01-Jun-98 0.5 05-Jul-99
43 21-Sep-98 0.5 08-Oct-98 0.2 09-Nov-98 0.4 16-Dec-98 0.7 28-Apr-99 0.4 25-M ay-99
45 05-Aug-96 0.2 17-Dec-96 0.4 07-Apr-97 0.4 06-Jun-97 0.8 13-Aug-97 0.5 19-Sep-97
50 28-Oct-97 0.7 10-Nov-97 0.1 18-Nov-97 0.4 05-Nov-99 0.6 02-Jan-98 0.1 31-Mar-98
52 09-Sep-98 0.1 10-Oct-98 0.5 09-Feb-99 0.5 20-May-99 2.6 01-Aug-00
55 19-Jan-98 0.1 01-Apr-98 0.3 01-Jul-98
58 17-Oct-95 0.3 01-Nov-96 0.5 01-Jul-98 1.5 02-Dec-98 1.4 14-Mar-99 1.82 26-Jan-00
59 26-Jul-00 0.2 07-Jan-01 0.6 03-Apr-01
60 15-Nov-00 No nadir
64 13-Sep-OO 0.2 30-Aug-01 AA
74 01-Jun-94 1.4 17-Mar-95 0.8 23-Jun-95 0.8 31-Aug-95
75 17-Jul-96 1.6 01-Dec-96 3.3 01-Apr-97
78 15-Dec-99 0.1 20-Jan-00 0.4 04-May-00 1.2 8-00 bone mets 08-Sep-00
79 10-May-00 0.1 22-May-00 0.1 10-Jul-00 0.2 13-Nov-OO 0.18 24-Jan-01 0.33 02-May-01
AA = Antiandrogens, DXR = Radiotherapy
Appendix 4. PSA follow-up in matched patients - Relapse
R andom
n u m b er
Date of 
Surgery PostPSA 6
PostPSA 6
Date
P o s t PSA 
7
P o s t PSA 7 
Date
P o s t PSA 
8
P o s t PSA8 
Date
P o s t PSA 
9
P o s t PSA 9 
Date
P o s t PSA 
10
P o s t PSA 
10 Date
P o s t PSA 
11
P o s t PSA 
11 Date
P o s t PSA 
12
1 12-Jan-98 0.3 01-Dec-98 1 01-Aug-99 0.9 06-Aug-99 0.59 AA 21-Sep-99 0.3 05-Jan-00 0.4 05-Apr-00 0.4
2 03-Feb-98 0.3 04-Mar-99 0.25 20-Sep-99 0.42 03-Dec-99 0.5 26-Apr-00 0.6 26-Jul-00 0.7 03-0ct-00 0.5
3 13-May-98 0.1 01-Feb-99 0.1 23-Mar-99 0.1 21-Jun-99 0 3 08-Sep-99 0.4 28-Oct-99 0.5 16-Dec-99 0.5
4 01-Apr-98 0.5 26-Oct-99 1.1 03-Apr-00 0.1 Cas 06-Jul-00 0.2 21-Nov-00 0.2 17-May-01 0.3 05-Nov-01
6 10-Dec-97 0.35 09-Jul-99
7 04-Jul-94 0.3AA 26-Apr-96 0.4 21-Oct-96
11 17-Oct-97 0.1AA/DXF 28-Sep-98 0.1 25-Mar-99 0.02 26-Apr-99 0.04 24-Apr-01 Died AML
15 27-Nov-95 0.6 13-May-99 0.8 07-Jun-99 0.9 08-Aug-99 0.5 18-NOV-99 0.8 09-Feb-00 0.7 10-May-00 0.6
16 23-Mar-99 0.2 18-Apr-00 0.4 11-Aug-00 0.2 13-Dec-00 0.2 14-Mar-01 0.1 18-Jul-01 0.1 14-Nov-01
18 13-Jan-95
22 02-May-95 0.7 31-Jul-01 0.4 18-Jan-02
24 16-Sep-98 0.2 22-Mar-00 0.5 29-Jun-00 0.1 AA 27-Sep-00 0.1 27-Mar-01 0.1 20-Sep-01 0.1 03-Oct-01
25 08-Jul-98 6.4 AA 26-Jul-99 2.1 AA 08-Nov-99 17.8 16-Mar-00 18.9 31-Mar-00 6.58 16-May-00 5.5 24-Aug-00 42
27 21-Jul-97 0.5 13-Feb-99 0.3 17-Jul-99 0.3 15-Jan-00 0.3 15-Jul-00 0.4 20-Jan-01 0.5 23-Jun-01 1.1
35 09-Sep-96
38 18-Oct-94 2.1 01-Jan-97 0.5 01-May-99 0.5 09-Aug-99 0.5 01-Dec-99 0.5 08-Feb-00 0.1 29-Mar-00 0.1
39 09-Sep-96 0.6 13-Mar-98 1.1 23-Jun-98 1.1 01-Oct-98 0.2 02-Dec-98 0.2 19-Feb-99 0.2 24-NOV-99 0.3
42 31-Dec-97
43 21-Sep-98
45 05-Aug-96
50 28-Oct-97 0.1 30-Jun-98 0.1 29-Sep-98 0.3 29-Mar-99 0.3 08-Apr-99 0.3 01-Jul-99 0.4 04-Oct-99 0.6
52 09-Sep-98
55 19-Jan-98
58 17-Oct-95
59 26-Jul-00
60 15-Nov-00
64 13-Sep-00
74 01-Jun-94
75 17-Jul-96
78
79
15-Dec-99 
10-M ay-00 0.26 06-Jun-01
POSTOPERATIVE PSA 2. - RELAPSE
AA = Antiandrogens, DXR = Radiotherapy
Appendix 4. PSA follow-up in matched patients - Relapse
R andom
nu m b er
Date of 
Surgery
P o s t PSA 
14
P o s t PSA 
14 Date
P o s t PSA 
15
P o s t PSA 
15 Date
P o s t PSA 
16
P o s t PSA 
16 Date
P o s t PSA 
17
P o s t PSA 
17 Date
P o s t PSA 
18
P o s t PSA 18 
Date
P o s t PSA 
19
P o s t PSA 
19 Date
P o s t PSA 
20
1 09-Jan-98 2 12-Jan-01 0.8 02-Mar-01
2 03-Feb-98 0.04 DXR 12-Nov-01
3 13-May-98 1.7 10-Jul-00 2.2 16-Oct-OO 2.5 21-Nov-00 6.2 26-Jan-01 3.4 Cas 29-Mar-01 146 25-Jun-01 156.5
4 01-Apr-98
6 10-Dec-97
7 04-Jul-94
11 17-Oct-97
15 27-NOV-95 0.5 06-Feb-01 0.5 05-Jun-01 Died CaP 5/02
16 23-Mar-99
18 13-Jan-95
22 02-May-95
24 16-Sep-98
25 08-Jul-98 Died CaP
27 21-Jul-97
35 09-Sep-96
38 18-Oct-94 0.1 16-Oct-OO 0.1 12-Feb-01 0.1 14-May-01 0.1 11-Sep-01
39 09-Sep-96 1.3 04-Jun-01 0.3 28-Aug-01
42 31-Dec-97
43 21-Sep-98
45 05-Aug-96
50 28-Oct-97 0.8 13-Jul-00 0.8 31-Oct-OO 1.1 01-Feb-01 0.3 14-Sep-01 0.3 03-Dec-01
52 09-Sep-98
55 19-Jan-98
58 17-Oct-95
59 26-Jul-00
60 15-Nov-00
64 13-Sep-OO
74 01-Jun-94
75 17-Jul-96
78 15-Dec-99
79 10-May-00
AA = Antiandrogens, DXR = Radiotherapy
Appendix 4. PSA follow-up in matched patients -  Non-relapse
-------------------------------
Random Date of Post Post PSA 1 Post PSA Post PSA 2 Post PSA Post PSA 3 Post PSA Post PSA 4 Post PSA Post PSA 5
number Surgery PSA1 Date 2 Date 3 Date 4 Date 5 Date
5 04-Feb-98 0.1 23-Feb-98 0.1 31-Mar-98 0.1 09-Jul-98 0.1 15-Oct-98 0.1 19-Jan-99
9 14-Dec-95 0.6 22-Dec-95 0.1 01-Dec-96 0.1 01-Aug-98 0.1 07-Jan-99 0.1 08-Jun-99
10 02-Dec-97 0.3 17-Dec-97 0.1 05-Mar-98 0.1 25-Jun-98 0.1 25-Jun-98 Never >0.2 8/01
12 29-Feb-96 0.7 04-Mar-96 0.2 12-Mar-96 0.1 18-Mar-96 0.1 01-May-96 Never >0.2 8/01
13 04-Aug-97 0.1 01-Nov-97 0.1 01-Feb-98 0.1 01-May-98 0.1 29-Jun-98 0.1 22-Aug-98
17 11-Mar-97 0.5 28-Jul-97 0.5 20-Oct-97 0.5 14-Apr-98 0.5 10-Oct-98 0.5 26-Apr-99
19 02-Apr-96 0.5 20-May-96 0.5 22-Jul-96 0.5 21-Oct-96 0.5 21-Apr-97 0.5 20-Mar-98
20 31-Oct-95 0.5 18-Dec-95 0.5 19-Feb-96 0.5 01-Jul-96 0.5 02-Dec-96 0.5 12-May-97
21 10-Dec-97 0.9 22-Dec-97 0.1 02-Feb-98 0.1 05-May-98 0.1 10-Sep-98 0.1 18-Nov-98
23 02-Oct-96 0.1 29-Oct-96 0.1 11-Mar-97 0.05 22-Sep-97 0.05 14-Mar-98 0.05 01-Sep-98
26 22-Jan-97 1.2 03-Feb-97 0.1 01-Apr-97 0.1 01-Jul-97 0.1 01-Oct-97 0.1 08-Jul-98
28 27-Sep-93 0.5 22-May-95 0.5 20-Nov-95 0.5 20-May-96 0.5 18-Nov-96 0.5 17-Nov-97
29 27-Jan-98 0.5 02-Mar-98 0.5 15-Jun-98 0.5 11-Feb-99 0.5 23-Aug-99 0.5 09-Dec-99
30 21-Apr-98 0.1 05-May-98 0.1 11-Jun-98 0.1 16-Jul-98 0.1 03-Sep-98 0.1 13-Mar-99
31 22-Sep-98 0.1 16-Nov-98 0.1 15-Mar-99 0.1 17-Jun-99 0.1 28-Sep-99 0.1 27-Mar-00
32 27-Apr-98 never>0.2 01-Aug-01
33 09-Oct-95 never>0.2 01-Aug-01
34 12-Nov-96 0.5 13-Jan-97 0.5 24-Feb-97 0.5 28-Jul-97 0.5 26-Jan-98 0.5 25-Jan-99
36 14-Oct-97 0.5 02-Feb-98 0.5 05-May-98 0.5 09-Nov-98 0.5 11-Nov-98 0.5 01-May-99
37 10-Dec-91 0.5 07-Dec-92 0.5 21-Jun-93 0.1 01-Sep-95
44 09-Feb-98 0.5 23-Mar-98 0.5 08-Jun-98 0.5 12-Oct-98 0.5 18-Jan-99 0.5 01-Jul-99
48 24-Apr-96 0.1 01-Dec-96 0.5 01-Jun-97 never >0.2 01-Aug-01
49 08-Sep-97 0.5 24-Oct-97 0.5 27-Feb-98 never >0.2 02-Sep-02
51 28-Jul-98 0.02 07-Sep-98 0.2 17-Nov-98 0.02 03-Feb-99 0.02 07-Jun-99 Rose 6/01
53 18-Sep-95 0.1 01-Dec-95 0.1 03-Apr-96 0.1 01-Jun-96 0.10 01-Sep-96 0.1 01-Jan-97
54 20-May-98 never>0.2 01-Aug-01 <0.2 08-Aug-02
56 06-May-97 0.2 19-May-97 0.1 01-Aug-97 0.1 01-May-98
57 20-Aug-97 0.6 29-Aug-97 0.1 07-Oct-97 0.1 15- Jan-98 0.1 22-Apr-98 0.1 17-Aug-98
61 21-Aug-96 1.2 29-Aug-96 0.1 01-Nov-96 0.1 01-Feb-97 0.1 01-Aug-97
62 22-Auq-95 0.5 01-Nov-95 never>0.2 01-Aug-01
77 12-Nov-97 0.1 25-Nov-97 0.2 01-Feb-98 0.1 01-May-98 0.1 01-Oct-98 0.1 21-Apr-99
AA = Antiandrogens, DXR = Radiotherapy
230
Appendix 4. PSA follow-up in matched patients -  Non-relapse
--------------------------------------------------------------------------------
R andom
n u m b er
Date of 
_ S “ rcjery__ PostPSA 6
PostPSA 6
Date
P o s t PSA 
7
P o s t PSA 7 
Date
P o s t PSA 
8
P o s t PSA8 
Date
P o s t PSA 
9
P o s t PSA 9 
Date
P o s t PSA 
10
P o s t PSA 
10 Date
P o s t PSA 
11
P o s t PSA 
11 Date
P o s t PSA 
12
5 04-Feb-98 0.1 20-Jul-99 0.1 03-Jul-00 0.1 24-Jul-01
9 14-Dec-95 0.1 15-Dec-99 0.1 01-Aug-00
10 02-Dec-97
12 29-Feb-96
13 04-Aug-97 0.1 02-Mar-99 0.12 08-Nov-99 Not >0.2 08-Jan-02
17 11-Mar-97 0.5 25-Apr-00 0.7 30-Apr-01 0.6 29-Apr-02 No treatment
19 02-Apr-96 0.5 23-Sep-98 0.5 25-Mar-99 0.1 13-Apr-00 0.1 24-Apr-01 0.1 17-Apr-02
20 31-Oct-95 0.5 10-Nov-97 0.5 01-Aug-98 0.5 01-Jul-99 0.5 01-Oct-99 0.1 01-Sep-00
21 10-Dec-97 0.1 12-Mar-99 0.1 26-May-99 0.1 31-Aug-99 0.1 20-Dec-99 0.1 03-Jul-00 0.1 28-Nov-00 0.1
23 02-Oct-96 0.05 01-Sep-98 0.05 19-Apr-99 0.05 10-Sep-99 0.05 24-Oct-01
26 22-Jan-97 0.1 02-Aug-99 0.1 01-Sep-00 1.5 09-Nov-00 0.1 27-Mar-01 0.1 26-Jun-01 0.1 01-Oct-01 0.1
28 27-Sep-93 0.5 16-Nov-98 0.5 15-Nov-99 0.1 11-Dec-00
29 27-Jan-98 0.1 26-Feb-01
30 21-Apr-98 0.1 03-Jul-01
31 22-Sep-98 0.1 04-Sep-01
32 27-Apr-98
33 09-Oct-95
34 12-Nov-96 0.5 01-Jul-99
36 14-Oct-97 0.5 01-May-00 <0.1 13-Jun-01 <0.5 10-Dec-01 0.3 01-Jul-02
37 10-Dec-91
44 09-Feb-98 0.5 18-Jan-00 <0.1 17-Jul-00 <0.1 02-Aug-01 <0 1 17-Jul-02
48 24-Apr-96
49 08-Sep-97
51 28-Jul-98
53 18-Sep-95 0.1 01-May-97 never >0.2
54 20-May-98
56 06-May-97
57 20-Aug-97 0.1 04-Feb-99 0.1 05-Aug-99 0.1 25-Jan-00 0.2 07-Aug-00 0.1 24-Aug-00 0.1 14-Nov-OO 0.2
61 21-Aug-96
62 22-Aug-95
77 12-Nov-97 0.1 17-Sep-99 0.1 31-Mar-00 0.1 20-Sep-00 0.1 12-Sep-01
AA = Antiandrogens, DXR = Radiotherapy
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Appendix 5. Procedure for staining with haematoxylin and eosin
Procedure Time
1. D ew ax sections in Xylene 3 mins
2. R epeat dew ax sections in Xylene 3 mins
3. W ash  in 100%  ethanol 1 mins
4. R epeat wash in 100%  ethanol 1 mins
5. W ash  70%  ethanol 1 mins
6. Rehydrate in tap w ater 1 mins
7. Stain with Haem otoxylin 5 mins
8. W ash  in running tap w ater 3 mins
9. D ifferentiate in 1%  acid-alcohol 6 secs
10. W ash  Scott's tap w ater 5 mins
11. W ash  in tap w ater 30 secs
12. Stain with 1% Eosin 5 mins
13. W ash  in running tap w ater 1 mins
14. Dry in 70%  ethanol 15 secs
15. Dry in 100%  ethanol 30 secs
16. Dry in 100%  ethanol 30 secs
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Appendix 6. The ABgene™ DNA block 96 well plates arranged for genotyping
1 2 3 4 5 6 7 8 9 10 11 12
A 1R 3R 10R 12R 19R 21R 27R 29R 35R 37R 45R 49R
B 5R 7 R 15R 17R 23R 25R 31R 33R 39R 43R 51R 53R
C 1L 3L 10L 12L 19L 21L 27L 29L 35L 37L 45L 49L
D 5L 7L 15L 17L 23L 25L 31L 33L 39L 43L 51L 53L
E 2R 4R 11R 13R 20R 22 R 28R 30R 36R 38R 48R 50R
F 6R 9R 16R 18R 24R 26R 32R 34R 42R 44R 52R
G 2L 4L 11L 13L 20L 22L 28L 30L 36L 38L 48L 50L
H 6L 9L 16L 18L 24L 26L 32L 34L 42L 44L 52L water
1 2 3 4 5 6 7 8 9 10 11 12
A 54R 56R 62R 74R
B 58R 60R 77R 79R
C 54L 56L 62L 74L
D 58L 60L 77L 79L
E 55R 57R 64R 75R
F 59R 61R 78R
G 55L 57L 64L 75L
F 59L 61L 78L water
Number denotes patient number (matched patients only) 
R = Radical prostatectomy specimen (cancer)
L = Lymph node or seminal vesicle specimen (contol)
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Appendix 7 Features of the polymorphic markers used in the allelic imbalance stud]/
Primer G ene T ype o f  
repeat Frequency T issu e T echnique R eference
D1S422 Familial prostate cancer Di 15% of
D1S414 ATF3 Di
D1S158 H PC 1 (hereditary) Oi 5% of 21 T3 and T4 autoradiography- loss of 60% by eye Latini JM J Urol 2001; 166: 1931-36
D1S305 PSMBA Di
D2S222 not known Di 6% of 17 (informative cases) primary from RP autoradiography-formally assessed Saric T Int J Cancer 1999; 81: 219-224
D5S656 close to APC Di
D5S500 close to CTNNA1 Di
D6S501 not known Tetra 11 % of 52 (informative cases) RP specimens autoradiography - 50% loss by eye Cooney KA Cancer Res 1996; 56: 4150-53
D6S314 not known Di 2% of 52 (informative cases) RP specimens autoradiography - 50% loss by eye Cooney KA Cancer Res 1996; 56: 4150-53
D7S480 close to MET Di 0% primary, mets or HRCAP Autopsy HRCAP autoradiography - 50% formally assessed Kawana Y Prostate 2002, 53:60
D7S480 close to MET Di 17% of 46 (informative cases) RP specimens autoradiography - 1 .5x formally assessed Takahashi S Cancer Res 1995; 55: 4114-9
D7S480 close to MET Di 46% of 33 (informative cases) T1-3, NO-1, MO-1 autoradiography - loss of >30% formally assessed Latil A. Clin Cancer Res 1995; 1: 1385-9
D7S480 close to MET Di 27% of 11 (informative cases) RP or LN if LN+ at RP autoradiography - loss <30% formally assessed Zenklusen J Cancer Res 1994; 54: 6370-3
D7S523 close to MET Di 3% of 47 (informative cases) RP and TURP autoradiography - by eye Huge) A Br J Cancer 1999; 79: 551-57
D7S523 close to MET Di 24% of 42 (informative cases) RP specimens autoradiography -1 5x formally assessed Takahashi S Cancer Res 1995; 55: 4114-9
D7S523 close to MET Di 28% of 7 (infomative casesO RP or LN if LN+ at RP autoradiography - loss < 30% formally assessed Zenklusen J Cancer Res 1994; 54: 6370-3
D8S136 NKX3.1 Di 18% of 17 (informative cases) primary from RP autoradiography-formally assessed Saric T Int J Cancer 1999; 81: 219-224
D8S136 NKX3.1 Di 72% of 25 RP and TURP, any grade autoradiography-loss or faint to eye Emmert-Buck MR Can Res 1995; 55: 2959
D8S1991 MSR Di homozygous deletion in single pt RP LN mets in 1 pt multiplex PCR Bova GS Genomics 1996; 35: 46-54
NEFL not kncwn Di 27% of 60 RP patients with LN+ 8% Autoradiography loss of >50% Emmert-Buck MR Cancer Res 1995; 55: 2959
NEFL not known Di 72% of 29(homozygous deletion present) T2-T4N1M1 Autoradiography loss of >50% Macoska JA Cancer Res 1995; 55: 5390-5,
NEFL not kncwn Di 63% of 56 (informative cases) T2-T3bN1M1 Autoradiography-near or complete loss by eye VockeC Cancer Res 1996; 56; 2411-16
NEFL not kncwn Di 35% of 29 Cancer, 21% of 29 HGPIN RP specimens Autoradiography-<50% densometry Haggman M. Urology 1997; 50: 643-47
NEFL not known Di 54% of 45 RP specimens Autoradiography-<50% by eye Prasad M Gen Chrom Can 1998; 23:255
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Primer G en e
T ype o f  
rep eat F req uency T iss u e T ech n iq u e R eferen ce
D10S211 DI 17% of 35 RP spedm ens T2-T3N1 Autoradiography loss of >50% Trybus T et al Cancer Res 1996; 56: 2263
D10S211 DI 2 cases of 64 ?hcw many informative T2-4.N0-1 Autotoradiography-loss >50% formally assesed Ittmann M Cancer Res 1996, 56: 2143-47
D10S587 close to MXI1 Di 0% of 17 primary (informative cases) RP and mets autoradiography-formally assessed Saric T Int J Cancer 1999; 81: 219-224
D10S587 close to MXI1 DI 19% of 37 T1M0-T4M1 Fluorescent allele typing > 20% loss Gray IC et al Cancer Res 1995; 55: 4800-03
D10S587 close to MXI1 DI 1 cases of 64 ?how many informative T2-4.N0-1 Autotoradiography-loss >50% formally assesed Ittmann M Cancer Res 1996; 56: 2143-47
D10S1246 close to MXI1 Tetra
D11S902 close to KAI1 Di no I oh in primary or mets RP and autopsy mets of CaP death Autotoradiography-loss >50% formally assesed Kawana Y Prostate 1997; 32: 205-13
D11S916 close to GSTP1 Tetra
D11S2000
D12S1697 p27/kip1 Di 14% of 14 primary, 30% of 10 HRCAP mets Autopsy of CaP mets pts autoradiography - 50% loss formally Kawana Y Prostate 2002; 53: 60-64
D12S89 p27/kip1 Di 10% of 10 primary, 0% of 7 HRCAP mets Autopsy of CaP mets pts autoradiography - 50% loss formally Kawana Y Prostate 2002; 53: 60-64
D13S269 Di 27% of 41 TURP - 78% Gleason 8-10, all T4 autoradiography scanned <50% Dong JT Prostate 2001; 49: 166-171
D13S263 d o se  to RB1 Di 32% of 41 T U R P-78%  Gleason 8-10, allT4 autoradiography scanned <50% Dong JT Prostate 2001; 49: 166-171
D13S171 intragenic to BRAC1 Di
D15S1232 Tetra
D16S413 close c-mye, H- and M-cadherin Di 17% of 18 primary RP and mets autoradiography-formally assessed Saric T Int J Cancer 1999; 81: 219-224
D18S541 close to DPC4 and DCC Tetra 22% of 47 RP AND TURP autoradiography - by eye Hugel A Br J Cancer 1999; 79: 551-57
D19S223 close to C-CAM Di 100% of 25 RP specimens, all grades immunohistchemistry Kleinerman DI Cancer Res 1995; 55: 1215
D21S156 not known Di 35% of 17 primary RP and mets autoradiography-formally assessed Saric T Int J Cancer 1999; 81: 219-224
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bp base pairs
Cl Confidence Interval
CpG Cytosine phosphodiester Guanine
cT clinical tumour stage
CT Computerised Tomography
CZ Central Zone
DNA Deoxyribose Nucleic Acid
DRE Digital Rectal Examination
MRI Magnetic Resonance Imaging
NICE National Institute o f Clinical Excellence
PET Positron Emission Tomography
PSA Prostate Specific Antigen
PT postoperative/pathological tumour stage
PZ Peripheral Zone
RR Relative Risk
RT-PCR Reverse Transcriptase - Polymerase Chain Reaction
SD Standard Deviation
TNM Tumour Nodes Metastases
TRUS Trans Rectal Ultrasound Scan
TURP Trans Urethral Resection o f the Prostate
TZ Transition Zone
